U.S. patent application number 17/432497 was filed with the patent office on 2022-08-04 for imidazopyridinyl compounds and use thereof for treatment of proliferative disorders.
The applicant listed for this patent is 1ST Biotherapeutics, Inc.. Invention is credited to Suyeon JO, Jae Eun KIM, Misoon KIM, Jinhwa LEE, Keonseung LIM, A Yeong PARK, Inyoung YANG.
Application Number | 20220242861 17/432497 |
Document ID | / |
Family ID | |
Filed Date | 2022-08-04 |
United States Patent
Application |
20220242861 |
Kind Code |
A1 |
LEE; Jinhwa ; et
al. |
August 4, 2022 |
IMIDAZOPYRIDINYL COMPOUNDS AND USE THEREOF FOR TREATMENT OF
PROLIFERATIVE DISORDERS
Abstract
The present disclosure provides a compound of Formula (I) or
pharmaceutically acceptable salt, stereoisomers thereof, a
pharmaceutical composition comprising the compound, and a method to
treat or prevent cancer diseases and/or proliferative disorders
using the compound. ##STR00001##
Inventors: |
LEE; Jinhwa; (Gyeonggi-do,
KR) ; JO; Suyeon; (Gyeonggi-do, KR) ; LIM;
Keonseung; (Gyeonggi-do, KR) ; PARK; A Yeong;
(Gyeonggi-do, KR) ; KIM; Jae Eun; (Gyeonggi-do,
KR) ; KIM; Misoon; (Gyeonggi-do, KR) ; YANG;
Inyoung; (Seoul, KR) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
1ST Biotherapeutics, Inc. |
Gyeonggi-do |
|
KR |
|
|
Appl. No.: |
17/432497 |
Filed: |
February 21, 2020 |
PCT Filed: |
February 21, 2020 |
PCT NO: |
PCT/IB2020/051472 |
371 Date: |
August 20, 2021 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
62809230 |
Feb 22, 2019 |
|
|
|
International
Class: |
C07D 471/04 20060101
C07D471/04; A61K 31/437 20060101 A61K031/437; A61K 45/06 20060101
A61K045/06; C07D 519/00 20060101 C07D519/00; A61P 35/02 20060101
A61P035/02 |
Claims
1. A method for treating cancer in a subject, comprising:
administering to the subject in need thereof a therapeutically
effective amount of a compound of Formula (I) or a pharmaceutically
acceptable salt thereof. ##STR00133## wherein R.sup.1 is
cyclopropyl substituted with one or more groups selected from the
group consisting of halo, alkyl, hydroxyalkyl, haloalkyl, and
monoalkylaminoalkyl; R.sup.2 and R.sup.3 are independently --H,
halo, alkyl, alkoxy, --CF.sub.3, --CHF.sub.2, --CH.sub.2F, or
--OCF.sub.3; R.sup.4 is selected from the group consisting of
6-membered aryl, 6-membered heteroaryl, ##STR00134## wherein the
6-membered aryl or 6-membered heteroaryl is optionally substituted
with one or more groups selected from the group consisting of halo,
hydroxyl, alkyl, alkenyl, alkynyl, cycloalkyl, haloalkyl,
hydroxyalkyl, dialkylaminoalkyl, trimethylsilylethoxymethyl,
--CH.sub.2NHC(O)CH.sub.3, --NO.sub.2, --NR.sub.aR.sub.b,
--NR.sub.aC(.dbd.O)R.sub.b, --NR.sub.aC(.dbd.O)NR.sub.aR.sub.b,
--NR.sub.aC(.dbd.O)OR.sub.b, --OR.sub.a, --CN, --C(.dbd.O)R.sub.a,
--C(.dbd.O)OR.sub.a, --C(.dbd.O)NR.sub.aR.sub.b,
--OC(.dbd.O)R.sub.a, --OC(.dbd.O)OR.sub.a,
--OC(.dbd.O)NR.sub.aR.sub.b, --SR.sub.a, azetidinyl, oxetanyl,
tetrahydrofuranyl, furanyl, pyrrolidinyl, pyrrolyl, pyrazolyl,
thiophenyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, furazanyl,
oxadiazolyl, thiadiazolyl, phenyl, tetrahydropyranyl, pyranyl,
pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, piperidinyl,
piperazinyl, morpholinyl and thiomorpholinyl; R.sub.a and R.sub.b
are independently --H, halo, amino, alkyl, or haloalkyl; and
R.sup.5 is H, halo, or alkyl.
2. The method of claim 1, wherein R.sup.1 is cyclopropyl
substituted with one or more groups selected from the group
consisting of halo, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3
hydroxyalkyl and C.sub.1-C.sub.3 haloalkyl; R.sup.2 and R.sup.3 are
independently --H, halo, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3
alkoxy, --CF.sub.3, --CHF.sub.2, --CH.sub.2F, or --OCF.sub.3;
R.sup.4 is 6-membered aryl or 6-membered heteroaryl, wherein
R.sup.4 is optionally substituted with one or more groups selected
from the group consisting of halo, hydroxyl, C.sub.1-C.sub.3 alkyl,
C.sub.2--C.sub.3 alkenyl, C.sub.2--C.sub.3 alkynyl,
C.sub.3--C.sub.4 cycloalkyl, C.sub.1-C.sub.3 haloalkyl,
mono-C.sub.1-C.sub.3 alkylamino, di-C.sub.1-C.sub.3 alkylamino,
--CH.sub.2NHC(O)CH.sub.3, --NO.sub.2, --NR.sub.aR.sub.b,
--NR.sub.aC(.dbd.O)R.sub.b, --NR.sub.aC(.dbd.O)NR.sub.aR.sub.b,
--NR.sub.aC(.dbd.O)OR.sub.b, --OR.sub.a, --CN, --C(.dbd.O)R.sub.a,
--C(.dbd.O)OR.sub.a, --C(.dbd.O)NR.sub.aR.sub.b,
--OC(.dbd.O)R.sub.a, --OC(.dbd.O)OR.sub.a,
--OC(.dbd.O)NR.sub.aR.sub.b, --SR.sub.a, azetidinyl, oxetanyl,
tetrahydrofuranyl, furanyl, pyrrolidinyl, pyrrolyl, pyrazolyl,
thiophenyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, furazanyl,
oxadiazolyl, thiadiazolyl, phenyl, tetrahydropyranyl, pyranyl,
pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, piperidinyl,
piperazinyl, morpholinyl and thiomorpholinyl; R.sub.a and R.sub.b
are independently --H, halo, amino, C.sub.1-C.sub.3 alkyl, or
C.sub.1-C.sub.3 haloalkyl; and R.sup.5 is H, F--, Cl--, Br-- or
methyl.
3. The method of claim 1, wherein R.sup.1 is cyclopropyl
substituted with one or more selected from the group consisting of
fluoro, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 hydroxyalkyl and
C.sub.1-C.sub.3 fluoroalkyl; R.sup.2 and R.sup.3 are independently
--H, --F, --Br, --Cl, C.sub.1-C.sub.3 alkyl, or --CF.sub.3; R.sup.4
is phenyl, pyridinyl, pyrimidinyl, pyrazinyl, or pyridazinyl,
wherein R.sup.4 is optionally substituted with one or more groups
selected from the group consisting of halo, hydroxyl,
C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 haloalkyl,
mono(C.sub.1-C.sub.3)alkylamino, di(C.sub.1-C.sub.3)alkylamino,
--NR.sub.aR.sub.b, --OR.sub.a, --CN, --C(.dbd.O)R.sub.a,
--C(.dbd.O)OR.sub.a, --OC(.dbd.O)R.sub.a, --OC(.dbd.O)OR.sub.a,
--SR.sub.a, furanyl, pyrazolyl, imidazolyl, isothiazolyl,
thiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl and
pyrrolyl; and R.sub.a and R.sub.b are independently --H, halo,
amino, C.sub.1-C.sub.3 alkyl, or C.sub.1-C.sub.3 haloalkyl.
4. The method of claim 1, wherein R.sup.1 is cyclopropyl or
substituted with one or more groups selected from the group
consisting of fluoro, methyl, ethyl, hydroxymethyl, hydroxyethyl,
and methylaminom ethyl.
5. The method of claim 1, wherein R.sup.1 is fluorocyclopropyl,
hydroxycyclopropyl, hydroxymethylcyclopropyl, difluorocyclopropyl,
or methylaminomethylcyclopropyl; and R.sup.2 and R.sup.3 are
independently --H, methyl, or fluoro.
6. The method of claim, wherein R.sup.4 is fluoro-methylphenyl,
fluoro-hydroxymethylphenyl, chloro-methylphenyl, dimethylphenyl,
acetamido-methylphenyl, hydroxy-methylphenyl,
hydroxypropanyl-methylphenyl, methyl-propenylphenyl,
methyl-pyridinylethynylphenyl, methyl-pyrrolylphenyl,
methyl-thiazolylphenyl, imidazolyl-methylphenyl,
cyano-methylphenyl, methyl-pyrazolylphenyl, ethynyl-methylphenyl,
methylpyridinyl, fluoro-methyl-methylaminophenyl,
dimethylpyridinyl, fluoro-methylpyridinyl,
fluoromethyl-methylpyridinyl, cyanopyridinyl,
trifluoromethyl-methylpyridinyl, hydroxymethylpyridinyl,
hydroxymethyl-methylpyridinyl, hydroxyethyl-methylpyridinyl,
chloro-methylpyridinyl, aminopyridinyl, acetyl-methylpyridinyl,
amino-dimethylpyridinyl, hydroxyethyl-methylpyridinyl,
methylpyrimidinyl, dimethylpyrimidinyl, or
trifluoromethylpyrimidinyl.
7. The method of claim 1, wherein R.sup.4 is fluoro-methylphenyl,
fluoro-hydroxymethylphenyl, chloro-methylphenyl, dimethylphenyl,
acetamido-methylphenyl, hydroxyl-methylphenyl,
methyl-propenylphenyl, ethynyl-methylphenyl,
fluoro-methyl-methylaminophenyl, fluoro-hydroxyl-methylphenyl,
methyl-methylaminophenyl, methyl-pyrrolylphenyl,
methyl-thiazolylphenyl, cyano-methylphenyl,
imidazolyl-methylphenyl, methylpyridinyl, chloro-methylpyridinyl,
fluoro-methylpyridinyl, fluoromethyl-methylpyridinyl,
bimethylpyridinyl, aminopyridinyl, amino-dimethylpyridinyl,
methoxypyridinyl, acetyl-methylpyridinyl, hydroxymethylpyridinyl,
hydroxymethyl-methylpyridinyl, hydroxyethyl-methylpyridinyl,
cyanopyridinyl, trifluoromethylpyridinyl, methylpyrimidinyl, or
dimethylpyrimidinyl.
8. The method of claim 1, wherein R.sup.4 is selected from the
group consisting of phenyl, pyridinyl, and pyrimidinyl, wherein
R.sup.4 is optionally substituted with one or more groups selected
from the group consisting of halo, alkyl, alkynyl, hydroxyalkyl,
amino, cyano, acetyl, hydroxy, and haloalkyl.
9. The method of claim 1, wherein R.sup.4 is selected from the
group consisting of: ##STR00135## ##STR00136## ##STR00137##
##STR00138##
10. The method of claim 1, wherein R.sup.1 is
fluorocyclopropyl.
11. The method of claim 10, wherein R.sup.2 and R.sup.3 are H;
R.sup.4 is phenyl, pyridinyl, or indolinyl, wherein R.sup.4 is
optionally substituted with one or more groups selected from the
group consisting of halo, hydroxyl, alkyl, haloalkyl, hydroxyalkyl,
cycloalkyl, alkoxyalkyl, alkoxyalkoxy, alkylaminoalkyl,
--NR.sub.aR.sub.b, --NR.sub.aC(.dbd.O)R.sub.b, --OR.sub.a,
--SR.sub.a, --CN, --C(.dbd.O)R.sub.a, --C(.dbd.O)OR.sub.a,
--C(.dbd.O)NR.sub.aR.sub.b, --OC(.dbd.O)R.sub.a, furanyl, or
pyrrolyl; R.sub.a and R.sub.b are independently --H, halo, amino,
alkyl, or haloalkyl; and R.sup.5 is --H, halo, or methyl.
12. The method of claim 1, wherein the compound is a compound of
Formula (II): ##STR00139## wherein R.sup.6 is selected from the
group consisting of halo, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3
hydroxyalkyl and C.sub.1-C.sub.3 haloalkyl.
13. The method of claim 12, wherein R.sup.2 and R.sup.3 are --H;
R.sup.4 is phenyl or pyridinyl, wherein R.sup.4 is optionally
substituted with one or more groups selected from the group
consisting of halo, hydroxyl, alkyl, haloalkyl, hydroxyalkyl,
cycloalkyl, alkoxyalkyl, alkoxyalkoxy, alkylaminoalkyl,
--NR.sub.aR.sub.b, --NR.sub.aC(.dbd.O)R.sub.b, --OR.sub.a,
--SR.sub.a, --CN, --C(.dbd.O)R.sub.a, --C(.dbd.O)OR.sub.a,
--C(.dbd.O)NR.sub.aR.sub.b, --OC(.dbd.O)R.sub.a, furanyl, or
pyrrolyl; R.sub.a and R.sub.b are independently --H, halo, amino,
alkyl, or haloalkyl; and R.sup.5 is --H, halo, or alkyl.
14. The method of claim 12, wherein the compound is selected from
the group consisting of:
2-fluoro-N-(6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclopr-
opane-1-carboxamide;
2-fluoro-N-(6-(2-fluoro-6-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclopr-
opane-1-carboxamide;
N-(3-chloro-6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluo-
rocyclopropane-1-carboxamide;
N-(3-chloro-6-(2-fluoro-6-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluo-
rocyclopropane-1-carboxamide;
2-fluoro-N-(3-methyl-6-(4-methylpyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)c-
yclopropane-1-carboxamide;
2-fluoro-N-(6-(4-methylpyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)cyclopropa-
ne-1-carboxamide;
N-(3-chloro-6-(4-methylpyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)-2-fluoroc-
yclopropane-1-carboxamide;
2-fluoro-N-(6-(3-fluoro-2-methylphenyl)-3-methylimidazo[1,2-a]pyridin-2-y-
l)cyclopropane-1-carboxamide;
2-fluoro-N-(6-(2-fluoro-6-methylphenyl)-3-methylimidazo[1,2-a]pyridin-2-y-
l)cyclopropane-1-carboxamide;
2-fluoro-N-(6-(5-fluoro-4-methylpyridin-3-yI)-3-methylimidazo[1,2-a]pyrid-
in-2-yl)cyclopropane-1-carboxamide;
2-fluoro-N-(6-(5-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclopr-
opane-1-carboxamide;
2-fluoro-N-(6-(5-hydroxy-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclop-
ropane-1-carboxamide;
methyl-3-(2-(2-fluorocyclopropane-1-carboxamido)imidazo[1,2-a]pyridin-6-y-
l)-4-methylbenzoate;
2-fluoro-N-(6-(5-fluoro-4-methylpyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)c-
yclopropane-1-carboxamide;
N-(3-chloro-6-(5-fluoro-4-methylpyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)--
2-fluorocyclopropane-1-carboxamide;
N-(6-(5-cyano-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopro-
pane-1-carboxamide;
2-fluoro-N-(6-(3-hydroxy-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclop-
ropane-1-carboxamide;
N-(6-(4-chloropyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopropa-
ne-1-carboxamide;
N-(6-(2,3-dimethylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopropane-
-1-carboxamide;
N-(6-(5-amino-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopro-
pane-1-carboxamide;
2-fluoro-N-(6-(2-methyl-5-(methylamino)phenyl)imidazo[1,2-a]pyridin-2-yl)-
cyclopropane-1-carboxamide;
N-(6-(5-acetamido-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocycl-
opropane-1-carboxamide;
N-(6-(5-chloro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopr-
opane-1-carboxamide;
N-(6-(3-chloro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopr-
opane-1-carboxamide;
2-fluoro-N-(6-(4-(trifluoromethyl)pyridin-3-yl)imidazo[1,2-a]pyridin-2-yl-
)cyclopropane-1-carboxamide;
N-(6-(2,4-dimethylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopropane-
-1-carboxamide;
2-fluoro-N-(3-fluoro-6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropane-1-carboxamide;
N-(6-(2,5-dimethylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopropane-
-1-carboxamide;
N-(6-(4-cyanopyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopropan-
e-1-carboxamide;
2-fluoro-N-(6-(4-fluoro-2,3-dimethylphenyl)imidazo[1,2-a]pyridin-2-yl)cyc-
lopropane-1-carboxamide;
2-fluoro-N-(6-(4-fluoro-2,6-dimethylphenyl)imidazo[1,2-a]pyridin-2-yl)cyc-
lopropane-1-carboxamide;
2-fluoro-N-(6-(4-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclopr-
opane-1-carboxamide; 2-fluoro-N-(6-(2-methyl-5-(1
H-pyrrol-3-yl)phenyl)imidazo[l
,2-a]pyridin-2-yl)cyclopropane-1-carboxamide;
N-(6-(2,6-dimethylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopropane-
-1-carboxamide;
2-fluoro-N-(6-(4-fluoro-5-hydroxy-2-methylphenyl)imidazo[1,2-a]pyridin-2--
yl)cyclopropane-1-carboxamide;
N-(6-(3,4-difluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyc-
lopropane-1-carboxamide;
N-(6-(3,6-difluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyc-
lopropane-1-carboxamide;
N-(6-(4-chloro-3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluo-
rocyclopropane-1-carboxamide;
2-fluoro-N-(6-(2-fluoro-4-methylpyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)c-
yclopropane-1-carboxamide;
2-fluoro-N-(6-(4-methoxypyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)cycloprop-
ane-1-carboxamide;
N-(6-(6-amino-4-methylpyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocy-
clopropane-1-carboxamide;
N-(6-(5-amino-3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluor-
ocyclopropane-1-carboxamide;
N-(6-(2-chloro-6-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopr-
opane-1-carboxamide;
N-(6-(6-aminopyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopropan-
e-1-carboxamide;
2-fluoro-N-(6-(2-methyl-5-(1H-pyrazol-1-yl)phenyl)imidazo[1,2-a]pyridin-2-
-yl)cyclopropane-1-carboxamide;
2-fluoro-N-(6-(3-fluoro-2-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropane-1-carboxamide;
N-(3-bromo-6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluor-
ocyclopropane-1-carboxamide;
2-fluoro-N-(6-(3-fluoro-2-methoxyphenyl)imidazo[1,2-a]pyridin-2-yl)cyclop-
ropanecarboxamide;
N-(6-(2-cyano-3-fluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopro-
panecarboxamide;
N-(6-(2-chloro-3-fluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopr-
opanecarboxamide;
N-(6-(2,3-difluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopropane-
carboxamide;
2-fluoro-N-(6-(3-fluoro-2-(methoxymethyl)phenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropanecarboxamide;
2-fluoro-N-(6-(3-fluoro-2-(furan-2-yl)phenyl)imidazo[1,2-a]pyridin-2-yl)c-
yclopropanecarboxamide;
2-fluoro-N-(6-(3-fluoro-2-(methylthio)phenyl)imidazo[1,2-a]pyridin-2-yl)c-
yclopropanecarboxamide;
2-fluoro-N-(6-(6-fluoro-4-methylpyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)c-
yclopropanecarboxamide;
N-(6-(2-acetyl-3-fluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopr-
opanecarboxamide;
N-(6-(6-(dimethylamino)-4-methylpyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)--
2-fluorocyclopropanecarboxamide;
2-fluoro-N-(6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclopr-
opanecarboxamide;
2-fluoro-N-(6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclopr-
opanecarboxamide;
2-fluoro-N-(6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclopr-
opanecarboxamide;
N-(6-(2-(aminomethyl)-3-fluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluoro-
cyclopropanecarboxamide; N-(6-(2-(acetam
idomethyl)-3-fluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopropan-
ecarboxamide;
2,2-difluoro-N-(6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyc-
lopropanecarboxamide;
2-fluoro-N-(6-(3-fluoro-2-((methylamino)methyl)phenyl)imidazo[1,2-a]pyrid-
in-2-yl)cyclopropanecarboxamide;
2-fluoro-N-(6-(3-fluoro-2-((isopropylamino)methyl)phenyl)imidazo[1,2-a]py-
ridin-2-yl)cyclopropanecarboxamide;
2-fluoro-N-(6-(3-fluoro-2-((2-methoxyethoxy)methyl)phenyl)imidazo[1,2-a]p-
yridin-2-yl)cyclopropanecarboxamide;
2-fluoro-N-(6-(3-fluoro-2-((2-hydroxyethoxy)methyl)phenyl)imidazo[1,2-a]p-
yridin-2-yl)cyclopropanecarboxamide;
N-(6-(2-((dimethylamino)methyl)-3-fluorophenyl)imidazo[1,2-a]pyridin-2-yl-
)-2-fluorocyclopropanecarboxamide;
2-fluoro-N-(6-(o-tolyl)imidazo[1,2-a]pyridin-2-yl)cyclopropanecarboxamide-
;
2-fluoro-N-(6-(3-fluoro-2-hydroxyphenyl)imidazo[1,2-a]pyridin-2-yl)cyclo-
propanecarboxamide;
N-(6-(2-amino-3-fluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopro-
panecarboxamide;
N-(6-(2-(dimethylamino)-3-fluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluo-
rocyclopropanecarboxamide;
N-(6-(2-ethyl-3-fluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopro-
panecarboxamide;
2-fluoro-N-(6-(3-fluoro-2-(trifluoromethyl)phenyl)imidazo[1,2-a]pyridin-2-
-yl)cyclopropanecarboxamide;
N-(6-(2-cyclopropyl-3-fluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocy-
clopropanecarboxamide;
2-fluoro-N-(6-(3-fluoro-2-(methylamino)phenyl)imidazo[1,2-a]pyridin-2-yl)-
cyclopropanecarboxamide;
2-fluoro-N-(6-(3-fluoro-2-isopropylphenyl)imidazo[1,2-a]pyridin-2-yl)cycl-
opropanecarboxamide;
2-fluoro-N-(6-(3-fluoro-2-(trifluoromethyl)phenyl)imidazo[1,2-a]pyridin-2-
-yl)cyclopropane-1-carboxamide;
2-fluoro-N-(6-(3-fluoro-2,6-dimethylphenyl)imidazo[1,2-a]pyridin-2-yl)cyc-
lopropane-1-carboxamide;
N-(6-(2-ethyl-6-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopro-
pane-1-carboxamide
N-(6-(4-acetyl-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopr-
opane-1-carboxamide;
N-(6-(2-chloro-3,4-difluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyc-
lopropane-1-carboxamide;
N-(6-(2-chloro-3,6-difluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyc-
lopropane-1-carboxamide;
2-fluoro-N-(6-(3-fluoro-2-methylphenyl)-8-(trifluoromethyl)imidazo[1,2-a]-
pyridin-2-yl)cyclopropane-1-carboxamide;
N-(8-(difluoromethyl)-6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2--
yl)-2-fluorocyclopropane-1-carboxamide;
2-fluoro-N-(6-(3-fluoro-2-methylphenyl)-8-(fluoromethyl)imidazo[1,2-a]pyr-
idin-2-yl)cyclopropane-1-carboxamide;
2-fluoro-N-(8-fluoro-6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropane-1-carboxamide;
2-fluoro-N-(7-fluoro-6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropane-1-carboxamide;
2-fluoro-N-(6-(4-fluoro-2-methylphenyl)-8-(trifluoromethyl)imidazo[1,2-a]-
pyridin-2-yl)cyclopropane-1-carboxamide;
N-(8-(difluoromethyl)-6-(4-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2--
yl)-2-fluorocyclopropane-1-carboxamide;
2-fluoro-N-(6-(4-fluoro-2-methylphenyl)-8-(fluoromethyl)imidazo[1,2-a]pyr-
idin-2-yl)cyclopropane-1-carboxamide;
2-fluoro-N-(8-fluoro-6-(4-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropane-1-carboxamide;
2-fluoro-N-(7-fluoro-6-(4-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropane-1-carboxamide;
2-fluoro-N-(6-(5-fluoro-2-methylphenyl)-8-(trifluoromethyl)imidazo[1,2-a]-
pyridin-2-yl)cyclopropane-1-carboxamide;
N-(8-(difluoromethyl)-6-(5-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2--
yl)-2-fluorocyclopropane-1-carboxamide;
2-fluoro-N-(6-(5-fluoro-2-methylphenyl)-8-(fluoromethyl)imidazo[1,2-a]pyr-
idin-2-yl)cyclopropane-1-carboxamide;
2-fluoro-N-(8-fluoro-6-(5-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropane-1-carboxamide;
2-fluoro-N-(7-fluoro-6-(5-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropane-1-carboxamide;
2-fluoro-N-(6-(2-fluoro-6-methylphenyl)-8-(trifluoromethyl)imidazo[1,2-a]-
pyridin-2-yl)cyclopropane-1-carboxamide;
N-(8-(difluoromethyl)-6-(2-fluoro-6-methylphenyl)imidazo[1,2-a]pyridin-2--
yl)-2-fluorocyclopropane-1-carboxamide;
2-fluoro-N-(6-(2-fluoro-6-methylphenyl)-8-(fluoromethyl)imidazo[1,2-a]pyr-
idin-2-yl)cyclopropane-1-carboxamide;
2-fluoro-N-(8-fluoro-6-(2-fluoro-6-methylphenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropane-1-carboxamide; and
2-fluoro-N-(7-fluoro-6-(2-fluoro-6-methylphenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropane-1-carboxamide.
15. The method of claim 12, wherein the compound is selected from
the group consisting of:
2-fluoro-N-(6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclopr-
opane-1-carboxamide;
2-fluoro-N-(6-(2-fluoro-6-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclopr-
opane-1-carboxamide;
N-(3-chloro-6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluo-
rocyclopropane-1-carboxamide;
N-(3-chloro-6-(2-fluoro-6-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluo-
rocyclopropane-1-carboxamide'
2-fluoro-N-(6-(3-fluoro-2-methylphenyl)-3-methylimidazo[1,2-a]pyridin-2-y-
l)cyclopropane-1-carboxamide;
2-fluoro-N-(6-(2-fluoro-6-methylphenyl)-3-methylimidazo[1,2-a]pyridin-2-y-
l)cyclopropane-1-carboxamide;
2-fluoro-N-(6-(5-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclopr-
opane-1-carboxamide;
2-fluoro-N-(6-(5-hydroxy-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclop-
ropane-1-carboxamide;
2-fluoro-N-(6-(3-hydroxy-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclop-
ropane-1-carboxamide;
N-(6-(2,3-dimethylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopropane-
-1-carboxamide;
2-fluoro-N-(6-(2-methyl-5-(methylamino)phenyl)imidazo[1,2-a]pyridin-2-yl)-
cyclopropane-1-carboxamide;
N-(6-(2,4-dimethylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopropane-
-1-carboxamide;
2-fluoro-N-(3-fluoro-6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropane-1-carboxamide;
N-(6-(2,5-dimethylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopropane-
-1-carboxamide;
2-fluoro-N-(6-(2-methyl-5-(1H-pyrrol-3-yl)phenyl)imidazo[1,2-a]pyridin-2--
yl)cyclopropane-1-carboxamide;
N-(6-(2,6-dimethylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopropane-
-1-carboxamide;
2-fluoro-N-(6-(4-fluoro-5-hydroxy-2-methylphenyl)imidazo[1,2-a]pyridin-2--
yl)cyclopropane-1-carboxamide;
N-(3-bromo-6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluor-
ocyclopropane-1-carboxamide;
2-fluoro-N-(6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclopr-
opanecarboxamide;
2-fluoro-N-(6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclopr-
opanecarboxamide; and
2-fluoro-N-(6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclopr-
opanecarboxamide.
16. The method of claim 1, wherein the compound is a compound of
Formula (III): ##STR00140## wherein R.sup.6 is selected from the
group consisting of halo, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3
hydroxyalkyl and C.sub.1-C.sub.3 haloalkyl.
17. The method of claim 16, wherein R.sup.2 and R.sup.3 are --H;
R.sup.4 is phenyl or pyridinyl wherein R.sup.4 is optionally
substituted with one or more groups selected from the group
consisting of halo, hydroxyl, alkyl, haloalkyl, hydroxyalkyl,
cycloalkyl, alkoxyalkyl, alkoxyalkoxy, alkylaminoalkyl,
--NR.sub.aR.sub.b, --NR.sub.aC(.dbd.O)R.sub.b, --OR.sub.a,
--SR.sub.a, --CN, --C(.dbd.O)R.sub.a, --C(.dbd.O)OR.sub.a,
--C(.dbd.O)NR.sub.aR.sub.b, --OC(.dbd.O)R.sub.a, furanyl, or
pyrrolyl; R.sub.a and R.sub.b are independently --H, halo, amino,
alkyl, or haloalkyl; and R.sup.5 is --H, halo, or alkyl.
18. The method of claim 16, wherein the compound is selected from
the group consisting of: (1 S,2
S)-2-fluoro-N-(6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cycl-
opropane-1-carboxamide; (1 S,2
S)-2-fluoro-N-(6-(2-fluoro-6-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cycl-
opropane-1-carboxamide; (1 S,2
S)-N-(3-chloro-6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-f-
luorocyclopropane-1-carboxamide; (1 S,2
S)-N-(3-chloro-6-(2-fluoro-6-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-f-
luorocyclopropane-1-carboxamide; (1 S,2
S)-2-fluoro-N-(3-methyl-6-(4-methylpyridin-3-yl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropane-1-carboxamide; (1 S,2
S)-2-fluoro-N-(6-(4-methylpyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)cyclopr-
opane-1-carboxamide; (1 S,2
S)-N-(3-chloro-6-(4-methylpyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)-2-fluo-
rocyclopropane-1-carboxamide; (1 S,2
S)-2-fluoro-N-(6-(3-fluoro-2-methylphenyl)-3-methylimidazo[1,2-a]pyridin--
2-yl)cyclopropane-1-carboxamide; (1 S,2
S)-2-fluoro-N-(6-(2-fluoro-6-methylphenyl)-3-methylimidazo[1,2-a]pyridin--
2-yl)cyclopropane-1-carboxamide; (1 S,2
S)-2-fluoro-N-(6-(5-fluoro-4-methylpyridin-3-yl)-3-methylimidazo[1,2-a]py-
ridin-2-yl)cyclopropane-1-carboxamide; (1 S,2
S)-2-fluoro-N-(6-(5-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cycl-
opropane-1-carboxamide; (1 S,2
S)-2-fluoro-N-(6-(5-hydroxy-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyc-
lopropane-1-carboxamide; methyl 3-(2-((1 S,2
S)-2-fluorocyclopropane-1-carboxamido)imidazo[1,2-a]pyridin-6-yl)-4-methy-
lbenzoate; (1 S,2
S)-2-fluoro-N-(6-(5-fluoro-4-methylpyridin-3-yl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropane-1-carboxamide; (1 S,2
S)-N-(3-chloro-6-(5-fluoro-4-methylpyridin-3-yl)imidazo[1,2-a]pyridin-2-y-
l)-2-fluorocyclopropane-1-carboxamide; (1 S,2
S)-N-(6-(5-cyano-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclo-
propane-1-carboxamide; (1 S,2
S)-2-fluoro-N-(6-(3-hydroxy-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyc-
lopropane-1-carboxamide; (1 S,2
S)-N-(6-(4-chloropyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopr-
opane-1-carboxamide; (1 S,2
S)-N-(6-(2,3-dimethylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocycloprop-
ane-1-carboxamide; (1 S,2
S)-N-(6-(5-amino-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclo-
propane-1-carboxamide; (1 S,2
S)-2-fluoro-N-(6-(2-methyl-5-(methylamino)phenyl)imidazo[1,2-a]pyridin-2--
yl)cyclopropane-1-carboxamide; (1 S,2
S)-N-(6-(5-acetamido-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluoroc-
yclopropane-1-carboxamide; (1 S,2
S)-N-(6-(5-chloro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocycl-
opropane-1-carboxamide; (1 S,2
S)-2-fluoro-N-(6-(2-methyl-5-(1H-pyrazol-3-yl)phenyl)imidazo[1,2-a]pyridi-
n-2-yl)cyclopropane-1-carboxamide; (1 S,2
S)-N-(6-(4-chloro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocycl-
opropane-1-carboxamide; (1 S,2
S)-N-(6-(3-chloro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocycl-
opropane-1-carboxamide; (1 S,2
S)-2-fluoro-N-(6-(4-(trifluoromethyl)pyridin-3-yl)imidazo[1,2-a]pyridin-2-
-yl)cyclopropane-1-carboxamide; (1 S,2
S)-N-(6-(2,4-dimethylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocycloprop-
ane-1-carboxamide; (1 S,2
S)-2-fluoro-N-(3-fluoro-6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin--
2-yl)cyclopropane-1-carboxamide; (1 S,2
S)-N-(6-(2,5-dimethylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocycloprop-
ane-1-carboxamide; (1 S,2
S)-N-(6-(4-cyanopyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopro-
pane-1-carboxamide; (1 S,2
S)-2-fluoro-N-(6-(4-fluoro-2,3-dimethylphenyl)imidazo[1,2-a]pyridin-2-yl)-
cyclopropane-1-carboxamide; (1 S,2
S)-2-fluoro-N-(6-(4-fluoro-2,6-dimethylphenyl)imidazo[1,2-a]pyridin-2-yl)-
cyclopropane-1-carboxamide; (1 S,2
S)-2-fluoro-N-(6-(4-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cycl-
opropane-1-carboxamide; (1 S,2
S)-2-fluoro-N-(6-(2-methyl-5-(1H-pyrrol-3-yl)phenyl)imidazo[1,2-a]pyridin-
-2-yl)cyclopropane-1-carboxamide; (1 S,2
S)-2-fluoro-N-(6-(3-methylthiophen-2-yl)imidazo[1,2-a]pyridin-2-yl)cyclop-
ropane-1-carboxamide; (1 S,2
S)-N-(6-(2,6-dimethylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocycloprop-
ane-1-carboxamide; (1 S,2
S)-2-fluoro-N-(6-(4-fluoro-5-hydroxy-2-methylphenyl)imidazo[1,2-a]pyridin-
-2-yl)cyclopropane-1-carboxamide; (1 S,2
S)-N-(6-(3,4-difluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluoro-
cyclopropane-1-carboxamide; (1 S,2
S)-N-(6-(3,6-difluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluoro-
cyclopropane-1-carboxamide; (1 S,2
S)-N-(6-(4-chloro-3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-f-
luorocyclopropane-1-carboxamide; (1 S,2
S)-2-fluoro-N-(6-(2-fluoro-4-methylpyridin-3-yl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropane-1-carboxamide; (1 S,2
S)-2-fluoro-N-(6-(4-methoxypyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)cyclop-
ropane-1-carboxamide; (1 S,2
S)-N-(6-(6-amino-4-methylpyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)-2-fluor-
ocyclopropane-1-carboxamide; (1 S,2
S)-N-(6-(5-amino-3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fl-
uorocyclopropane-1-carboxamide; (1 S,2
S)-N-(6-(2-chloro-6-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocycl-
opropane-1-carboxamide; (1 S,2
S)-N-(6-(6-aminopyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopro-
pane-1-carboxamide; (1 S,2
S)-2-fluoro-N-(6-(2-methyl-5-(1H-pyrazol-1-yl)phenyl)imidazo[1,2-a]pyridi-
n-2-yl)cyclopropane-1-carboxamide; (1 S,2
S)-2-fluoro-N-(6-(3-fluoro-2-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin--
2-yl)cyclopropane-1-carboxamide; (1 S,2
S)-N-(3-bromo-6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fl-
uorocyclopropane-1-carboxamide; (1 S,2
S)-2-fluoro-N-(6-(3-fluoro-2-methoxyphenyl)imidazo[1,2-a]pyridin-2-yl)cyc-
lopropanecarboxamide; (1 S,2
S)-N-(6-(2-cyano-3-fluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclo-
propanecarboxamide; (1 S,2
S)-N-(6-(2-chloro-3-fluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocycl-
opropanecarboxamide; (1 S,2
S)-N-(6-(2,3-difluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocycloprop-
anecarboxamide; (1 S,2
S)-2-fluoro-N-(6-(3-fluoro-2-(methoxymethyl)phenyl)imidazo[1,2-a]pyridin--
2-yl)cyclopropanecarboxamide; (1 S,2
S)-2-fluoro-N-(6-(3-fluoro-2-(furan-2-yl)phenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropanecarboxamide; (1 S,2
S)-2-fluoro-N-(6-(3-fluoro-2-(methylthio)phenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropanecarboxamide; (1 S,2
S)-2-fluoro-N-(6-(6-fluoro-4-methylpyridin-3-yl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropanecarboxamide; (1 S,2
S)-N-(6-(2-acetyl-3-fluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocycl-
opropanecarboxamide; (1 S,2
S)-N-(6-(6-(dimethylamino)-4-methylpyridin-3-yl)imidazo[1,2-a]pyridin-2-y-
l)-2-fluorocyclopropanecarboxamide; (1 S,2
S)-N-(6-(2-(aminomethyl)-3-fluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-flu-
orocyclopropanecarboxamide; (1 S,2
S)-N-(6-(2-(acetamidomethyl)-3-fluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-
-fluorocyclopropanecarboxamide; (1 S,2
S)-2-fluoro-N-(6-(3-fluoro-2-((methylamino)methyl)phenyl)imidazo[1,2-a]py-
ridin-2-yl)cyclopropanecarboxamide; (1 S,2
S)-2-fluoro-N-(6-(3-fluoro-2-((isopropylamino)methyl)phenyl)imidazo[1,2-a-
]pyridin-2-yl)cyclopropanecarboxamide; (1 S,2
S)-2-fluoro-N-(6-(3-fluoro-2-((2-methoxyethoxy)methyl)phenyl)imidazo[1,2--
a]pyridin-2-yl)cyclopropanecarboxamide; (1 S,2
S)-2-fluoro-N-(6-(3-fluoro-2-((2-hydroxyethoxy)methyl)phenyl)imidazo[1,2--
a]pyridin-2-yl)cyclopropanecarboxamide; (1 S,2
S)-N-(6-(2-((dimethylamino)methyl)-3-fluorophenyl)imidazo[1,2-a]pyridin-2-
-yl)-2-fluorocyclopropanecarboxamide; (1 S,2
S)-2-fluoro-N-(6-(o-tolypimidazo[1,2-a]pyridin-2-yl)cyclopropanecarboxami-
de; (1 S,2
S)-2-fluoro-N-(6-(3-fluoro-2-hydroxyphenyl)imidazo[1,2-a]pyridi-
n-2-yl)cyclopropanecarboxamide; (1 S,2
S)-N-(6-(2-amino-3-fluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclo-
propanecarboxamide; (1 S,2
S)-N-(6-(2-(dimethylamino)-3-fluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-f-
luorocyclopropanecarboxamide; (1 S,2
S)-N-(6-(2-ethyl-3-fluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclo-
propanecarboxamide; (1 S,2
S)-2-fluoro-N-(6-(3-fluoro-2-(trifluoromethyl)phenyl)imidazo[1,2-a]pyridi-
n-2-yl)cyclopropanecarboxamide; (1 S,2
S)-N-(6-(2-cyclopropyl-3-fluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluor-
ocyclopropanecarboxamide; (1 S,2
S)-2-fluoro-N-(6-(3-fluoro-2-(methylamino)phenyl)imidazo[1,2-a]pyridin-2--
yl)cyclopropanecarboxamide; (1 S,2
S)-2-fluoro-N-(6-(3-fluoro-2-isopropylphenyl)imidazo[1,2-a]pyridin-2-yl)c-
yclopropanecarboxamide.
19. The method of claim 16, which is selected from the group
consisting of: (1 S,2
S)-2-fluoro-N-(6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cycl-
opropane-1-carboxamide; (1 S,2
S)-2-fluoro-N-(6-(5-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cycl-
opropane-1-carboxamide; (1 S,2
S)-2-fluoro-N-(6-(5-hydroxy-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyc-
lopropane-1-carboxamide; (1 S,2
S)-N-(6-(4-chloropyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopr-
opane-1-carboxamide; (1 S,2
S)-2-fluoro-N-(6-(2-methyl-5-(methylamino)phenyl)imidazo[1,2-a]pyridin-2--
yl)cyclopropane-1-carboxamide; (1 S,2
S)-2-fluoro-N-(6-(3-methylthiophen-2-yl)imidazo[1,2-a]pyridin-2-yl)cyclop-
ropane-1-carboxamide; and (1 S,2
S)-N-(6-(3,4-difluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluoro-
cyclopropane-1-carboxamide.
20. (canceled)
21. (canceled)
22. (canceled)
23. (canceled)
24. The method of claim 1, wherein the salt is hydrochloric acid
salt, tartaric acid salt, phosphoric acid salt, or maleic acid
salt.
25. The method of claim 1, wherein the compound is administered in
a form of a pharmaceutical composition comprising at least one
pharmaceutically acceptable carrier.
26. The method of claim 25, wherein the composition further
comprises one or more active ingredient that is useful to treat
cancer.
27. The method of claim 1, wherein the cancer is selected from the
group consisting of acute lymphocytic leukemia, acute myelogeneous
leukemia, chronic myelogenous leukemia, chronic lymphocytic
leukemia, gastrointestinal stromal tumors, systemic mastocytosis,
melanoma, seminoma, intercranial germ cell tumors, and Non-Hodgkin
lymphoma (NHL).
28. The method of claim 1, wherein the cancer is selected from the
group consisting of breast cancer, ovarian cancer, and non-small
cell lung cancer.
29. The method of claim 1, wherein the cancer is selected from the
group consisting of systemic mastocytosis, gastrointestinal stromal
tumor, acute myeloid leukemia, melanoma, and seminoma.
30. The method of claim 1, wherein the cancer is selected from the
group consisting of Ewing's sarcoma, diffuse large B cell lymphoma,
dysgerminoma, myelodysplastic syndrome, nasal NK/T-cell lymphoma,
chronic myelomonocytic leukemia, and brain cancer.
31. The method of claim 1, wherein the cancer is selected from the
group consisting of gastrointestinal stromal tumor (GIST), stomach
cancer, colorectal cancer, melanoma, chronic lymphocytic leukemia
(CLL), acute lymphocytic leukemia (ALL), and acute myelogeneous
leukem ia(AML).
32. The method of claim 1, wherein the cancer is selected from the
group consisting of gastrointestinal stromal tumor (GIST), melanoma
and chronic lymphocytic leukemia (CLL).
33. The method of claim 1, wherein the subject is a human.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application claims the benefit and priority to U.S.
Provisional Patent Application No. 62/809,230, filed on 22 Feb.
2019. The entire disclosure of the application identified in this
paragraph is incorporated herein by reference.
FIELD
[0002] The present disclosure generally relates to compounds having
enzyme inhibitory activity, pharmaceutical compositions comprising
the compound, and methods of using the compounds for treating
cancer and/or proliferative disorders.
BACKGROUND
[0003] The c-Abl protein is a tightly regulated nonreceptor
tyrosine kinase that is involved in the regulation of cell
proliferation, cell survival, cell adhesion, cell migration and
apoptosis. The c-Abl protein is located both in the nucleus and the
cytoplasm. In the nucleus, c-Abl protein is known to be activated
in response to DNA damage and contributes to apoptosis (Wang,
2000). Cytoplasmic c-Abl is associated with growth factor receptor
signaling that can affect cell mobility and cell adhesion
(Taagepera et al., 1998). The oncogenic effects of Abl are believed
to reside in cytoplasmic forms of c-Abl. Several studies have shown
that c-Abl is downregulated in part by intramolecular interactions
that provide autoinhibitory kinase effects (Pendergast, 2002; Pluk
et al., 2002; Hantschel et al., 2003). Studies have also found that
c-Abl kinase activity is regulated by intermolecular interactions
with negative regulators, which include Bcr (Liu et al., 1996; Ling
et al., 2003), PAG (Wen and Van Etten, 1997), F-actin (Woodring et
al., 2003) and phosphoinositides (Plattner and Pendergast,
2003).
[0004] The c-Abl protein is widely expressed in all tissues and
until recently oncogenically activated forms of Abl were believed
to be restricted to hematopoietic malignancies, principally chronic
myeloid leukemia (CML) and to a lesser degree in acute lymphocytic
B-cell leukemia. Over 95% of CML patients have an abnormal
chromosome 22 known as the Philadelphia chromosome (Ph). The Ph
fuses 50 portions of BCR to the second exon of the c-ABL gene. The
first exon of c-ABL encodes sequences involved in the
autoinhibition of the c-Abl tyrosine kinase, so deletion of these
sequences is thought to contribute to the activated state of the
Abl tyrosine kinase domain.
[0005] Recent findings demonstrate that activated c-Abl tyrosine
kinase may also play a role in non-small cell lung cancer (NSCLC)
(Lin et al., 2005, 2007). Activation of c-Abl tyrosine kinase in
some solid tumors is further supported by studies from Plattner and
co-workers (Srinivasan and Plattner, 2006; Srinivasan et al.,
2008), whose findings indicate active c-Abl tyrosine kinase plays a
role in aggressive human breast cancer cell lines (J Lin and R
Arlinghaus; Oncogene 2008, 27, 4385).
[0006] The enzyme KIT (also called CD 117) is a receptor tyrosine
kinase expressed on a wide variety of cell types. The KIT molecule
contains a long extracellular domain, a transmembrane segment, and
an intracellular portion. The ligand for KIT is stem cell factor
(SCF), whose binding to the extracellular domain of KIT induces
receptor dimerization and activation of downstream signaling
pathways. KIT mutations generally occur in the DNA encoding the
juxtumembrane domain (exon 11). They also occur, with less
frequency, in exons 7, 8, 9, 13, 14, 17, and 18. Mutations make KIT
function independent of activation by SCF, leading to a high cell
division rate and possibly genomic instability. Mutant KIT has been
implicated in the pathogenesis of several disorders and conditions
including systemic mastocytosis, GIST (gastrointestinal stromal
tumors), AML (acute myeloid leukemia), melanoma, and seminoma. As
such, there is a need for therapeutic agents that inhibit KIT, and
especially agents that inhibit mutant KIT.
[0007] Platelet-derived growth factor (PDGF) has been studied in
relation to tumor angiogenesis binds to a large spectrum of
mesoderm-derived cells such as fibroblasts, pericytes, glial or
mesangial cells. PDGF isoforms bind two distinct receptors,
PDGF-alpha and -beta, and this mechanism induces receptor
autophosphorylation and activation of several signaling molecules.
PDGF receptors are expressed in tumor cells and stromal cells in
both normal and tumoral tissue. They play an important role in
tumor progression as being part of a group of receptors that are
expressed along the membrane of tumor cells (Adina Octavia Due et
al. Rom J Morphol Embryol 2012, 53(3 Suppl):749) including
Non-Hodgkin lymphoma (NHL) especially B cell lymphoma (BCLs), T
cell lymphoma and natural killer cell lymphoma.
[0008] And PDGFRA D842V mutation has been found in a distinct
subset of GIST, typically from the stomach. The D842V mutation is
known to be associated with tyrosine kinase inhibitor resistance.
As such, there is a need for agents that target this mutation.
(Valentina et al., Int. J. Mol. Sci. 2018, 19, 732).
SUMMARY
[0009] The present disclosure provides a compound having c-abl, KIT
and/or PDGFR inhibitory activity, a composition comprising the
compound and a method useful to treat cancer and/or proliferative
disorders.
[0010] In an embodiment, there are provided a compound of Formula
(I) and a pharmaceutically acceptable salt thereof:
##STR00002##
wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, and R.sup.5 are as
defined herebelow.
[0011] In another embodiment, the present disclosure provides
pharmaceutical compositions comprising a therapeutically effective
amount of a compound described herein and a pharmaceutically
acceptable carrier.
[0012] In yet another embodiment, the present disclosure provides
methods of inhibiting or treating cancer and/or a proliferative
disorder comprising administering to a subject in need thereof a
therapeutically effective amount of one or more compounds described
herein.
DETAILED DESCRIPTION
[0013] The following description is merely exemplary in nature and
is not intended to limit the present disclosure, application, or
uses.
Definitions
[0014] The generic terms used in the present disclosure are herein
defined for clarity.
[0015] This specification uses the terms "substituent", "radical",
"group", "moiety", and "fragment" interchangeably.
[0016] As used herein, the term "alkenyl" refers to a straight or
branched hydrocarbonyl group with at least one site of
unsaturation, i.e., a carbon-carbon, sp2 double bond. In an
embodiment, alkenyl has from 2 to 12 carbon atoms. In some
embodiments, alkenyl is a C.sub.2--C.sub.10 alkenyl group or a
C.sub.2--C.sub.6 alkenyl group. Examples of alkenyl group include,
but are not limited to, ethylene or vinyl (CH.dbd.CH.sub.2), allyl
(--CH.sub.2CH.dbd.CH.sub.2), cyclopentenyl (--C.sub.5H.sub.7), and
5-hexenyl (--CH.sub.2CH.sub.2CH.sub.2CH.sub.2CH.dbd.CH.sub.2).
[0017] As used herein, the term "alkoxy" is RO-- where R is alkyl.
Non-limiting examples of alkoxy groups include methoxy, ethoxy and
propoxy.
[0018] As used herein, the term "alkoxyalkyl" refers to an alkyl
moiety substituted with an alkoxy group. Examples of alkoxyalkyl
groups include methoxymethyl, methoxyethyl, methoxypropyl and
ethoxyethyl.
[0019] As used herein, the term "alkoxycarbonyl" is ROC(O)--, where
R is an alkyl group as defined herein. In various embodiments, R is
a C.sub.1-C.sub.10 alkyl group or a C.sub.1-C.sub.6 alkyl
group.
[0020] As used herein, the term "alkyl" refers to a straight or
branched chain hydrocarbonyl group. In an embodiment, alkyl has
from 1 to 12 carbon atoms. In some embodiments, alkyl is a
C.sub.1-C.sub.10 alkyl group or a C.sub.1-C.sub.6 alkyl group.
Examples of alkyl groups include, but are not limited to, methyl,
ethyl, propyl, isopropyl, butyl, isobutyl, t-butyl, pentyl, hexyl,
heptyl, octyl, nonyl and decyl. "lower alkyl" means alkyl having
from 1 to 4 carbon atoms.
[0021] As used herein, the term "alkylamino" refers to an amino
group substituted with one or more alkyl groups. "N-(alkyl)amino"
is RNH-- and "N,N-(alkyl)2amino" is R.sub.2N--, where the R groups
are alkyl as defined herein and are the same or different. In
various embodiments, R is a C.sub.1-C.sub.10 alkyl group or a
C.sub.1-C.sub.6 alkyl group. Examples of alkylamino groups include
methylamino, ethylamino, propylamino, butylamino, dimethylamino,
diethylamino, and methylethylamno.
[0022] As used herein, the term "alkylaminoalkyl" refers to an
alkyl moiety substituted with an alkylamino group, wherein
alkylamino is as defined herein. Examples of alkylaminoakyl groups
include methylaminomethyl and ethylaminomethyl.
[0023] As used herein, the term "alkynyl" refers to a straight or
branched carbon-chain group with at least one site of unsaturation,
i.e., a carbon-carbon, sp triple bond. In an embodiment, alkynyl
has from 2 to 12 carbon atoms. In some embodiments, alkynyl is a
C.sub.2--C.sub.10 alkynyl group or a C.sub.2--C.sub.6 alkynyl
group. Examples of alkynyl groups include acetylenic (--C.ident.CH)
and propargyl (--CH.sub.2C.ident.CH).
[0024] As used herein, the term "aryl" refers to any monocyclic or
bicyclic carbon ring of up to 7 atoms in each ring, wherein at
least one ring is aromatic, or an aromatic ring system of 5 to 14
carbon atoms which includes a carbocyclic aromatic group fused with
a 5-or 6-membered cycloalkyl group. Representative examples of aryl
groups include, but are not limited to, phenyl, tolyl, xylyl,
naphthyl, tetrahydronaphthyl, anthracenyl, fluorenyl, indenyl,
azulenyl and indanyl. A carbocyclic aromatic group can be
unsubstituted or optionally substituted.
[0025] As used herein, the term "cycloalkyl" is a hydrocarbyl group
containing at least one saturated or partially unsaturated ring
structure, and attached via a ring carbon. In various embodiments,
it refers to a saturated or a partially unsaturated
C.sub.3--C.sub.12 cyclic moiety, examples of which include
cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl,
cyclohexenyl, cycloheptyl and cyclooctyl. "Cycloalkyloxy" is RO--,
where R is cycloalkyl.
[0026] As used herein, the terms "halogen" and "halo" refers to
chloro (--Cl), bromo (--Br), fluoro (--F) or iodo (--I).
"Haloalkoxy" refers to an alkoxy group substituted with one or more
halo groups and examples of haloalkoxy groups include, but are not
limited to, --OCF.sub.3, --OCHF.sub.2 and --OCH.sub.2F.
"Haloalkoxyalkyl" refers to an alkyl moiety substituted with a
haloalkoxy group, wherein haloalkoxy is as defined herein. Examples
of haloalkoxyalkyl groups include trifluoromethoxymethyl,
trifluoroethoxymethyl and trifluoromethoxyethyl. "Haloalkyl" refers
to an alkyl moiety substituted with one or more halo groups.
Examples of haloalkyl groups include --CF.sub.3 and CHF.sub.2.
[0027] As used herein, the term "heteroalkyl" refers to a straight-
or branched-chain alkyl group having from 2 to 14 carbons (in some
embodiments, 2 to 10 carbons) in the chain, one or more of which
has been replaced by a heteroatom selected from S, 0, P and N.
Exemplary heteroalkyls include alkyl ethers, secondary and tertiary
alkyl amines, amides, alkyl sulfides, and the like.
[0028] As used herein, the term "heterocyclyl" includes the
heteroaryls defined below and refers to a saturated or partially
unsaturated monocyclic, bicyclic or tricyclic group of 2 to 14
ring-carbon atoms and, in addition to ring-carbon atoms, 1 to 4
heteroatoms selected from P, N, O and S. In various embodiments the
heterocyclic group is attached to another moiety through carbon or
through a heteroatom, and is optionally substituted on carbon or a
heteroatom. Examples of heterocyclyl include azetidinyl,
benzoimidazolyl, benzofuranyl, benzofurazanyl, benzopyrazolyl,
benzotriazolyl, benzothiophenyl, benzoxazolyl, carbazolyl,
carbolinyl, cinnolinyl, furanyl, imidazolyl, indolinyl, indolyl,
indolazinyl, indazolyl, isobenzofuranyl, isoindolyl, isoquinolyl,
isothiazolyl, isoxazolyl, naphthpyridinyl, oxadiazolyl, oxazolyl,
oxazoline, isoxazoline, oxetanyl, pyranyl, pyrazinyl, pyrazolyl,
pyridazinyl, pyridopyridinyl, pyridazinyl, pyridyl, pyrimidyl,
pyrrolyl, quinazolinyl, quinolyl, quinoxalinyl, tetrahydropyranyl,
tetrahydrothiopyranyl, tetrahydroisoquinolinyl, tetrazolyl,
tetrazolopyridyl, thiadiazolyl, thiazolyl, thienyl, triazolyl,
azetidinyl, 1,4-dioxanyl, hexahydroazepinyl, piperazinyl,
piperidinyl, pyridin-2-onyl, pyrrolidinyl, morpholinyl,
thiomorpholinyl, dihydrobenzoimidazolyl, dihydrobenzofuranyl,
dihydrobenzothiophenyl, dihydrobenzoxazolyl, dihydrofuranyl,
dihydroimidazolyl, dihydroindolyl, dihydroisooxazolyl,
dihydroisothiazolyl, dihydrooxadiazolyl, dihydrooxazolyl,
dihydropyrazinyl, dihydropyrazolyl, dihydropyridinyl,
dihydropyrimidinyl, dihydropyrrolyl, dihydroquinolinyl,
dihydrotetrazolyl, dihydrothiadiazolyl, dihydrothiazolyl,
dihydrothienyl, dihydrotriazolyl, dihydroazetidinyl,
methylenedioxybenzoyl, tetrahydrofuranyl, and tetrahydrothienyl,
and N-oxides thereof. "Heterocyclyloxy" is RO--, where R is
heterocyclyl. "Heterocyclylthio" is RS, where R is
heterocyclyl.
[0029] As used herein, the term "3- or 4-membered heterocyclyl"
refers to a monocyclic ring having 3 or 4 ring atoms wherein at
least one ring atom is heteroatom selected from the group
consisting of N, O and S. Non-limiting examples of 3- or 4-membered
heterocyclyl include aziridinyl, 2H-azirinyl, oxiranyl, thiiranyl,
azetidinyl, 2,3-dihyroazetyl, azetyl, 1,3-diazetidinyl, oxetanyl,
2H-oxetyl, thietanyl, and 2H-thietyl.
[0030] As used herein, the term "heteroaryl" refers to a
monocyclic, bicyclic or tricyclic ring having up to 7 atoms in each
ring, wherein at least one ring is aromatic and contains from 1 to
4 heteroatoms in the ring selected from the group consisting of N,
O and S. Non-limiting examples of heteroaryl include pyridyl,
thienyl, furanyl, pyrimidyl, imidazolyl, pyranyl, pyrazolyl,
thiazolyl, thiadiazolyl, isothiazolyl, oxazolyl, isoxazoyl,
pyrrolyl, pyridazinyl, pyrazinyl, quinolinyl, isoquinolinyl,
benzofuranyl, dibenzofuranyl, dibenzothiophenyl, benzothienyl,
indolyl, benzothiazolyl, benzooxazolyl, benzimidazolyl, isoindolyl,
benzotriazolyl, purinyl, thianaphthenyl and pyrazinyl. Attachment
of heteroaryl can occur via an aromatic ring, or, if heteroaryl is
bicyclic or tricyclic and one of the rings is not aromatic or
contains no heteroatoms, through a non-aromatic ring or a ring
containing no heteroatoms. "Heteroaryl" is also understood to
include the N-oxide derivative of any nitrogen containing
heteroaryl. "Heteroaryloxy" is RO--, where R is heteroaryl.
[0031] As used herein, the term "hydroxyalkoxy" refers to an alkoxy
group substituted with a hydroxyl group (OH), wherein alkoxy is as
defined herein. An example of hydroxyalkoxy is hydroxyethoxy.
[0032] As used herein, the term "hydroxyalkyl" refers to a linear
or branched monovalent C.sub.1-C.sub.10 hydrocarbon group
substituted with at least one hydroxy group and examples of
hydroxyalkyl groups include, but are not limited to, hydroxymethyl,
hydroxyethyl, hydroxypropyl and hydroxybutyl.
[0033] As used herein, the term "pharmaceutically acceptable" means
suitable for use in pharmaceutical preparations, generally
considered as safe for such use, officially approved by a
regulatory agency of a national or state government for such use,
or being listed in the U.S. Pharmacopoeia or other generally
recognized pharmacopoeia for use in animals, and more particularly
in humans.
[0034] As used herein, the term "pharmaceutically acceptable
carrier" refers to a diluent, adjuvant, excipient, or carrier, or
other ingredient which is pharmaceutically acceptable and with
which a compound of the invention is administered.
[0035] As used herein, the term "pharmaceutically acceptable salt"
refers to a salt which may enhance desired pharmacological
activity. Examples of pharmaceutically acceptable salts include
acid addition salts formed with inorganic or organic acids, metal
salts and amine salts. Examples of acid addition salts formed with
inorganic acids include salts with hydrochloric acid, hydrobromic
acid, sulfuric acid, nitric acid and phosphoric acid. Examples of
acid addition salts formed with organic acids such as acetic acid,
propionic acid, hexanoic acid, heptanoic acid,
cyclopentanepropionic acid, glycolic acid, pyruvic acid, lactic
acid, malonic acid, succinic acid, malic acid, maleic acid, fumaric
acid, tartaric acid, citric acid, benzoic acid,
o-(4-hydroxy-benzoyl)-benzoic acid, cinnamic acid, mandelic acid,
methanesulfonic acid, ethanesulfonic acid, 1,2-ethanedisulfonic
acid, 2-hydroxyethane-sulfonic acid, benzenesulfonic acid,
p-chlorobenzenesulfonic acid, 2-naphthalenesulfonic acid,
p-toluenesulfonic acid, camphorsulfonic acid,
4-methyl-bicyclo[2.2.2]oct-2-ene1-carboxylic acid, gluco-heptonic
acid, 4,4'-methylenebis(3-hydroxy-2-naphthoic) acid,
3-phenylpropionic acid, trimethyl-acetic acid, tertiary butylacetic
acid, lauryl sulfuric acid, gluconic acid, glutamic acid,
hydroxy-naphthoic acids, salicylic acid, stearic acid and muconic
acid. Examples of metal salts include salts with sodium, potassium,
calcium, magnesium, aluminum, iron, and zinc ions. Examples of
amine salts include salts with ammonia and organic nitrogenous
bases strong enough to form salts with carboxylic acids.
[0036] As used herein, the term "therapeutically effective amount"
means when applied to a compound of the invention is intended to
denote an amount of the compound that is sufficient to ameliorate,
palliate, stabilize, reverse, slow or delay the progression of a
disorder or disease state, or of a symptom of the disorder or
disease. In an embodiment, the method of the present invention
provides for administration of combinations of compounds. In such
instances, the "therapeutically effective amount" is the amount of
a compound of the present invention in the combination sufficient
to cause the intended biological effect.
[0037] As used herein, the term "treatment" or "treating" as used
herein means ameliorating or reversing the progress or severity of
a disease or disorder, or ameliorating or reversing one or more
symptoms or side effects of such disease or disorder. "Treatment"
or "treating", as used herein, also means to inhibit or block, as
in retard, arrest, restrain, impede or obstruct, the progress of a
system, condition or state of a disease or disorder. For purposes
of this invention, "treatment" or "treating" further means an
approach for obtaining beneficial or desired clinical results,
where "beneficial or desired clinical results" include, without
limitation, alleviation of a symptom, diminishment of the extent of
a disorder or disease, stabilized (i.e., not worsening) disease or
disorder state, delay or slowing of a disease or disorder state,
amelioration or palliation of a disease or disorder state, and
remission of a disease or disorder, whether partial or total.
[0038] In another embodiment, the compounds of Formula (I) are used
for modulating the activity of a protein kinase c-abl, KIT and
PDGFR.
[0039] As used herein, the term "modulating" or "modulation" refers
to the alteration of the catalytic activity of a protein kinase. In
particular, modulating refers to the activation or inhibition of
the catalytic activity of a protein kinase, depending on the
concentration of the compound or salt to which the protein kinase
is exposed or, more preferably, the inhibition of the catalytic
activity of a protein kinase. The term "catalytic activity" as used
herein refers to the rate of phosphorylation of tyrosine, serine or
threonine under the influence, direct or indirect, of a protein
kinase.
[0040] The three main classes that pharmacological inhibitors of
kinase activity are categorized by are (1) Type I, or "DFG-in" ATP
competitive inhibitors, which directly compete with ATP in the ATP
binding site (i.e., Src and Abl inhibitor dasatinib, (2) Type II,
or "DFG-out" ATP competitive inhibitors, which, in addition to
binding the ATP binding site also engage an adjacent hydrophobic
binding site that is only accessible when the kinase is in an
inactivated configuration (i.e., the activation loop is oriented in
a conformation that would block substrate binding) (i.e., imatinib,
nilotinib), and (3) non-ATP competitive inhibitors that bind at
sites outside the ATP binding site that affect the activity of the
kinase (i.e. GNF-2).
[0041] As used herein, the phrase "compound(s) of this/the
disclosure" includes any compound(s) of Formula (I), as well as
clathrates, hydrates, solvates, or polymorphs thereof. And, even if
the term "compound(s) of the disclosure" does not mention its
pharmaceutically acceptable sat, the term includes salts thereof.
In one embodiment, the compounds of this disclosure include
stereochemically pure compounds, e.g., those substantially free
(e.g., greater than 85% ee, greater than 90% ee, greater than 95%
ee, greater than 97% ee, or greater than 99% ee) of other
stereoisomers. That is, if the compounds of Formula (I) according
to the present disclosure or salts thereof are tautomeric isomers
and/or stereoisomers (e.g., geometrical isomers and conformational
isomers), such isolated isomers and their mixtures also are
included in the scope of this disclosure. If the compounds of the
present disclosure or salts thereof have an asymmetric carbon in
their structures, their active optical isomers and their racemic
mixtures also are included in the scope of this disclosure.
[0042] As used herein, the term "polymorph" refers to solid
crystalline forms of a compound of this disclosure or complex
thereof. Different polymorphs of the same compound can exhibit
different physical, chemical and/or spectroscopic properties.
Different physical properties include, but are not limited to
stability (e.g., to heat or light), compressibility and density
(important in formulation and product manufacturing), and
dissolution rates (which can affect bioavailability). Differences
in stability can result from changes in chemical reactivity (e.g.,
differential oxidation, such that a dosage form discolors more
rapidly when comprised of one polymorph than when comprised of
another polymorph) or mechanical characteristics (e.g., tablets
crumble on storage as a kinetically favored polymorph converts to
thermodynamically more stable polymorph) or both (e.g., tablets of
one polymorph are more susceptible to breakdown at high humidity).
Different physical properties of polymorphs can affect their
processing. For example, one polymorph might be more likely to form
solvates or might be more difficult to filter or wash free of
impurities than another due to, for example, the shape or size
distribution of particles of it.
[0043] As used herein, the term "solvate" means a compound or its
salt according to this disclosure that further includes a
stoichiometric or non-stoichiometric amount of a solvent bound by
non-covalent intermolecular forces. Preferred solvents are
volatile, non-toxic, and/or acceptable for administration to humans
in trace amounts.
[0044] As used herein, the term "hydrate" means a compound or its
salt according to this disclosure that further includes a
stoichiometric or non-stoichiometric amount of water bound by
non-covalent intermolecular forces.
[0045] As used herein, the term "clathrate" means a compound or its
salt in the form of a crystal lattice that contains spaces (e.g.,
channels) that have a guest molecule (e.g., a solvent or water)
trapped within.
Compounds of the Present Disclosure
[0046] The present disclosure provides compounds according to
Formula (I):
##STR00003##
[0047] or a pharmaceutically acceptable salt thereof, wherein:
[0048] R.sup.1 is cyclopropyl, cyclobutyl, or 4-membered
heterocyclyl, wherein R.sup.1 is optionally substituted with one or
more groups selected from the group consisting of halo, alkyl,
hydroxyalkyl, haloalkyl, and monoalkylaminoalkyl,
[0049] R.sup.2 and R.sup.3 are independently --H, halo, alkyl,
alkoxy, --CF.sub.3,--CHF.sub.2, --CH.sub.2F, or --OCF.sub.3,
[0050] R.sup.4 is aryl, heteroaryl, cycloalkyl, heterocyclyl, or
heteroalkyl, wherein R.sup.4 is optionally substituted with one or
more groups selected from the group consisting of halo, hydroxyl,
alkyl, alkenyl, alkynyl, cycloalkyl, haloalkyl, hydroxyalkyl,
dialkylaminoalkyl, trimethylsilylethoxymethyl,
--CH.sub.2NHC(O)CH.sub.3, --NO.sub.2, --NR.sub.aR.sub.b,
--NR.sub.aC(.dbd.O)R.sub.b, --NR.sub.aC(.dbd.O)NR.sub.aR.sub.b,
--NR.sub.aC(.dbd.O)OR.sub.b, --OR.sub.a, --CN, --C(.dbd.O)R.sub.a,
--C(.dbd.O)OR.sub.a, --C(.dbd.O)NR.sub.aR.sub.b,
--OC(.dbd.O)R.sub.a, --OC(.dbd.O)OR.sub.a,
--OC(.dbd.O)NR.sub.aR.sub.b, --SR.sub.a, azetidinyl, oxetanyl,
tetrahydrofuranyl, furanyl, pyrrolidinyl, pyrrolyl, pyrazolyl,
thiophenyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, furazanyl,
oxadiazolyl, thiadiazolyl, phenyl, tetrahydropyranyl, pyranyl,
pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, piperidinyl,
piperazinyl, morpholinyl and thiomorpholinyl, R.sub.a and R.sub.b
are independently --H, halo, amino, alkyl, or haloalkyl, and
[0051] R.sup.5 is H, halo, or alkyl.
[0052] In some embodiments, R.sup.1 is cyclopropyl or cyclobutyl,
wherein R.sup.1 is optionally substituted with one or more groups
selected from the group consisting of halo, C.sub.1-C.sub.3 alkyl,
C.sub.1-C.sub.3 hydroxyalkyl and C.sub.1-C.sub.3 haloalkyl; R.sup.2
and R.sup.3 are independently --H, halo, C.sub.1-C.sub.3 alkyl,
C.sub.1-C.sub.3 alkoxy, --CF.sub.3, --CHF.sub.2, --CH.sub.2F, or
--OCF.sub.3; R.sup.4 is aryl, heteroaryl, cycloalkyl, or
heterocyclyl, wherein R.sup.4 is optionally substituted with one or
more groups selected from the group consisting of halo, hydroxyl,
C.sub.1-C.sub.3 alkyl, C.sub.2--C.sub.3 alkenyl, C.sub.2--C.sub.3
alkynyl, C.sub.3--C.sub.4 cycloalkyl, C.sub.1-C.sub.3 haloalkyl,
mono-C.sub.1-C.sub.3 alkylamino, di-C.sub.1-C.sub.3 alkylamino,
--NO.sub.2, --NR.sub.aR.sub.b, --NR.sub.aC(.dbd.O)R.sub.b,
--NR.sub.aC(.dbd.O)NR.sub.aR.sub.b, --NR.sub.aC(.dbd.O)OR.sub.b,
--OR.sub.a, --CN, --C(.dbd.O)R.sub.a, --C(.dbd.O)OR.sub.a,
--C(.dbd.O)NR.sub.aR.sub.b, --OC(.dbd.O)R.sub.a, --OC(.dbd.O)0
R.sub.a, --OC(.dbd.O)NR.sub.aR.sub.b, --SR.sub.a, azetidinyl,
oxetanyl, tetrahydrofuranyl, furanyl, pyrrolidinyl, pyrrolyl,
pyrazolyl, thiophenyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl,
furazanyl, oxadiazolyl, thiadiazolyl, phenyl, tetrahydropyranyl,
pyranyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl,
piperidinyl, piperazinyl, morpholinyl and thiomorpholinyl; R.sub.a
and R.sub.b are independently --H, halo, amino, C.sub.1-C.sub.3
alkyl, or C.sub.1-C.sub.3 haloalkyl; and R.sup.5 is H, F--, Cl--,
Br-- or methyl
[0053] In various embodiments, R.sup.1 is cyclopropyl or
cyclobutyl, wherein R.sup.1 is optionally substituted with one or
more groups selected from the group consisting of halo,
C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 hydroxyalkyl and
C.sub.1-C.sub.3 haloalkyl. In particular embodiments, R.sup.1 is
cyclopropyl, fluorocyclopropyl, hydroxycyclopropyl,
hydroxymethylcyclopropyl, difluorocyclopropyl,
methylaminomethylcyclopropyl, cyclobutyl, fluorocyclobutyl, or
difluorocyclobutyl. In other particular embodiments, R.sup.1 is
cyclopropyl, fluorocyclopropyl, cyclobutyl, or
fluorocyclobutyl.
[0054] In some other embodiments, R.sup.1 is 4-membered
heterocyclyl which is optionally substituted with one or more
groups selected from the group consisting of halo, C.sub.1-C.sub.3
alkyl, C.sub.1-C.sub.3 hydroxyalkyl and C.sub.1-C.sub.3 haloalkyl.
In particular embodiments, the 4-membered heterocyclyl is selected
from the group consisting of aziridinyl, 2H-azirinyl, oxiranyl,
thiiranyl, azetidinyl, 2,3-dihyroazetyl, azetyl, 1,3-diazetidinyl,
oxetanyl, 2H-oxetyl, thietanyl, and 2H-thietyl.
[0055] In some embodiments, R.sup.2 and R.sup.3 are independently
H, methyl, or fluoro.
[0056] In some embodiments, R.sup.4 is phenyl, pyridinyl,
pyrimidinyl, indolinyl, pyrazolyl, thiazolyl, oxoindolinyl,
pyrrolopyridinyl, pyrazolyl, pyrazolopyridinyl,
oxodihydropyrrolopyridinyl, oxodihydrobenzothiazolyl,
benzoimidazolyl, bezooxazolyl, beznothiazolyl, thiophenyl,
pyrrolopyridinyl or isothiazolyl, wherein R.sup.4 is optionally
substituted with one or more groups selected from the group
consisting of halo, alkyl, alkenyl, alkynyl, hydroxyalkyl, amino,
cyano, acetyl, hydroxy, and haloalkyl. In particular embodiments,
R.sup.4 is fluoro-methylphenyl, fluoro-hydroxymethylphenyl,
chloro-hydroxymethylphenyl, methyl-hydroxymethylphenyl,
difluoro-hydroxymethylphenyl, chloro-fluoro-hydroxymethylphenyl,
fluoro-methyl-hydroxymethylphenyl, chloro-methylphenyl,
dimethylphenyl, acetamido-methylphenyl, hydroxy-methylphenyl,
hydroxypropanyl-methylphenyl, methyl-propenylphenyl,
methyl-pyridinylethynylphenyl, methyl-pyrrolylphenyl,
methyl-thiazolylphenyl, imidazolyl-methylphenyl,
cyano-methylphenyl, methyl-pyrazolylphenyl, ethynyl-methylphenyl,
methylpyridinyl, fluoro-methyl-methylaminophenyl,
dimethylpyridinyl, fluoro-methylpyridinyl,
fluoromethyl-methylpyridinyl, cyanopyridinyl,
trifluoromethyl-methylpyridinyl, hydroxymethylpyridinyl,
hydroxymethyl-methylpyridinyl, hydroxyethyl-methylpyridinyl,
chloro-methylpyridinyl, aminopyridinyl, acetyl-methylpyridinyl,
amino-dimethylpyridinyl, hydroxyethyl-methylprydinyl,
methylindolyl, methyloxoindolyl, trimethylsilylethoxymethylindolyl,
acetyl-methylindolinyl, methylpyrimidinyl, dimethylpyrimidinyl,
trifluoromethylpyrimidinyl, pyrazolyl, methylthiazolyl,
methyloxoindolinyl, pyrrolopyridinyl, methylpyrrolopyridinyl,
methyl-tetrahydropyranyl, methylpyrazolyl,
methyl-oxodihydrobibenzothiazolyl, pyrazolopyridinyl,
oxodihydropyrrolopyridinyl, methylisothiazolyl,
chloro-methylisothiazolyl, dimethylisothiazolyl, or
fluoro-methylindolyl. In particular embodiments, R.sup.4 is
fluoro-methylphenyl, fluoro-hydroxymethylphenyl,
chloro-hydroxymethylphenyl, methyl-hydroxymethylphenyl,
difluoro-hydroxymethylphenyl, chloro-fluoro-hydroxymethylphenyl,
fluoro-methyl-hydroxymethylphenyl, chloro-methylphenyl,
dimethylphenyl, acetam ido-methylphenyl, hydroxyl-methylphenyl,
methyl-propenylphenyl, ethynyl-methylphenyl,
fluoro-methyl-methylaminophenyl, fluoro-hydroxyl-methylphenyl,
methyl-methylaminophenyl, methyl-pyrrolylphenyl,
methyl-thiazolylphenyl, cyano-methylphenyl,
imidazolyl-methylphenyl, methylpyridinyl, chloro-methylpyridinyl,
fluoro-methylpyridinyl, fluoromethyl-methylpyridinyl,
bimethylpyridinyl, aminopyridinyl, amino-dimethylpyridinyl,
methoxypyridinyl, acetyl-methylpyridinyl, hydroxymethylpyridinyl,
hydroxymethyl-methylpyridinyl, hydroxyethyl-methylpyridinyl,
cyanopyridinyl, trifluoromethylpyridinyl, methylthiophenyl,
methylindolinyl, methylpyrimidinyl, dimethylpyrimidinyl, pyrazolyl,
methylpyrazolyl, methylindolinyl, methyloxoindolinyl,
pyrrolopyridinyl, methylpyrrolopyridinyl, methylpyrrolyl,
pyrazolopyridinyl, dihydropyrrolopyridinyl, methylisothiazolyl,
dimethylisothiazolyl, methyl indazolyl, or methyl-benzothiazolyl.
In particular embodiments, R.sup.4 is pyridinyl or phenyl that has
one or more substitutions selected from the group consisting of
alkyl, alkenyl, alkynyl, cycloalkyl, halo, hydroxyl, hydroxyalkyl,
haloalkyl, cyano, amino, alkoxy, alkoxyalkoxyalkyl, alkoxyalkyl,
and haloalkoxy. In some particular embodiments, R.sup.4 is selected
from the group consisting of:
##STR00004## ##STR00005## ##STR00006## ##STR00007## ##STR00008##
##STR00009## ##STR00010##
[0057] In some embodiments, R.sup.1 is cyclopropyl,
fluorocyclopropyl, difluorocyclopropyl, cyclobutyl,
fluorocyclobutyl, or difluorocyclobutyl; R.sup.2 and R.sup.3 are
independently H, methyl, or fluoro; and R.sup.4 is
fluoro-methylphenyl, fluoro-hydroxymethylphenyl,
chloro-methylphenyl, dimethylphenyl, acetamido-methylphenyl,
hydroxyl-methylphenyl, methyl-propenylphenyl, ethynyl-methylphenyl,
fluoro-methyl-methylaminophenyl, methyl-pyrrolylphenyl,
methyl-thiazolylphenyl, cyano-methylphenyl,
imidazolyl-methylphenyl, methylpyridinyl, chloro-methylpyridinyl,
fluoro-methylpyridinyl, fluoromethyl-methylpyridinyl,
bimethylpyridinyl, aminopyridinyl, amino-dimethylpyridinyl,
methoxypyridinyl, acetyl-methylpyridinyl, hydroxymethylpyridinyl,
hydroxymethyl-methylpyridinyl, hydroxyethyl-methylpyridinyl,
cyanopyridinyl, trifluoromethylpyridinyl, methylthiophenyl,
methylindolinyl, methylpyrimidinyl, dimethylpyrimidinyl, pyrazolyl,
methylpyrazolyl, methylindolinyl, methyloxoindolinyl,
pyrrolopyridinyl, methylpyrrolopyridinyl, methylpyrrolyl,
pyrazolopyridinyl, dihydropyrrolopyridinyl, methylisothiazolyl,
dimethylisothiazolyl, methylindazolyl, or
methyl-bibenzothiazolyl.
[0058] The compounds described herein have c-abl inhibition
activity and selectivity against c-abl. The compounds are effective
to treat cancer and/or a proliferative disorder.
[0059] In an embodiment, R.sup.1 is cyclopropyl, fluorocyclopropyl,
cyclobutyl, fluorocyclobutyl, or difluorocyclobutyl; R.sup.2 and
R.sup.3 are H; R.sup.4 is phenyl, pyridinyl, pyrazolyl,
pyrrolopyridinyl, indolinyl, oxoindolinyl, bezothiazolyl,
benzoimidazolyl, benzooxazolyl, or thiophenyl, wherein R.sup.4 is
optionally substituted with one or more groups selected from the
group consisting of halo, hydroxyl, alkyl, haloalkyl, hydroxyalkyl,
cycloalkyl, alkoxyalkyl, alkoxyalkoxy, alkylaminoalkyl,
--NR.sub.aR.sub.b, --NR.sub.aC(.dbd.O)R.sub.b, --OR.sub.a,
-SR.sub.a, --CN, --C(.dbd.O)R.sub.a, --C(.dbd.O)OR.sub.a,
--C(.dbd.O)NR.sub.aR.sub.b, --OC(.dbd.O)R.sub.a, furanyl, or
pyrrolyl; R.sub.a and R.sub.b are independently --H, halo, amino,
alkyl, or haloalkyl; and R.sup.5 is --H, halo, or C.sub.1-C.sub.3
alkyl.
[0060] In various embodiments, R.sup.1 is fluorocyclopropyl, and
such compounds include, but are not limited to, the following
compounds and salts thereof: [0061]
2-fluoro-N-(6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclopr-
opane-1-carboxamide; [0062]
2-fluoro-N-(6-(2-fluoro-6-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclopr-
opane-1-carboxamide; [0063]
N-(3-chloro-6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluo-
rocyclopropane-1-carboxamide; [0064]
N-(3-chloro-6-(2-fluoro-6-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluo-
rocyclopropane-1-carboxamide; [0065]
2-fluoro-N-(3-methyl-6-(4-methylpyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)c-
yclopropane-1-carboxamide; [0066]
2-fluoro-N-(6-(4-methylpyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)cyclopropa-
ne-1-carboxamide; [0067]
N-(3-chloro-6-(4-methylpyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)-2-fluoroc-
yclopropane-1-carboxamide; [0068]
2-fluoro-N-(6-(3-fluoro-2-methylphenyl)-3-methylimidazo[1,2-a]pyridin-2-y-
l)cyclopropane-1-carboxamide; [0069]
2-fluoro-N-(6-(2-fluoro-6-methylphenyl)-3-methylimidazo[1,2-a]pyridin-2-y-
l)cyclopropane-1-carboxamide; [0070]
2-fluoro-N-(6-(5-fluoro-4-methylpyridin-3-yI)-3-methylimidazo[1,2-a]pyrid-
in-2-yl)cyclopropane-1-carboxamide; [0071]
2-fluoro-N-(6-(5-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclopr-
opane-1-carboxamide; [0072]
2-fluoro-N-(6-(5-hydroxy-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclop-
ropane-1-carboxamide; [0073]
methyl3-(2-(2-fluorocyclopropane-1-carboxamido)imidazo[1,2-a]pyridin-6-yl-
)-4-methylbenzoate; [0074]
2-fluoro-N-(6-(5-fluoro-4-methylpyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)c-
yclopropane-1-carboxamide; [0075]
2-fluoro-N-(6-(5-methyl-1H-indol-4-yl)imidazo[1,2-a]pyridin-2-yl)cyclopro-
pane-1-carboxamide; [0076]
N-(3-chloro-6-(5-fluoro-4-methylpyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)--
2-fluorocyclopropane-1-carboxamide; [0077]
N-(6-(5-cyano-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopro-
pane-1-carboxamide; [0078]
N-(6-(1H-pyrazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopropane-1--
carboxamide; [0079]
2-fluoro-N-(6-(4-methyl-1H-pyrazol-3-yl)imidazo[1,2-a]pyridin-2-yl)cyclop-
ropane-1-carboxamide; [0080]
2-fluoro-N-(6-(3-hydroxy-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclop-
ropane-1-carboxamide; [0081]
N-(6-(4-chloropyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopropa-
ne-1-carboxamide; [0082]
N-(6-(2,3-dimethylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopropane-
-1-carboxamide; [0083]
N-(6-(5-amino-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopro-
pane-1-carboxamide; [0084]
2-fluoro-N-(6-(2-methyl-5-(methylamino)phenyl)imidazo[1,2-a]pyridin-2-yl)-
cyclopropane-1-carboxamide; [0085]
N-(6-(5-acetamido-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocycl-
opropane-1-carboxamide; [0086]
N-(6-(5-chloro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopr-
opane-1-carboxamide; [0087]
N-(6-(1H-pyrrolo[2,3-b]pyridin-5-yl)imidazo[1,2-a]pyridin-2-yl)-2-fluoroc-
yclopropane-1-carboxamide; [0088]
2-fluoro-N-(6-(2-methyl-5-(1H-pyrazol-3-yl)phenyl)imidazo[1,2-a]pyridin-2-
-yl)cyclopropane-1-carboxamide; [0089]
N-(6-(4-chloro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopr-
opane-1-carboxamide; [0090]
N-(6-(3-chloro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopr-
opane-1-carboxamide; [0091]
2-fluoro-N-(6-(4-(trifluoromethyl)pyridin-3-yl)imidazo[1,2-a]pyridin-2-yl-
)cyclopropane-1-carboxamide; [0092]
N-(6-(2,4-dimethylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopropane-
-1-carboxamide; [0093]
2-fluoro-N-(3-fluoro-6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropane-1-carboxamide; [0094]
N-(6-(2,5-dimethylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopropane-
-1-carboxamide; [0095]
2-fluoro-N-(6-(2-oxoindolin-6-yl)imidazo[1,2-a]pyridin-2-yl)cyclopropane--
1-carboxamide; [0096]
N-(6-(4-cyanopyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopropan-
e-1-carboxamide; [0097]
2-fluoro-N-(6-(4-fluoro-2,3-dimethylphenyl)imidazo[1,2-a]pyridin-2-yl)cyc-
lopropane-1-carboxamide; [0098]
2-fluoro-N-(6-(4-fluoro-2,6-dimethylphenyl)imidazo[1,2-a]pyridin-2-yl)cyc-
lopropane-1-carboxamide; [0099]
2-fluoro-N-(6-(4-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclopr-
opane-1-carboxamide; [0100]
2-fluoro-N-(6-(2-methyl-5-(1H-pyrrol-3-yl)phenyl)imidazo[1,2-a]pyridin-2--
yl)cyclopropane-1-carboxamide; [0101]
2-fluoro-N-(6-(3-methylthiophen-2-yl)imidazo[1,2-a]pyridin-2-yl)cycloprop-
ane-1-carboxamide; [0102]
N-(6-(2,6-dimethylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopropane-
-1-carboxamide; [0103]
2-fluoro-N-(6-(4-fluoro-5-hydroxy-2-methylphenyl)imidazo[1,2-a]pyridin-2--
yl)cyclopropane-1-carboxamide; [0104]
N-(6-(3,4-difluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyc-
lopropane-1-carboxamide; [0105]
N-(6-(3,6-difluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyc-
lopropane-1-carboxamide; [0106]
N-(6-(4-chloro-3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluo-
rocyclopropane-1-carboxamide; [0107]
2-fluoro-N-(6-(2-fluoro-4-methylpyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)c-
yclopropane-1-carboxamide; [0108]
2-fluoro-N-(6-(4-methoxypyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)cycloprop-
ane-1-carboxamide; [0109]
N-(6-(6-amino-4-methylpyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocy-
clopropane-1-carboxamide; [0110]
N-(6-(5-amino-3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluor-
ocyclopropane-1-carboxamide; [0111]
2-fluoro-N-(6-(5-methyl-2-oxoindolin-4-yl)imidazo[1,2-a]pyridin-2-yl)cycl-
opropane-1-carboxamide; [0112]
N-(6-(2-chloro-6-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopr-
opane-1-carboxamide; [0113]
2-fluoro-N-(6-(3-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)imidazo[1,2-a]pyrid-
in-2-yl)cyclopropane-1-carboxamide; [0114]
2-fluoro-N-(6-(2-oxo-2,3-dihydrobenzo[d]thiazol-5-yl)imidazo[1,2-a]pyridi-
n-2-yl)cyclopropane-1-carboxamide; [0115]
N-(6-(6-aminopyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopropan-
e-1-carboxamide; [0116]
2-fluoro-N-(6-(2-methyl-5-(1H-pyrazol-1-yl)phenyl)imidazo[1,2-a]pyridin-2-
-yl)cyclopropane-1-carboxamide; [0117]
2-fluoro-N-(6-(3-fluoro-2-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropane-1-carboxamide; [0118]
N-(3-bromo-6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluor-
ocyclopropane-1-carboxamide; [0119]
2-fluoro-N-(6-(3-fluoro-2-methoxyphenyl)imidazo[1,2-a]pyridin-2-yl)cyclop-
ropanecarboxamide; [0120]
N-(6-(2-cyano-3-fluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopro-
panecarboxamide; [0121]
N-(6-(2-chloro-3-fluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopr-
opanecarboxamide; [0122]
N-(6-(2,3-difluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopropane-
carboxamide; [0123]
N-(6-(3,5-dimethyl-1H-indol-4-yl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocycl-
opropanecarboxamide; [0124]
2-fluoro-N-(6-(3-fluoro-2-(methoxymethyl)phenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropanecarboxamide; [0125]
2-fluoro-N-(6-(3-fluoro-2-(furan-2-yl)phenyl)imidazo[1,2-a]pyridin-2-yl)c-
yclopropanecarboxamide; [0126]
2-fluoro-N-(6-(3-fluoro-2-(methylthio)phenyl)imidazo[1,2-a]pyridin-2-yl)c-
yclopropanecarboxamide; [0127]
2-fluoro-N-(6-(6-fluoro-4-methylpyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)c-
yclopropanecarboxamide; [0128]
N-(6-(2-acetyl-3-fluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopr-
opanecarboxamide; [0129]
N-(6-(6-(dimethylamino)-4-methylpyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)--
2-fluorocyclopropanecarboxamide; [0130]
N-(6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclopropanecarb-
oxamide; [0131]
2-fluoro-N-(6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclopr-
opanecarboxamide; [0132]
2-fluoro-N-(6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclopr-
opanecarboxamide; [0133]
2-fluoro-N-(6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclopr-
opanecarboxamide; [0134]
N-(6-(2-(aminomethyl)-3-fluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluoro-
cyclopropanecarboxamide; [0135]
N-(6-(2-(acetamidomethyl)-3-fluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-fl-
uorocyclopropanecarboxamide; [0136]
2,2-difluoro-N-(6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyc-
lopropanecarboxamide; [0137]
2-fluoro-N-(6-(3-fluoro-2-((methylamino)methyl)phenyl)imidazo[1,2-a]pyrid-
in-2-yl)cyclopropanecarboxamide; [0138]
2-fluoro-N-(6-(3-fluoro-2-((isopropylamino)methyl)phenyl)imidazo[1,2-a]py-
ridin-2-yl)cyclopropanecarboxamide; [0139]
2-fluoro-N-(6-(3-fluoro-2-((2-methoxyethoxy)methyl)phenyl)imidazo[1,2-a]p-
yridin-2-yl)cyclopropanecarboxamide; [0140]
2-fluoro-N-(6-(3-fluoro-2-((2-hydroxyethoxy)methyl)phenyl)imidazo[1,2-a]p-
yridin-2-yl)cyclopropanecarboxamide; [0141]
N-(6-(2-((dimethylamino)methyl)-3-fluorophenyl)imidazo[1,2-a]pyridin-2-yl-
)-2-fluorocyclopropanecarboxamide; [0142]
N-(6-(1H-pyrrolo[2,3-b]pyridin-5-yl)imidazo[1,2-a]pyridin-2-yl)-2-fluoroc-
yclopropanecarboxamide; [0143]
2-fluoro-N-(6-(4-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)imidazo[1,2-a]pyrid-
in-2-yl)pcyclopropanecarboxamide; [0144]
N-(6-(4-chloro-1H-pyrrolo[2,3-b]pyridin-5-yl)imidazo[1,2-a]pyridin-2-yl)--
2-fluorocyclopropanecarboxamide; [0145]
2-fluoro-N-(6-(o-tolyl)imidazo[1,2-a]pyridin-2-yl)cyclopropanecarboxamide-
; [0146]
2-fluoro-N-(6-(3-fluoro-2-hydroxyphenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropanecarboxamide; [0147]
N-(6-(2-amino-3-fluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopro-
panecarboxamide; [0148]
2-fluoro-N-(6-(5-methyl-1H-indol-6-yl)imidazo[1,2-a]pyridin-2-yl)cyclopro-
panecarboxamide; [0149]
2-fluoro-N-(6-(6-methyl-1H-indol-5-yl)imidazo[1,2-a]pyridin-2-yl)cyclopro-
panecarboxamide; [0150]
N-(6-(2-(dimethylamino)-3-fluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluo-
rocyclopropanecarboxamide; [0151]
2-fluoro-N-(6-(5-methyl-1H-benzo[d]imidazol-6-yl)imidazo[1,2-a]pyridin-2--
yl)pcyclopropanecarboxamide; [0152]
N-(6-(2-ethyl-3-fluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopro-
panecarboxamide; [0153]
2-fluoro-N-(6-(3-fluoro-2-(trifluoromethyl)phenyl)imidazo[1,2-a]pyridin-2-
-yl)cyclopropanecarboxamide; [0154]
N-(6-(2-cyclopropyl-3-fluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocy-
clopropanecarboxamide; [0155]
2-fluoro-N-(6-(3-fluoro-2-(methylamino)phenyl)imidazo[1,2-a]pyridin-2-yl)-
cyclopropanecarboxamide; [0156]
2-fluoro-N-(6-(5-methylbenzo[d]oxazol-6-yl)imidazo[1,2-a]pyridin-2-yl)pcy-
clopropanecarboxamide; [0157]
2-fluoro-N-(6-(5-methyl-1H-benzo[d]imidazol-4-yl)imidazo[1,2-a]pyridin-2--
yl)cyclopropane-1-carboxamide; [0158]
2-fluoro-N-(6-(6-methylbenzo[d]thiazol-5-yl)imidazo[1,2-a]pyridin-2-yl)cy-
clopropanecarboxamide; [0159]
2-fluoro-N-(6-(5-methylbenzo[d]oxazol-4-yl)imidazo[1,2-a]pyridin-2-yl)cyc-
lopropanecarboxamide; [0160]
2-fluoro-N-(6-(5-methylbenzo[d]thiazol-6-yl)imidazo[1,2-a]pyridin-2-yl)pc-
yclopropanecarboxamide; [0161]
2-fluoro-N-(6-(7-methylbenzo[d]thiazol-6-yl)imidazo[1,2-a]pyridin-2-yl)cy-
clopropanecarboxamide; [0162]
2-fluoro-N-(6-(3-fluoro-2-isopropylphenyl)imidazo[1,2-a]pyridin-2-yl)cycl-
opropanecarboxamide; [0163]
2-fluoro-N-(6-(2-methyl-3-(trifluoromethyl)phenyl)imidazo[1,2-a]pyridin-2-
-yl)cyclopropane-1-carboxamide; [0164]
2-fluoro-N-(6-(3-fluoro-2-(trifluoromethyl)phenyl)imidazo[1,2-a]pyridin-2-
-yl)cyclopropane-1-carboxamide; [0165]
2-fluoro-N-(6-(3-fluoro-2,6-dimethylphenyl)imidazo[1,2-a]pyridin-2-yl)cyc-
lopropane-1-carboxamide; [0166]
N-(6-(2-ethyl-6-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopro-
pane-1-carboxamide [0167]
N-(6-(4-acetyl-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopr-
opane-1-carboxamide; [0168]
N-(6-(2-chloro-3,4-difluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyc-
lopropane-1-carboxamide; [0169]
N-(6-(2-chloro-3,6-difluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyc-
lopropane-1-carboxamide; [0170]
2-fluoro-N-(6-(furan-2-yl)imidazo[1,2-a]pyridin-2-yl)cyclopropane-1-carbo-
xamide; [0171]
2-fluoro-N-(6-(thiophen-2-yl)imidazo[1,2-a]pyridin-2-yl)cyclopropane-1-ca-
rboxamide; [0172]
2-fluoro-N-(6-(thiazol-5-yl)imidazo[1,2-a]pyridin-2-yl)cyclopropane-1-car-
boxamide; [0173]
2-fluoro-N-(6-(3-methylisothiazol-5-yl)imidazo[1,2-a]pyridin-2-yl)cyclopr-
opane-1-carboxamide; [0174]
2-fluoro-N-(6-(5-methylthiazol-4-yl)imidazo[1,2-a]pyridin-2-yl)cyclopropa-
ne-1-carboxamide; [0175]
2-fluoro-N-(6-(3-fluoro-2-methylphenyl)-8-(trifluoromethyl)imidazo[1,2-a]-
pyridin-2-yl)cyclopropane-1-carboxamide; [0176]
N-(8-(difluoromethyl)-6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2--
yl)-2-fluorocyclopropane-1-carboxamide; [0177]
2-fluoro-N-(6-(3-fluoro-2-methylphenyl)-8-(fluoromethyl)imidazo[1,2-a]pyr-
idin-2-yl)cyclopropane-1-carboxamide; [0178]
2-fluoro-N-(8-fluoro-6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropane-1-carboxamide; [0179]
2-fluoro-N-(7-fluoro-6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropane-1-carboxamide; [0180]
2-fluoro-N-(6-(4-fluoro-2-methylphenyl)-8-(trifluoromethyl)imidazo[1,2-a]-
pyridin-2-yl)cyclopropane-1-carboxamide; [0181]
N-(8-(difluoromethyl)-6-(4-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2--
yl)-2-fluorocyclopropane-1-carboxamide; [0182]
2-fluoro-N-(6-(4-fluoro-2-methylphenyl)-8-(fluoromethyl)imidazo[1,2-a]pyr-
idin-2-yl)cyclopropane-1-carboxamide; [0183]
2-fluoro-N-(8-fluoro-6-(4-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropane-1-carboxamide; [0184]
2-fluoro-N-(7-fluoro-6-(4-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropane-1-carboxamide; [0185]
2-fluoro-N-(6-(5-fluoro-2-methylphenyl)-8-(trifluoromethyl)imidazo[1,2-a]-
pyridin-2-yl)cyclopropane-1-carboxamide; [0186]
N-(8-(difluoromethyl)-6-(5-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2--
yl)-2-fluorocyclopropane-1-carboxamide; [0187]
2-fluoro-N-(6-(5-fluoro-2-methylphenyl)-8-(fluoromethyl)imidazo[1,2-a]pyr-
idin-2-yl)cyclopropane-1-carboxamide; [0188]
2-fluoro-N-(8-fluoro-6-(5-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropane-1-carboxamide; [0189]
2-fluoro-N-(7-fluoro-6-(5-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropane-1-carboxamide; [0190]
2-fluoro-N-(6-(2-fluoro-6-methylphenyl)-8-(trifluoromethyl)imidazo[1,2-a]-
pyridin-2-yl)cyclopropane-1-carboxamide; [0191]
N-(8-(difluoromethyl)-6-(2-fluoro-6-methylphenyl)imidazo[1,2-a]pyridin-2--
yl)-2-fluorocyclopropane-1-carboxamide; [0192]
2-fluoro-N-(6-(2-fluoro-6-methylphenyl)-8-(fluoromethyl)imidazo[1,2-a]pyr-
idin-2-yl)cyclopropane-1-carboxamide; [0193]
2-fluoro-N-(8-fluoro-6-(2-fluoro-6-methylphenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropane-1-carboxamide; [0194]
2-fluoro-N-(7-fluoro-6-(2-fluoro-6-methylphenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropane-1-carboxamide; [0195]
N-(6-(3-fluoro-2-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-yl)cyclopr-
opanecarboxamide; [0196]
N-(6-(4-fluoro-2-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-yl)cyclopr-
opanecarboxamide; [0197]
2-fluoro-N-(6-(4-fluoro-2-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropane-1-carboxamide; [0198]
N-(6-(5-fluoro-2-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-yl)cyclopr-
opanecarboxamide; [0199]
2-fluoro-N-(6-(5-fluoro-2-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropane-1-carboxamide; [0200]
N-(6-(2-fluoro-6-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-yl)cyclopr-
opanecarboxamide; [0201]
2-fluoro-N-(6-(2-fluoro-6-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropane-1-carboxamide;
[0202]
N-(6-(3-chloro-2-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-yl)-
cyclopropanecarboxamide; [0203]
N-(6-(3-chloro-2-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluo-
rocyclopropane-1-carboxamide; [0204]
N-(6-(4-chloro-2-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-yl)cyclopr-
opanecarboxamide; [0205]
N-(6-(4-chloro-2-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluo-
rocyclopropane-1-carboxamide; [0206]
N-(6-(5-chloro-2-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-yl)cyclopr-
opanecarboxamide; [0207]
N-(6-(5-chloro-2-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluo-
rocyclopropane-1-carboxamide; [0208]
N-(6-(2-chloro-6-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-yl)cyclopr-
opanecarboxamide; [0209]
N-(6-(2-chloro-6-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluo-
rocyclopropane-1-carboxamide; [0210]
N-(6-(2-(hydroxymethyl)-3-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclopr-
opanecarboxamide; [0211]
2-fluoro-N-(6-(2-(hydroxymethyl)-3-methylphenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropane-1-carboxamide; [0212]
N-(6-(2-(hydroxymethyl)-4-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclopr-
opanecarboxamide; [0213]
2-fluoro-N-(6-(2-(hydroxymethyl)-4-methylphenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropane-1-carboxamide; [0214]
N-(6-(2-(hydroxymethyl)-5-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclopr-
opanecarboxamide; [0215]
2-fluoro-N-(6-(2-(hydroxymethyl)-5-methylphenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropane-1-carboxamide; [0216]
N-(6-(2-(hydroxymethyl)-6-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclopr-
opanecarboxamide; [0217]
2-fluoro-N-(6-(2-(hydroxymethyl)-6-methylphenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropane-1-carboxamide; [0218]
N-(6-(3,4-difluoro-2-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-yl)cyc-
lopropanecarboxamide; [0219]
N-(6-(3,4-difluoro-2-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-yl)-2--
fluorocyclopropane-1-carboxamide; [0220]
N-(6-(4,5-difluoro-2-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-yl)cyc-
lopropanecarboxamide; [0221]
N-(6-(4,5-difluoro-2-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-yl)-2--
fluorocyclopropane-1-carboxamide; [0222]
N-(6-(2,3-difluoro-6-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-yl)cyc-
lopropanecarboxamide; [0223]
N-(6-(2,3-difluoro-6-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-yl)-2--
fluorocyclopropane-1-carboxamide; [0224]
N-(6-(3,6-difluoro-2-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-yl)cyc-
lopropanecarboxamide; [0225]
N-(6-(3,6-difluoro-2-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-yl)-2--
fluorocyclopropane-1-carboxamide; [0226]
N-(6-(3-chloro-4-fluoro-2-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropanecarboxamide; [0227]
N-(6-(3-chloro-4-fluoro-2-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-y-
l)-2-fluorocyclopropane-1-carboxamide; [0228]
N-(6-(4-chloro-5-fluoro-2-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropanecarboxamide; [0229]
N-(6-(4-chloro-5-fluoro-2-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-y-
l)-2-fluorocyclopropane-1-carboxamide; [0230]
N-(6-(3-chloro-2-fluoro-6-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropanecarboxamide; [0231]
N-(6-(3-chloro-2-fluoro-6-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-y-
l)-2-fluorocyclopropane-1-carboxamide; [0232]
N-(6-(6-chloro-3-fluoro-2-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropanecarboxamide; [0233]
N-(6-(6-chloro-3-fluoro-2-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-y-
l)-2-fluorocyclopropane-1-carboxamide; [0234]
N-(6-(4-fluoro-2-(hydroxymethyl)-3-methylphenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropanecarboxamide; [0235]
2-fluoro-N-(6-(4-fluoro-2-(hydroxymethyl)-3-methylphenyl)imidazo[1,2-a]py-
ridin-2-yl)cyclopropane-1-carboxamide; [0236]
N-(6-(5-fluoro-2-(hydroxymethyl)-4-methylphenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropanecarboxamide; [0237]
2-fluoro-N-(6-(5-fluoro-2-(hydroxymethyl)-4-methylphenyl)imidazo[1,2-a]py-
ridin-2-yl)cyclopropane-1-carboxamide; [0238]
N-(6-(2-fluoro-6-(hydroxymethyl)-3-methylphenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropanecarboxamide; [0239]
2-fluoro-N-(6-(2-fluoro-6-(hydroxymethyl)-3-methylphenyl)imidazo[1,2-a]py-
ridin-2-yl)cyclopropane-1-carboxamide; [0240]
N-(6-(3-fluoro-2-(hydroxymethyl)-6-methylphenyl)imidazo[1,2-a]pyridin-2-y-
l)pcyclopropanecarboxamide; [0241]
2-fluoro-N-(6-(3-fluoro-2-(hydroxymethyl)-6-methylphenyl)imidazo[1,2-a]py-
ridin-2-yl)cyclopropane-1-carboxamide; [0242]
N-(6-(4-chloro-3-fluoro-2-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropanecarboxamide; [0243]
N-(6-(4-chloro-3-fluoro-2-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-y-
l)-2-fluorocyclopropane-1-carboxamide; [0244]
N-(6-(3-fluoro-2-(hydroxymethyl)-4-methylphenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropanecarboxamide; [0245]
2-fluoro-N-(6-(3-fluoro-2-(hydroxymethyl)-4-methylphenyl)imidazo[1,2-a]py-
ridin-2-yl)cyclopropane-1-carboxamide; [0246]
N-(6-(3,5-difluoro-2-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-yl)cyc-
lopropanecarboxamide; [0247]
N-(6-(3,5-difluoro-2-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-yl)-2--
fluorocyclopropane-1-carboxamide; [0248]
N-(6-(5-chloro-3-fluoro-2-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropanecarboxamide; [0249]
N-(6-(5-chloro-3-fluoro-2-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-y-
l)-2-fluorocyclopropane-1-carboxamide; [0250]
N-(6-(3-fluoro-2-(hydroxymethyl)-5-methylphenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropanecarboxamide; [0251]
2-fluoro-N-(6-(3-fluoro-2-(hydroxymethyl)-5-methylphenyl)imidazo[1,2-a]py-
ridin-2-yl)cyclopropane-1-carboxamide; [0252]
N-(6-(5-chloro-4-fluoro-2-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropanecarboxamide; [0253]
N-(6-(5-chloro-4-fluoro-2-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-y-
l)-2-fluorocyclopropane-1-carboxamide; [0254]
N-(6-(3,4-difluoro-2-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-yl)cyc-
lopropanecarboxamide; [0255]
N-(6-(3,4-difluoro-2-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-yl)-2--
fluorocyclopropane-1-carboxamide; [0256]
N-(6-(2,4-difluoro-6-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-yl)cyc-
lopropanecarboxamide; [0257]
N-(6-(2,4-difluoro-6-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-yl)-2--
fluorocyclopropane-1-carboxamide; [0258]
N-(6-(2-chloro-4-fluoro-6-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropanecarboxamide; [0259]
N-(6-(2-chloro-4-fluoro-6-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-y-
l)-2-fluorocyclopropane-1-carboxamide; [0260]
N-(6-(4-fluoro-2-(hydroxymethyl)-6-methylphenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropanecarboxamide; [0261]
2-fluoro-N-(6-(4-fluoro-2-(hydroxymethyl)-6-methylphenyl)imidazo[1,2-a]py-
ridin-2-yl)cyclopropane-1-carboxamide; [0262]
N-(6-(2-chloro-3-fluoro-6-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropanecarboxamide; [0263]
N-(6-(2-chloro-3-fluoro-6-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-y-
l)-2-fluorocyclopropane-1-carboxamide; [0264]
N-(6-(3,5-difluoro-2-(hydroxymethyl)-6-methylphenyl)imidazo[1,2-a]pyridin-
-2-yl)cyclopropanecarboxamide; [0265]
N-(6-(3,5-difluoro-2-(hydroxymethyl)-6-methylphenyl)imidazo[1,2-a]pyridin-
-2-yl)-2-fluorocyclopropane-1-carboxamide; [0266]
N-(6-(3-chloro-5-fluoro-2-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropanecarboxamide; [0267]
N-(6-(3-chloro-5-fluoro-2-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-y-
l)-2-fluorocyclopropane-1-carboxamide; [0268]
N-(6-(5-fluoro-2-(hydroxymethyl)-3-methylphenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropanecarboxamide; [0269]
2-fluoro-N-(6-(5-fluoro-2-(hydroxymethyl)-3-methylphenyl)imidazo[1,2-a]py-
ridin-2-yl)cyclopropane-1-carboxamide; [0270]
N-(6-(5-fluoro-2-(hydroxymethyl)-4-methylphenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropanecarboxamide; [0271]
2-fluoro-N-(6-(5-fluoro-2-(hydroxymethyl)-4-methylphenyl)imidazo[1,2-a]py-
ridin-2-yl)cyclopropane-1-carboxamide; [0272]
N-(6-(3-chloro-6-fluoro-2-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropanecarboxamide; [0273]
N-(6-(3-chloro-6-fluoro-2-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-y-
l)-2-fluorocyclopropane-1-carboxamide; [0274]
N-(6-(6-fluoro-2-(hydroxymethyl)-3-methylphenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropanecarboxamide; [0275]
2-fluoro-N-(6-(6-fluoro-2-(hydroxymethyl)-3-methylphenyl)imidazo[1,2-a]py-
ridin-2-yl)cyclopropane-1-carboxamide; [0276]
N-(6-(4-chloro-2-fluoro-6-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropanecarboxamide; [0277]
N-(6-(4-chloro-2-fluoro-6-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin-2-y-
l)-2-fluorocyclopropane-1-carboxamide; [0278]
N-(6-(2-fluoro-6-(hydroxymethyl)-4-methylphenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropanecarboxamide; [0279]
2-fluoro-N-(6-(2-fluoro-6-(hydroxymethyl)-4-methylphenyl)imidazo[1,2-a]py-
ridin-2-yl)cyclopropane-1-carboxamide; [0280]
N-(6-(5-(hydroxymethyl)-1H-indol-4-yl)imidazo[1,2-a]pyridin-2-yl)cyclopro-
panecarboxamide; [0281]
2-fluoro-N-(6-(5-(hydroxymethyl)-1H-indol-4-yl)imidazo[1,2-a]pyridin-2-yl-
)cyclopropane-1-carboxamide; [0282]
N-(6-(4-(hydroxymethyl)-1H-pyrazol-3-yl)imidazo[1,2-a]pyridin-2-yl)cyclop-
ropanecarboxamide; [0283]
2-fluoro-N-(6-(4-(hydroxymethyl)-1H-pyrazol-3-yl)imidazo[1,2-a]pyridin-2--
yl)cyclopropane-1-carboxamide; [0284]
N-(6-(2-(hydroxymethyl)-5-(1H-pyrazol-3-yl)phenyl)imidazo[1,2-a]pyridin-2-
-yl)cyclopropanecarboxamide; [0285]
2-fluoro-N-(6-(2-(hydroxymethyl)-5-(1H-pyrazol-3-yl)phenyl)imidazo[1,2-a]-
pyridin-2-yl)cyclopropane-1-carboxamide; [0286]
N-(6-(2-(hydroxymethyl)-5-(1H-pyrrol-3-yl)phenyl)imidazo[1,2-a]pyridin-2--
yl)cyclopropanecarboxamide; [0287]
2-fluoro-N-(6-(2-(hydroxymethyl)-5-(1H-pyrrol-3-yl)phenyl)imidazo[1,2-a]p-
yridin-2-yl)cyclopropane-1-carboxamide; [0288]
N-(6-(3-(hydroxymethyl)thiophen-2-yl)imidazo[1,2-a]pyridin-2-yl)cycloprop-
anecarboxamide; [0289]
2-fluoro-N-(6-(3-(hydroxymethyl)thiophen-2-yl)imidazo[1,2-a]pyridin-2-yl)-
cyclopropane-1-carboxamide; [0290]
N-(6-(5-(hydroxymethyl)-2-oxoindolin-4-yl)imidazo[1,2-a]pyridin-2-yl)cycl-
opropanecarboxamide; [0291]
2-fluoro-N-(6-(5-(hydroxymethyl)-2-oxoindolin-4-yl)imidazo[1,2-a]pyridin--
2-yl)cyclopropane-1-carboxamide; [0292]
N-(6-(3-(hydroxymethyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)imidazo[1,2-a]pyrid-
in-2-yl)cyclopropanecarboxamide; [0293]
2-fluoro-N-(6-(3-(hydroxymethyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)imidazo[1,-
2-a]pyridin-2-yl)cyclopropane-1-carboxamide; [0294]
N-(6-(2-(hydroxymethyl)-5-(1H-pyrazol-1-yl)phenyl)imidazo[1,2-a]pyridin-2-
-yl)cyclopropanecarboxamide; [0295]
2-fluoro-N-(6-(2-(hydroxymethyl)-5-(1H-pyrazol-1-yl)phenyl)imidazo[1,2-a]-
pyridin-2-yl)cyclopropane-1-carboxamide; [0296]
N-(6-(5-(hydroxymethyl)-3-methyl-1H-indol-4-yl)imidazo[1,2-a]pyridin-2-yl-
)cyclopropanecarboxamide; [0297]
2-fluoro-N-(6-(5-(hydroxymethyl)-3-methyl-1H-indol-4-yl)imidazo[1,2-a]pyr-
idin-2-yl)cyclopropane-1-carboxamide; [0298]
N-(6-(4-(hydroxymethyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)imidazo[1,2-a]pyrid-
in-2-yl)cyclopropanecarboxamide; [0299]
2-fluoro-N-(6-(4-(hydroxymethyl)-1H-pyrrolo[2,3-b]pyridin-5-yl)imidazo[1,-
2-a]pyridin-2-yl)cyclopropane-1-carboxamide; [0300]
N-(6-(5-(hydroxymethyl)-1H-indol-6-yl)imidazo[1,2-a]pyridin-2-yl)cyclopro-
panecarboxamide; [0301]
2-fluoro-N-(6-(5-(hydroxymethyl)-1H-indol-6-yl)imidazo[1,2-a]pyridin-2-yl-
)cyclopropane-1-carboxamide; [0302]
N-(6-(6-(hydroxymethyl)-1H-indol-5-yl)imidazo[1,2-a]pyridin-2-yl)cyclopro-
panecarboxamide; [0303]
2-fluoro-N-(6-(6-(hydroxymethyl)-1H-indol-5-yl)imidazo[1,2-a]pyridin-2-yl-
)cyclopropane-1-carboxamide; [0304]
N-(6-(5-(hydroxymethyl)-1H-benzo[d]imidazol-6-yl)imidazo[1,2-a]pyridin-2--
yl)cyclopropanecarboxamide; [0305]
2-fluoro-N-(6-(5-(hydroxymethyl)-1H-benzo[d]imidazol-6-yl)imidazo[1,2-a]p-
yridin-2-yl)cyclopropane-1-carboxamide; [0306]
N-(6-(5-(hydroxymethyl)benzo[d]oxazol-6-yl)imidazo[1,2-a]pyridin-2-yl)cyc-
lopropanecarboxamide; [0307]
2-fluoro-N-(6-(5-(hydroxymethyl)benzo[d]oxazol-6-yl)imidazo[1,2-a]pyridin-
-2-yl)cyclopropane-1-carboxamide; [0308]
N-(6-(5-(hydroxymethyl)-1H-benzo[d]imidazol-4-yl)imidazo[1,2-a]pyridin-2--
yl)cyclopropanecarboxamide; [0309]
2-fluoro-N-(6-(5-(hydroxymethyl)-1H-benzo[d]imidazol-4-yl)imidazo[1,2-a]p-
yridin-2-yl)cyclopropane-1-carboxamide; [0310]
N-(6-(5-(hydroxymethyl)benzo[d]thiazol-4-yl)imidazo[1,2-a]pyridin-2-yl)cy-
clopropanecarboxamide; [0311]
2-fluoro-N-(6-(5-(hydroxymethyl)benzo[d]thiazol-4-yl)imidazo[1,2-a]pyridi-
n-2-yl)cyclopropane-1-carboxamide; [0312]
N-(6-(5-(hydroxymethyl)benzo[d]oxazol-4-yl)imidazo[1,2-a]pyridin-2-yl)cyc-
lopropanecarboxamide; [0313]
2-fluoro-N-(6-(5-(hydroxymethyl)benzo[d]oxazol-4-yl)imidazo[1,2-a]pyridin-
-2-yl)cyclopropane-1-carboxamide; [0314]
N-(6-(5-(hydroxymethyl)benzo[d]thiazol-6-yl)imidazo[1,2-a]pyridin-2-yl)cy-
clopropanecarboxamide; [0315]
2-fluoro-N-(6-(5-(hydroxymethyl)benzo[d]thiazol-6-yl)imidazo[1,2-a]pyridi-
n-2-yl)cyclopropane-1-carboxamide; [0316]
N-(6-(7-(hydroxymethyl)benzo[d]thiazol-6-yl)imidazo[1,2-a]pyridin-2-yl)cy-
clopropanecarboxamide; [0317]
2-fluoro-N-(6-(7-(hydroxymethyl)benzo[d]thiazol-6-yl)imidazo[1,2-a]pyridi-
n-2-yl)cyclopropane-1-carboxamide; [0318]
N-(6-(5-(hydroxymethyl)thiazol-4-Amidazo[1,2-a]pyridin-2-yl)cyclopropanec-
arboxamide; and [0319]
2-fluoro-N-(6-(5-(hydroxymethyl)thiazol-4-yl)imidazo[1,2-a]pyridin-2-yl)c-
yclopropane-1-carboxamide.
[0320] In an embodiment, R.sup.1 is fluorocyclopropyl; R.sup.2 and
R.sup.3 are H; R.sup.4 is phenyl, indolinyl, oxoindolinyl, or
benzothiazolyl, wherein R.sup.4 is optionally substituted with one
or more groups selected from the group consisting of halo,
hydroxyl, alkyl, alkylamino, and pyrrolyl; and R.sup.5 is --H,
halo, or C.sub.1-C.sub.3 alkyl. In various embodiments, such
compounds include, but are not limited to, the following compounds
and salts thereof: [0321]
2-fluoro-N-(6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclopr-
opane-1-carboxamide; [0322]
2-fluoro-N-(6-(2-fluoro-6-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclopr-
opane-1-carboxamide; [0323]
N-(3-chloro-6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluo-
rocyclopropane-1-carboxamide; [0324]
N-(3-chloro-6-(2-fluoro-6-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluo-
rocyclopropane-1-carboxamide; [0325]
2-fluoro-N-(6-(3-fluoro-2-methylphenyl)-3-methylimidazo[1,2-a]pyridin-2-y-
l)cyclopropane-1-carboxamide; [0326]
2-fluoro-N-(6-(2-fluoro-6-methylphenyl)-3-methylimidazo[1,2-a]pyridin-2-y-
l)cyclopropane-1-carboxamide; [0327]
2-fluoro-N-(6-(5-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclopr-
opane-1-carboxamide; [0328]
2-fluoro-N-(6-(5-hydroxy-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclop-
ropane-1-carboxamide; [0329]
2-fluoro-N-(6-(5-methyl-1H-indol-4-yl)imidazo[1,2-a]pyridin-2-yl)cyclopro-
pane-1-carboxamide; [0330]
2-fluoro-N-(6-(3-hydroxy-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclop-
ropane-1-carboxamide; [0331]
N-(6-(2,3-dimethylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopropane-
-1-carboxamide; [0332]
2-fluoro-N-(6-(2-methyl-5-(methylamino)phenyl)imidazo[1,2-a]pyridin-2-yl)-
cyclopropane-1-carboxamide; [0333]
N-(6-(2,4-dimethylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopropane-
-1-carboxamide; [0334]
2-fluoro-N-(3-fluoro-6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropane-1-carboxamide; [0335]
N-(6-(2,5-dimethylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopropane-
-1-carboxamide; [0336]
2-fluoro-N-(6-(2-oxoindolin-6-yl)imidazo[1,2-a]pyridin-2-yl)cyclopropane--
1-carboxamide; [0337]
2-fluoro-N-(6-(2-methyl-5-(1H-pyrrol-3-yl)phenyl)imidazo[1,2-a]pyridin-2--
yl)cyclopropane-1-carboxamide; [0338]
N-(6-(2,6-dimethylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopropane-
-1-carboxamide; [0339]
2-fluoro-N-(6-(4-fluoro-5-hydroxy-2-methylphenyl)imidazo[1,2-a]pyridin-2--
yl)cyclopropane-1-carboxamide; [0340]
2-fluoro-N-(6-(5-methyl-2-oxoindolin-4-yl)imidazo[1,2-a]pyridin-2-yl)cycl-
opropane-1-carboxamide; [0341]
N-(3-bromo-6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluor-
ocyclopropane-1-carboxamide; [0342]
N-(6-(3,5-dimethyl-1H-indol-4-yl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocycl-
opropanecarboxamide; [0343]
2-fluoro-N-(6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclopr-
opanecarboxamide; [0344]
2-fluoro-N-(6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclopr-
opanecarboxamide; [0345]
2-fluoro-N-(6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclopr-
opanecarboxamide; [0346]
2-fluoro-N-(6-(5-methyl-1H-indol-6-yl)imidazo[1,2-a]pyridin-2-yl)cyclopro-
panecarboxamide; [0347]
2-fluoro-N-(6-(6-methyl-1H-indol-5-yl)imidazo[1,2-a]pyridin-2-yl)cyclopro-
panecarboxamide; and [0348]
2-fluoro-N-(6-(5-methylbenzo[d]thiazol-6-yl)imidazo[1,2-a]pyridin-2-yl)cy-
clopropanecarboxamide.
[0349] In one embodiment, the compound of Formula (I) is selected
from compounds according to Formula (II) and pharmaceutically
acceptable salts thereof:
##STR00011##
[0350] wherein R.sup.6 is selected from the group consisting of
halo, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 hydroxyalkyl and
C.sub.1-C.sub.3 haloalkyl and R.sup.2, R.sup.3, R.sup.4, and
R.sup.5 are as defined above.
[0351] In one embodiment, the compound of Formula (I) is a compound
of which R.sup.1 is cyclopropyl. In an embodiment, the compound of
Formula (I) is
N-(6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cycloprop-
anecarboxamide or a salt thereof.
[0352] In another embodiment, the compound of Formula (I) is a
compound of which R.sup.1 is cyclobutyl which is optionally
substituted with one or more groups selected from the group
consisting of halo, alkyl, hydroxyalkyl, haloalkyl, and
monoalkylaminoalkyl; and R.sup.2, R.sup.3, R.sup.4, and R.sup.5 are
as defined above. In various embodiments, the compound of Formula
(I) is selected from the group consisting of the following
compounds and salts thereof: [0353]
N-(6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclobutanecarbo-
xamide; [0354]
3-fluoro-N-(6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclobu-
tanecarboxamide; and [0355]
3,3-difluoro-N-(6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyc-
lobutanecarboxamide.
[0356] The compounds of the present disclosure include
stereoisomers of the compounds described herein. In some
embodiments, the compounds are stereochemically pure compounds such
as those substantially free (e.g., greater than 85% ee, greater
than 90% ee, greater than 95% ee, greater than 97% ee, or greater
than 99% ee) of other stereoisomers. Examples of such stereoisomers
include, but are not limited to,
##STR00012##
wherein R.sup.2, R.sup.3, R.sup.4, R.sup.5, and R.sup.6 are as
defined above.
[0357] In one embodiment, the compound of Formula (I) is selected
from compounds according to Formula (III) and pharmaceutically
acceptable salts thereof:
##STR00013##
[0358] wherein R.sup.6 is selected from the group consisting of
halo, C.sub.1-C.sub.3 alkyl, C.sub.1-C.sub.3 hydroxyalkyl and
C.sub.1-C.sub.3 haloalkyl and R.sup.2, R.sup.3, R.sup.4, and
R.sup.5 are as defined above. Table 1 shows exemplary compounds
having the stereochemistry of Formula (III). Examples of the
compound of Formula (III) include, but are not limited to, the
following compounds and salts thereof: [0359] (1 S,2
S)-2-fluoro-N-(6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cycl-
opropane-1-carboxamide; [0360] (1 S,2
S)-2-fluoro-N-(6-(2-fluoro-6-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cycl-
opropane-1-carboxamide; [0361] (1 S,2
S)-N-(3-chloro-6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-f-
luorocyclopropane-1-carboxamide; [0362] (1 S,2
S)-N-(3-chloro-6-(2-fluoro-6-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-f-
luorocyclopropane-1-carboxamide; [0363] (1 S,2
S)-2-fluoro-N-(3-methyl-6-(4-methylpyridin-3-yl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropane-1-carboxamide; [0364] (1 S,2
S)-2-fluoro-N-(6-(4-methylpyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)cyclopr-
opane-1-carboxamide; [0365] (1 S,2
S)-N-(3-chloro-6-(4-methylpyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)-2-fluo-
rocyclopropane-1-carboxamide; [0366] (1 S,2
S)-2-fluoro-N-(6-(3-fluoro-2-methylphenyl)-3-methylimidazo[1,2-a]pyridin--
2-yl)cyclopropane-1-carboxamide; [0367] (1 S,2
S)-2-fluoro-N-(6-(2-fluoro-6-methylphenyl)-3-methylimidazo[1,2-a]pyridin--
2-yl)cyclopropane-1-carboxamide; [0368] (1 S,2
S)-2-fluoro-N-(6-(5-fluoro-4-methylpyridin-3-yl)-3-methylimidazo[1,2-a]py-
ridin-2-yl)cyclopropane-1-carboxamide; [0369] (1 S,2
S)-2-fluoro-N-(6-(5-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cycl-
opropane-1-carboxamide; [0370] (1 S,2
S)-2-fluoro-N-(6-(5-hydroxy-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyc-
lopropane-1-carboxamide; [0371] methyl 3-(2-((1 S,2
S)-2-fluorocyclopropane-1-carboxamido)imidazo[1,2-a]pyridin-6-yl)-4-methy-
lbenzoate; [0372] (1 S,2
S)-2-fluoro-N-(6-(5-fluoro-4-methylpyridin-3-yl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropane-1-carboxamide; [0373] (1 S,2
S)-2-fluoro-N-(6-(5-methyl-1H-indol-4-yl)imidazo[1,2-a]pyridin-2-yl)cyclo-
propane-1-carboxamide; [0374] (1 S,2
S)-N-(3-chloro-6-(5-fluoro-4-methylpyridin-3-yl)imidazo[1,2-a]pyridin-2-y-
l)-2-fluorocyclopropane-1-carboxamide; [0375] (1 S,2
S)-N-(6-(5-cyano-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclo-
propane-1-carboxamide; [0376] (1 S,2
S)-N-(6-(1H-pyrazol-3-yl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopropane-
-1-carboxamide; [0377] (1 S,2
S)-2-fluoro-N-(6-(4-methyl-1H-pyrazol-3-yl)imidazo[1,2-a]pyridin-2-yl)cyc-
lopropane-1-carboxamide; [0378] (1 S,2
S)-2-fluoro-N-(6-(3-hydroxy-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyc-
lopropane-1-carboxamide; [0379] (1 S,2
S)-N-(6-(4-chloropyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopr-
opane-1-carboxamide; [0380] (1 S,2
S)-N-(6-(2,3-dimethylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocycloprop-
ane-1-carboxamide; [0381] (1 S,2
S)-N-(6-(5-amino-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclo-
propane-1-carboxamide; [0382] (1 S,2
S)-2-fluoro-N-(6-(2-methyl-5-(methylamino)phenyl)imidazo[1,2-a]pyridin-2--
yl)cyclopropane-1-carboxamide; [0383] (1 S,2
S)-N-(6-(5-acetamido-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluoroc-
yclopropane-1-carboxamide; [0384] (1 S,2
S)-N-(6-(5-chloro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocycl-
opropane-1-carboxamide; [0385] (1 S,2
S)-N-(6-(1H-pyrrolo[2,3-b]pyridin-5-yl)imidazo[1,2-a]pyridin-2-yl)-2-fluo-
rocyclopropane-1-carboxamide; [0386] (1 S,2
S)-2-fluoro-N-(6-(2-methyl-5-(1H-pyrazol-3-yl)phenyl)imidazo[1,2-a]pyridi-
n-2-yl)cyclopropane-1-carboxamide; [0387] (1 S,2
S)-N-(6-(4-chloro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocycl-
opropane-1-carboxamide; [0388] (1 S,2
S)-N-(6-(3-chloro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocycl-
opropane-1-carboxamide; [0389] (1 S,2
S)-2-fluoro-N-(6-(4-(trifluoromethyl)pyridin-3-yl)imidazo[1,2-a]pyridin-2-
-yl)cyclopropane-1-carboxamide; [0390] (1 S,2
S)-N-(6-(2,4-dimethylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocycloprop-
ane-1-carboxamide; [0391] (1 S,2
S)-2-fluoro-N-(3-fluoro-6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin--
2-yl)cyclopropane-1-carboxamide; [0392] (1 S,2
S)-N-(6-(2,5-dimethylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocycloprop-
ane-1-carboxamide; [0393] (1 S,2
S)-2-fluoro-N-(6-(2-oxoindolin-6-yl)imidazo[1,2-a]pyridin-2-yl)cyclopropa-
ne-1-carboxamide; [0394] (1 S,2
S)-N-(6-(4-cyanopyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopro-
pane-1-carboxamide; [0395] (1 S,2
S)-2-fluoro-N-(6-(4-fluoro-2,3-dimethylphenyl)imidazo[1,2-a]pyridin-2-yl)-
cyclopropane-1-carboxamide; [0396] (1 S,2
S)-2-fluoro-N-(6-(4-fluoro-2,6-dimethylphenyl)imidazo[1,2-a]pyridin-2-yl)-
cyclopropane-1-carboxamide; [0397] (1 S,2
S)-2-fluoro-N-(6-(4-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cycl-
opropane-1-carboxamide; [0398] (1 S,2
S)-2-fluoro-N-(6-(2-methyl-5-(1H-pyrrol-3-yl)phenyl)imidazo[1,2-a]pyridin-
-2-yl)cyclopropane-1-carboxamide; [0399] (1 S,2
S)-2-fluoro-N-(6-(3-methylthiophen-2-yl)imidazo[1,2-a]pyridin-2-yl)cyclop-
ropane-1-carboxamide; [0400] (1 S,2
S)-N-(6-(2,6-dimethylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocycloprop-
ane-1-carboxamide; [0401] (1 S,2
S)-2-fluoro-N-(6-(4-fluoro-5-hydroxy-2-methylphenyl)imidazo[1,2-a]pyridin-
-2-yl)cyclopropane-1-carboxamide; [0402] (1 S,2
S)-N-(6-(3,4-difluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluoro-
cyclopropane-1-carboxamide; [0403] (1 S,2
S)-N-(6-(3,6-difluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluoro-
cyclopropane-1-carboxamide; [0404] (1 S,2
S)-N-(6-(4-chloro-3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-f-
luorocyclopropane-1-carboxamide; [0405] (1 S,2
S)-2-fluoro-N-(6-(2-fluoro-4-methylpyridin-3-yl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropane-1-carboxamide; [0406] (1 S,2
S)-2-fluoro-N-(6-(4-methoxypyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)cyclop-
ropane-1-carboxamide; [0407] (1 S,2
S)-N-(6-(6-amino-4-methylpyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)-2-fluor-
ocyclopropane-1-carboxamide; [0408] (1 S,2
S)-N-(6-(5-amino-3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fl-
uorocyclopropane-1-carboxamide; [0409] (1 S,2
S)-2-fluoro-N-(6-(5-methyl-2-oxoindolin-4-yl)imidazo[1,2-a]pyridin-2-yl)c-
yclopropane-1-carboxamide; [0410] (1 S,2
S)-N-(6-(2-chloro-6-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocycl-
opropane-1-carboxamide; [0411] (1 S,2
S)-2-fluoro-N-(6-(3-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)imidazo[1,2-a]py-
ridin-2-yl)cyclopropane-1-carboxamide; [0412] (1 S,2
S)-2-fluoro-N-(6-(2-oxo-2,3-dihydrobenzo[d]thiazol-5-yl)imidazo[1,2-a]pyr-
idin-2-yl)cyclopropane-1-carboxamide; [0413] (1 S,2
S)-N-(6-(6-aminopyridin-3-yl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopro-
pane-1-carboxamide; [0414] (1 S,2
S)-2-fluoro-N-(6-(2-methyl-5-(1H-pyrazol-1-yl)phenyl)imidazo[1,2-a]pyridi-
n-2-yl)cyclopropane-1-carboxamide; [0415] (1 S,2
S)-2-fluoro-N-(6-(3-fluoro-2-(hydroxymethyl)phenyl)imidazo[1,2-a]pyridin--
2-yl)cyclopropane-1-carboxamide; [0416] (1 S,2
S)-N-(3-bromo-6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fl-
uorocyclopropane-1-carboxamide; [0417] (1 S,2
S)-2-fluoro-N-(6-(3-fluoro-2-methoxyphenyl)imidazo[1,2-a]
pyridin-2-yl)cyclopropanecarboxamide; [0418] (1 S,2
S)-N-(6-(2-cyano-3-fluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclo-
propanecarboxamide; [0419] (1 S,2
S)-N-(6-(2-chloro-3-fluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocycl-
opropanecarboxamide; [0420] (1 S,2
S)-N-(6-(2,3-difluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocycloprop-
anecarboxamide; [0421] (1 S,2
S)-N-(6-(3,5-dimethyl-1H-indol-4-yl)imidazo[1,2-a]pyridin-2-yl)-2-fluoroc-
yclopropanecarboxamide; [0422] (1 S,2
S)-2-fluoro-N-(6-(3-fluoro-2-(methoxymethyl)phenyl)imidazo[1,2-a]pyridin--
2-yl)cyclopropanecarboxamide; [0423] (1 S,2
S)-2-fluoro-N-(6-(3-fluoro-2-(furan-2-yl)phenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropanecarboxamide; [0424] (1 S,2
S)-2-fluoro-N-(6-(3-fluoro-2-(methylthio)phenyl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropanecarboxamide; [0425] (1 S,2
S)-2-fluoro-N-(6-(6-fluoro-4-methylpyridin-3-yl)imidazo[1,2-a]pyridin-2-y-
l)cyclopropanecarboxamide; [0426] (1 S,2
S)-N-(6-(2-acetyl-3-fluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocycl-
opropanecarboxamide; [0427] (1 S,2
S)-N-(6-(6-(dimethylamino)-4-methylpyridin-3-yl)imidazo[1,2-a]pyridin-2-y-
l)-2-fluorocyclopropanecarboxamide; [0428]
N-(6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclopropanecarb-
oxamide [0429] (1 S,2
S)-N-(6-(2-(aminomethyl)-3-fluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-flu-
orocyclopropanecarboxamide; [0430] (1 S,2
S)-N-(6-(2-(acetamidomethyl)-3-fluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-
-fluorocyclopropanecarboxamide; [0431] (1 S,2
S)-2-fluoro-N-(6-(3-fluoro-2-((methylamino) methyl)
phenyl)imidazo[1,2-a]pyridin-2-yl)cyclopropanecarboxamide; [0432]
(1 S,2
S)-2-fluoro-N-(6-(3-fluoro-2-((isopropylamino)methyl)phenyl)imidazo[1,2-a-
]pyridin-2-yl)cyclopropanecarboxamide; [0433] (1 S,2
S)-2-fluoro-N-(6-(3-fluoro-24(2-methoxyethoxy)methyl)phenyl)imidazo[1,2-a-
]pyridin-2-yl)cyclopropanecarboxamide; [0434] (1 S,2
S)-2-fluoro-N-(6-(3-fluoro-2-((2-hydroxyethoxy)methyl)phenyl)imidazo[1,2--
a]pyridin-2-yl)cyclopropanecarboxamide; [0435] (1 S,2
S)-N-(6-(2-((dimethylamino)methyl)-3-fluorophenyl)imidazo[1,2-a]pyridin-2-
-yl)-2-fluorocyclopropanecarboxamide; [0436] (1 S,2
S)-N-(6-(1H-pyrrolo[2,3-b]pyridin-5-yl)imidazo[1,2-a]pyridin-2-yl)-2-fluo-
rocyclopropanecarboxamide; [0437] (1 S,2
S)-2-fluoro-N-(6-(4-methyl-1H-pyrrolo[2,3-b]pyridin-5-yl)imidazo[1,2-a]py-
ridin-2-yl)cyclopropanecarboxamide; [0438] (1 S,2
S)-N-(6-(4-chloro-1H-pyrrolo[2,3-b]pyridin-5-yl)imidazo[1,2-a]pyridin-2-y-
l)-2-fluorocyclopropanecarboxamide; [0439] (1 S,2
S)-2-fluoro-N-(6-(o-tolyl)imidazo[1,2-a]pyridin-2-yl)cyclopropanecarboxam-
ide; [0440] (1 S,2
S)-2-fluoro-N-(6-(3-fluoro-2-hydroxyphenyl)imidazo[1,2-a]pyridin-2-yl)cyc-
lopropanecarboxamide; [0441] (1 S,2
S)-N-(6-(2-amino-3-fluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclo-
propanecarboxamide; [0442] (1 S,2
S)-2-fluoro-N-(6-(5-methyl-1H-indol-6-yl)imidazo[1,2-a]pyridin-2-yl)cyclo-
propanecarboxamide; [0443] (1 S,2
S)-2-fluoro-N-(6-(6-methyl-1H-indol-5-yl)imidazo[1,2-a]pyridin-2-yl)cyclo-
propanecarboxamide; [0444] (1 S,2
S)-N-(6-(2-(dimethylamino)-3-fluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-f-
luorocyclopropanecarboxamide; [0445] (1 S,2
S)-2-fluoro-N-(6-(5-methyl-1H-benzo[d]imidazol-6-yl)imidazo[1,2-a]pyridin-
-2-yl)cyclopropanecarboxamide; [0446] (1 S,2
S)-N-(6-(2-ethyl-3-fluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclo-
propanecarboxamide; [0447] (1 S,2
S)-2-fluoro-N-(6-(3-fluoro-2-(trifluoromethyl)phenyl)imidazo[1,2-a]pyridi-
n-2-yl)cyclopropanecarboxamide; [0448] (1 S,2
S)-N-(6-(2-cyclopropyl-3-fluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluor-
ocyclopropanecarboxamide; [0449] (1 S,2
S)-2-fluoro-N-(6-(3-fluoro-2-(methylamino)phenyl)imidazo[1,2-a]pyridin-2--
yl)cyclopropanecarboxamide; [0450] (1 S,2
S)-2-fluoro-N-(6-(5-methylbenzo[d]oxazol-6-yl)imidazo[1,2-a]pyridin-2-yl)-
cyclopropanecarboxamide; [0451] (1 S,2
S)-2-fluoro-N-(6-(5-methyl-1H-benzo[d]imidazol-4-yl)imidazo[1,2-a]pyridin-
-2-yl)cyclopropane-1-carboxamide; [0452] (1 S,2
S)-2-fluoro-N-(6-(6-methylbenzo[d]thiazol-5-yl)imidazo[1,2-a]pyridin-2-yl-
)cyclopropanecarboxamide; [0453] (1 S,2
S)-2-fluoro-N-(6-(5-methylbenzo[d]oxazol-4-yl)imidazo[1,2-a]pyridin-2-yl)-
cyclopropanecarboxamide; [0454] (1 S,2
S)-2-fluoro-N-(6-(5-methylbenzo[d]thiazol-6-yl)imidazo[1,2-a]pyridin-2-yl-
)cyclopropanecarboxamide; [0455] (1 S,2
S)-2-fluoro-N-(6-(7-methylbenzo[d]thiazol-6-yl)imidazo[1,2-a]pyridin-2-yl-
)cyclopropanecarboxamide; and [0456] (1 S,2
S)-2-fluoro-N-(6-(3-fluoro-2-isopropylphenyl)imidazo[1,2-a]pyridin-2-yl)c-
yclopropanecarboxamide.
[0457] In particular embodiments, the compound of Formula (I) is
selected from the group consisting of the following compounds and
salts thereof: [0458] (1 S,2
S)-2-fluoro-N-(6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cycl-
opropane-1-carboxamide; [0459] (1 S,2
S)-2-fluoro-N-(6-(5-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cycl-
opropane-1-carboxamide; [0460] (1 S,2
S)-2-fluoro-N-(6-(5-hydroxy-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyc-
lopropane-1-carboxamide; [0461] (1 S,2
S)-2-fluoro-N-(6-(5-methyl-1H-indol-4-yl)imidazo[1,2-a]pyridin-2-yl)cyclo-
propane-1-carboxamide; [0462] (1 S,2
S)-2-fluoro-N-(6-(2-methyl-5-(methylamino)phenyl)imidazo[1,2-a]pyridin-2--
yl)cyclopropane-1-carboxamide; [0463] (1 S,2
S)-N-(6-(2,5-dimethylphenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocycloprop-
ane-1-carboxamide; [0464] (1 S,2
S)-2-fluoro-N-(6-(2-methyl-5-(1H-pyrrol-3-yl)phenyl)imidazo[1,2-a]pyridin-
-2-yl)cyclopropane-1-carboxamide; [0465] (1 S,2
S)-2-fluoro-N-(6-(4-fluoro-5-hydroxy-2-methylphenyl)imidazo[1,2-a]pyridin-
-2-yl)cyclopropane-1-carboxamide; [0466] (1 S,2
S)-2-fluoro-N-(6-(6-methyl-1H-indol-5-yl)imidazo[1,2-a]pyridin-2-yl)cyclo-
propanecarboxamide; and [0467] (1 S,2
S)-2-fluoro-N-(6-(5-methylbenzo[d]thiazol-6-yl)imidazo[1,2-a]pyridin-2-yl-
)cyclopropanecarboxamide.
[0468] The present disclosure provides pharmaceutically acceptable
salts of the compounds described above. The pharmaceutically
acceptable salts are as defined above in the definition section. In
some embodiments, the salt is hydrochloric acid salt, tartaric acid
salt, phosphoric acid salt, or maleic acid salt.
[0469] Methods of Treatment
[0470] The present disclosure further provides methods for treating
cancer and/or proliferative disorders in a subject having or
susceptible to having such a disease or disorder, by administering
to the subject a therapeutically effective amount of one or more
compounds as described above.
[0471] 1. Diseases or Conditions
[0472] The compound of the present disclosure for inhibiting c-abl,
KIT and PDGFR activity is useful for treatment or prevention of
cancer diseases and proliferative disorders. The compound can be
used for inhibiting or hindering c-abl, KIT and/or PDGFR kinase
activity, and for treating cancer diseases and proliferative
disorders, or for preventing aggravation of such disease. Thus, the
present disclosure provides a method for inhibiting or hindering
c-abl, KIT and/or PDGFR activity in a cell, wherein the cell is
contacted with an effective amount of a compound of the present
disclosure. In one embodiment, such cell is present in a subject
(for example, CML patients). In another embodiment, there is
provided a medical use for treating or preventing cancer diseases
and proliferative disorders in a subject, using the compound
according to the present disclosure. The method of the present
disclosure comprises administering to a subject in need of
treatment or prevention of cancer diseases and proliferative
disorders with a pharmaceutical composition containing a
therapeutically or prophylactically effective amount of c-abl, KIT
and/or PDGFR inhibitor. The cancer diseases and proliferative
disorders include, but is not limited to, breast cancer, ovarian
cancer, NSCLC, acute lymphocytic leukemia acute myelogeneous
leukemia, chronic myelogenous leukemia and chronic lymphocytic
leukemia.
[0473] In another aspect, the compounds also described herein can
be useful for treating conditions associated with aberrant KIT
activity, in humans or non-humans. Activating mutations in KIT are
found in multiple indications, including systemic mastocytosis,
GIST (gastrointestinal stromal tumors), AML (acute myeloid
leukemia), melanoma, seminoma, intercranial germ cell tumors, and
Non-Hodgkin lymphoma (NHL) such as B cell lymphoma (BCLs), T cell
lymphoma and natural killer cell lymphoma. In addition, mutations
in KIT have been linked to Ewing's sarcoma, DLBCL (diffuse large B
cell lymphoma), dysgerminoma, MDS (myelodysplastic syndrome), NKTCL
(nasal NK/T-cell lymphoma), CMML (chronic myelomonocytic leukemia),
and brain cancers.
[0474] Mastocytosis refers to a group of disorders characterized by
excessive mast cell accumulation in one tissue, or in multiple
tissues. Mastocytosis is subdivided into two groups of disorders:
(1) cutaneous mastocytosis (CM) describes forms that are limited to
the skin; and (2) systemic mastocytosis (SM) describes forms in
which mast cells infiltrate extracutaneous organs, with or without
skin involvement. SM is further subdivided into five forms:
indolent (ISM), smoldering (SSM), aggressive (ASM), SM with
associated hematologic non-mast cell lineage disease (SM-AHNMD),
and mast cell leukemia (MCL).
[0475] Diagnosis of systemic mastocytosis is based in part on
histological and cytological studies of bone marrow showing
infiltration by mast cells of frequently atypical morphology, which
frequently abnormally express non-mast cell markers (CD25 and/or
CD2). Diagnosis of SM is confirmed when bone marrow mast cell
infiltration occurs in the context of one of the following: (1)
abnormal mast cell morphology (spindle-shaped cells); (2) elevated
level of serum tryptase above 20 ng/mL; or (3) the presence of the
activating KIT D816V mutation.
[0476] Activating mutations at the D816 position are found in the
vast majority of mastocytosis cases (90-98%), with the most common
mutations being D816V and D816H, and D816Y. The D816V mutation is
found in the activation loop of the kinase domain and leads to
constitutive activation of KIT kinase.
[0477] The compounds described herein may also be useful to treat
GIST. Complete surgical resection remains the principal treatment
of choice for patients with a primary GIST. Surgery is effective in
approximately 50% of patients with GIST; of the remaining patients,
tumor recurrence is frequent. Primary treatment with a KIT
inhibitor such as imatinib has also been shown to be sufficient for
initial treatment. However, resistance to imatinib occurs within
months through somatic mutation. These secondary imatinib resistant
mutations are most frequently located on Exon 11, 13, 14, 17 or 18.
Sunitinib is the standard of care second line treatment for most
imatinib resistant tumors and is effective for those containing
mutations in exons 11, 13 and 14. However, secondary KIT mutations
in exons 17 and 18 are resistant to sunitinib treatment and
furthermore, tumors containing tertiary resistance mutations in
exon 17 and 18 emerge several months after sunitinib treatment.
Regorafenib has shown promising results in a phase 3 clinical trial
of imatinib, sunitinib resistant GISTs with activity against
several but not all exon 17 and 18 mutations, of which D816 is one.
Thus, there is a need for therapeutic agents to treat GIST patients
with exon 17 mutations not addressed by regorafenib. In addition to
the use of the compounds described herein as single agents in the
refractory GIST setting, the use of combinations of imatinib,
sunitinib and/or regorafenib with the compounds disclosed herein
may allow for the prevention of emergence of resistance to exon 17
mutations.
[0478] The compounds described herein may also be useful in
treating AML. AML patients harbor KIT mutations as well, with the
majority of these mutations at the D816 position.
[0479] There is a subset of GIST patients with a D842V mutation in
PDGFRa; this subgroup of GIST patients can be stratified by
identifying this mutation. This subset of patients is refractory to
all tyrosine kinase inhibitors currently available. The compounds
described herein, due to their activity against PDGFR.alpha. D842V,
can be useful in treating these patients.
[0480] In various embodiments, the method above is used to treat
gastrointestinal stromal tumor(GIST), GI tract cancers such as
stomach cancer and colorectal cancer, melanoma, chronic lymphocytic
leukemia (CLL), acute lymphocytic leukem ia(ALL), or acute
myelogeneous leukemia(AML). In particular embodiments, the method
is used to treat gastrointestinal stromal tumor(GIST), melanoma or
chronic lymphocytic leukemia (CLL).
[0481] 2. Subjects
[0482] Suitable subjects to be treated according to the present
disclosure include mammalian subjects. Mammals according to the
present disclosure include, but are not limited to, human, canine,
feline, bovine, caprine, equine, ovine, porcine, rodents,
lagomorphs, primates, and the like, and encompass mammals in utero.
Subjects may be of either gender and at any stage of development.
In one embodiment, the suitable subject to be treated according to
the present disclosure is human.
[0483] 3. Administration and Dosing
[0484] The compounds of the present disclosure are generally
administered in a therapeutically effective amount. The compounds
of the present disclosure can be administered by any suitable route
in the form of a pharmaceutical composition adapted to such a
route, and in a dose effective for the treatment intended. An
effective dosage is typically in the range of about 0.001 to about
100 mg per kg body weight per day, preferably about 0.01 to about
50 mg/kg/day, in single or divided doses. Depending on age, species
and disease or condition being treated, dosage levels below the
lower limit of this range may be suitable. In other cases, still
larger doses may be used without harmful side effects. Larger doses
may also be divided into several smaller doses, for administration
throughout the day. Methods for determining suitable doses are well
known in the art to which the present disclosure pertains. For
example, Remington: The Science and Practice of Pharmacy, Mack
Publishing Co., 20th ed., 2000 can be used.
[0485] Pharmaceutical Compositions, Dosage Forms and Administration
Routes
[0486] For the treatment of the diseases or conditions referred to
above, the compounds described herein or pharmaceutically
acceptable salts thereof can be administered as follows:
[0487] Oral Administration
[0488] The compounds of the present disclosure may be administered
orally, including by swallowing, so that the compound enters the
gastrointestinal tract, or absorbed into the blood stream directly
from the mouth (e.g., buccal or sublingual administration).
[0489] Suitable compositions for oral administration include solid,
liquid, gel or powder formulations, and have a dosage form such as
tablet, lozenge, capsule, granule or powder.
[0490] Compositions for oral administration may be formulated as
immediate or modified release, including delayed or sustained
release, optionally with enteric coating.
[0491] Liquid formulations can include solutions, syrups and
suspensions, which can be used in soft or hard capsules. Such
formulations may include a pharmaceutically acceptable carrier, for
example, water, ethanol, polyethylene glycol, cellulose, or an oil.
The formulation may also include one or more emulsifying agents
and/or suspending agents.
[0492] In a tablet dosage form the amount of drug present may be
from about 0.05% to about 95% by weight, more typically from about
2% to about 50% by weight of the dosage form. In addition, tablets
may contain a disintegrant, comprising from about 0.5% to about 35%
by weight, more typically from about 2% to about 25% of the dosage
form. Examples of disintegrants include, but are not limited to,
lactose, starch, sodium starch glycolate, crospovidone,
croscarmellose sodium, maltodextrin, or mixtures thereof.
[0493] Suitable lubricants, for use in a tablet, may be present in
amounts from about 0.1% to about 5% by weight, and include, but are
not limited to, talc, silicon dioxide, stearic acid, calcium, zinc
or magnesium stearate, sodium stearyl fumarate and the like.
[0494] Suitable binders, for use in a tablet, include, but are not
limited to, gelatin, polyethylene glycol, sugars, gums, starch,
polyvinyl pyrrolidone, hydroxypropyl cellulose, hydroxypropylmethyl
cellulose and the like. Suitable diluents, for use in a tablet,
include, but are not limited to, mannitol, xylitol, lactose,
dextrose, sucrose, sorbitol, microcrystalline cellulose and
starch.
[0495] Suitable solubilizers, for use in a tablet, may be present
in amounts from about 0.1% to about 3% by weight, and include, but
are not limited to, polysorbates, sodium lauryl sulfate, sodium
dodecyl sulfate, propylene carbonate, diethyleneglycol monoethyl
ether, dimethyl isosorbide, polyethylene glycol (natural or
hydrogenated) castor oil, HCOR.TM. (Nikkol), oleyl ester,
Gelucire.TM., caprylic/caprylic acid mono/diglyceride, sorbitan
fatty acid esters, and Solutol HS.TM..
[0496] Parenteral Administration
[0497] Compounds of the present disclosure may be administered
directly into the blood stream, muscle, or internal organs.
Suitable means for parenteral administration include intravenous,
intra-muscular, subcutaneous intraarterial, intraperitoneal,
intrathecal, intracranial, and the like. Suitable devices for
parenteral administration include injectors (including needle and
needle-free injectors) and infusion methods.
[0498] Compositions for parenteral administration may be formulated
as immediate or modified release, including delayed or sustained
release. Most parenteral formulations are aqueous solutions
containing excipients, including salts, buffering agents and
isotonic agents. Parenteral formulations may also be prepared in a
dehydrated form (e.g., by lyophilization) or as sterile non-aqueous
solutions. These formulations can be used with a suitable vehicle,
such as sterile water. Solubility-enhancing agents may also be used
in preparation of parenteral solutions.
[0499] Transdermal Administration
[0500] Compounds of the present disclosure may be administered
topically to the skin or transdermally. Formulations for this
topical administration can include lotions, solutions, creams,
gels, hydrogels, ointments, foams, implants, patches and the like.
Pharmaceutically acceptable carriers for topical administration
formulations can include water, alcohol, mineral oil, glycerin,
polyethylene glycol and the like. Topical or transdermal
administration can also be performed by electroporation,
iontophoresis, phonophoresis and the like.
[0501] Compositions for topical administration may be formulated as
immediate or modified release, including delayed or sustained
release.
[0502] Combination Therapy
[0503] A pharmaceutical composition according to the present
disclosure may contain one or more additional therapeutic agents,
for example, to increase the efficacy or decrease the side effects.
In some embodiments, accordingly, a pharmaceutical composition
further contains one or more additional therapeutic agents selected
from active ingredients useful to treat or inhibit diseases
mediated directly or indirectly by c-abl, c-abl, KIT and/or PDGFR
kinase. Examples of such active ingredients are, without
limitation, agents such asimatinib, sunitinib and regorafenib.
Other agents include the compounds described in WO 2014/039714 and
WO 2014/100620.
[0504] References for Preparing Pharmaceutical Compositions
[0505] Methods for preparing pharmaceutical compositions for
treating or preventing a disease or condition are well known in the
art to which the present disclosure pertains. For example, based on
Handbook of Pharmaceutical Excipients (7th ed.), Remington: The
Science and Practice of Pharmacy (20th ed.), Encyclopedia of
Pharmaceutical Technology (3.sup.rd ed.), or Sustained and
Controlled Release Drug Delivery Systems (1978), pharmaceutically
acceptable excipients, carriers, additives and so on can be
selected and then mixed with the compounds of the present
disclosure for making the pharmaceutical compositions.
[0506] The present disclosure provides a compound having various
pharmacological effects by inhibiting c-abl, KIT and/or PDGFR
activity, a pharmaceutical composition having the compound as an
effective agent, a medical use, particularly for treating cancer
diseases and proliferative disorders, of the compound, and a method
of treatment or prevention comprising administering the compound to
a subject in need of such treatment or prevention. The compounds of
the present disclosure and pharmaceutically acceptable salts
thereof have good safety and high selectivity for c-abl, KIT and/or
PDGFR, and thus exhibit superior properties as a drug.
EXAMPLES
[0507] Hereinafter, the present disclosure is described in
considerable detail with examples to help those skilled in the art
understand the present disclosure. However, the following examples
are offered by way of illustration and are not intended to limit
the scope of the invention. It is apparent that various changes may
be made without departing from the spirit and scope of the
invention or sacrificing all of its material advantages.
[0508] Synthesis of Formula (I) Compounds
[0509] Synthetic methods A to N were used to prepare the compounds
of the following. Below, the illustrating synthetic examples of
some compounds of the present disclosure are described, and other
compounds can be prepared by the similar method to the one
described below with different starting or reacting materials.
[0510] Synthetic Method A
Example 1
(1 S,2 S)-2-fluoro-N-(6-(3-fluoro-2-methylphenyl)imidazo[1,
2-a]pyridin-2-yl)cyclopropane-1-carboxamide hydrochloride
##STR00014##
[0511] Step 1) 6-iodoimidazo[1,2-a]pyridin-2-amine
[0512] A mixture of Compound 1 (10.000 g, 28.164 mmol) and lithium
hydroxide monohydrate (4.727 g, 112.657 mmol) in water (100
mL)/methanol (300 mL) was heated at reflux for 18 hr, cooled down
to the room temperature, concentrated under the reduced pressure,
and partitioned between ethyl acetate and saturated aqueous
ammonium chloride solution. The organic layer was washed with
aqueous saturated sodium chloride solution, separated, dried with
anhydrous MgSO.sub.4, filtered, and concentrated in vacuo. The
residue was diluted with dichloromethane (30 mL) and hexane (200
mL) and stirred at the ambient temperature. The resulting
precipitates were collected by filtration, washed by hexane, and
dried to give Compound 2 as brown solid (5.890 g, 80.7%).
Step 2) (1 S,2
S)-2-fluoro-N-(6-iodoimidazo[1,2-a]pyridin-2-yl)cyclopropane-1-carboxamid-
e
[0513] A mixture of Compound 2 (5.890 g, 22.737 mmol), (1 S,2
S)-2-fluorocyclopropane-1-carboxylic acid (3.076 g, 29.558 mmol)
and 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride
(EDC-HCl, 6.538 g, 34.105 mmol) in dichloromethane (100 mL) was
treated at the room temperature with N,N-diisopropylethylamine
(2.376 mL, 13.642 mmol), stirred at the same temperature for 40 hr.
The precipitates were collected by filtration, washed by
dichloromethane, and dried to give Compound 3 as beige solid (3.870
g, 49.3%).
[0514] 1H NMR (400 MHz, DMSO-d6) .delta.10.99 (s, 1H), 8.87 (s,
1H), 8.02 (s, 1H), 7.36.about.7.23 (m, 2H), 4.97.about.4.77 (m,
1H), 2.09.about.2.07 (m, 1H), 1.65.about.1.57 (m, 1H),
1.16.about.1.09 (m, 1H).
Step 3) (1 S,2 S)-2-fluoro-N-(6-(3-fluoro-2-methylphenyl)imidazo[1,
2-a]pyrid in-2-yl)cyclopropane-1-carboxamide
[0515] Compound 3 (1.000 g, 2.898 mmol),
(3-fluoro-2-methylphenyl)boronic acid (0.535 g, 3.477 mmol),
[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II)
(Pd(dppf)Cl.sub.2, 0.212 g, 0.290 mmol) and cesium carbonate (1.416
g, 4.346 mmol) in tetrahydrofuran (12 mL)/water (3 mL) was mixed at
the room temperature and then heated at 100.degree. C. under the
microwaves for 30 min, cooled down to the room temperature,
filtered through a celite pad to remove solids, and partitioned
between ethyl acetate and saturated aqueous sodium bicarbonate
solution. The organic layer was washed with aqueous saturated
sodium chloride solution, separated, dried (anhydrous MgSO.sub.4),
filtered, and concentrated in vacuo. The residue was
chromatographed (SiO.sub.2, 45 g cartridge; ethyl acetate/hexane
=70% to 100%) to give the crude product which was crystallized at
the room temperature using diethylether (5 mL). The resulting
precipitates were filtered, washed by diethylether, and dried to
give Compound 4 as white solid (0.700 g, 73.8%)
Step 4) (1 S,2 S)-2-fluoro-N-(6-(3-fluoro-2-methylphenyl)imidazo[1,
2-a]pyridin-2-yl)cyclopropane-1-carboxamide hydrochloride
[0516] A solution of Compound 4 (0.600 g, 1.833 mmol) in ethyl
acetate (100 mL) was mixed at the room temperature with
hydrochloric acid (1.00 M solution in EtOAc, 1.925 mL, 1.925 mmol).
The reaction mixture was stirred at the same temperature for 3 hr.
The precipitates were collected by filtration, washed by
diethylether, and dried to give Example 1 as white solid (0.665 g,
99.7%).
[0517] 1H NMR (400 MHz, DMSO-d6) .delta.11.67 (s, 1H), 8.74 (s,
1H), 8.13 (s, 1H), 7.69 (d, J=9.2 Hz, 1H), 7.55 (d, J=9.2 Hz, 1H),
7.35.about.7.30 (m, 1H), 7.23 (t, J=9.2 Hz, 1H), 7.15 (d, J=7.2 Hz,
1H), 5.05.about.4.85 (m, 1H), 7.21.about.7.14 (m, 4H),
1.69.about.1.63 (m, 1H), 1.21.about.1.18 (m, 1H).
[0518] Synthetic Method B
Example 3
(1 S,2 S)-N-(3-chloro-6-(3-fluoro-2-methylphenyl)imidazo[1,
2-a]pyridin-2-yl)-2-fluorocyclopropane-1-carboxamide
##STR00015##
[0520] Step 1) (1 S,2
S)-N-(3-chloro-6-(3-fluoro-2-methylphenyl)imidazo[1,
2-a]pyridin-2-yl)-2-fluorocyclopropane-1-carboxamide
[0521] A solution of Example 1 (0.060 g, 0.183 mmol) in
acetonitrile (8 mL) was mixed at the room temperature with
1-chloropyrrolidine-2,5-dione (NCS, 0.027 g, 0.202 mmol), stirred
at the same temperature for 3 hr, and partitioned between ethyl
acetate and saturated aqueous sodium bicarbonate solution. The
organic layer was washed with aqueous saturated sodium chloride
solution, separated, dried (anhydrous MgSO.sub.4), filtered, and
concentrated in vacuo. The residue was chromatographed (SiO.sub.2,
12 g cartridge; ethyl acetate/hexane =70% to 100%) to give the
crude product which was crystallized at the room temperature using
diethylether (5 mL). The resulting precipitates were filtered,
washed by diethylether, and dried to give Example 3 as white solid
(0.015 g, 22.6%).
[0522] 1H NMR (400 MHz, DMSO-d6) .delta.10.44 (s, 1H), 8.21 (s,
1H), 7.62 (d, J=9.6 Hz, 1H), 7.35 (dd, J=9.2, 1.6 Hz, 1H), 7.30 (t,
J=7.0 Hz, 1H), 7.24.about.7.19 (m, 2H), 5.01.about.4.83 (m, 1H),
2.15 (d, J=2.4 Hz, 3H), 2.06.about.2.03 (m, 1H), 1.64.about.1.56
(m, 1H), 1.15 1.08 (m, 1H).
[0523] Synthetic Method C
Example 5
(1 S,2 S)-2-fluoro-N-(3-methyl-6-(4-methylpyridin-3-yl)imidazo
[1,2-a]pyridin-2-yl)cyclopropane-1-carboxamide
##STR00016##
[0524] Step 1) (E)-2-(5-iodo-2-(tosylim
ino)pyridin-1(2H)-yl)propanamide
[0525] A mixture of Compound 5 and 2-bromopropanamide (4.549 g,
29.931 mmol) in N,N-dimethylformamide (40 mL) was treated at the
room temperature with N,N-diisopropylethylamine (5.213 mL, 29.931
mmol), stirred at the same temperature for 24 hr. The reaction
mixture was diluted with water (500 mL) and stirred at the ambient
temperature. The resulting precipitates were collected by
filtration, washed by water, and dried to give the crude product
which was re-dissolved in ethyl acetate (100 mL) and diethylether
(300 mL) and stirred at the ambient temperature. The resulting
precipitates were collected by filtration, washed by diethylether,
and dried to give Compound 6 as pale pink solid (4.220 g,
35.5%).
[0526] 1H NMR (400 MHz, DMSO-d6) .delta.8.15 (d, J=1.6 Hz, 1H),
7.87 (dd, J=9.6, 2.4 Hz, 1H), 7.75 (s, 1H), 7.62 (d, J=8.0 Hz, 2H),
7.38 (s, 1H), 7.24 (d, J=8.4 Hz, 2H), 7.16 (d, J=9.6 Hz, 1H), 5.63
(m, 1H), 2.30 (s, 3H), 1.60 (d, J=7.2 Hz, 3H).
Step 2)
2,2,2-trifluoro-N-(6-iodo-3-methylimidazo[1,2-a]pyridin-2-yl)aceta-
mide
[0527] A stirred slurry of Compound 6 (4.220 g, 9.477 mmol) in
dichloromethane (50 mL) was mixed at the room temperature with
trifluoroacetic anhydride (8.032 mL, 56.863 mmol). The reaction
mixture was heated at reflux for 4 hr, cooled down to the room
temperature, and concentrated under the reduced pressure. The
residue was diluted with diethylether (300 mL) and stirred at the
ambient temperature. The resulting precipitates were collected by
filtration, washed by diethylether, and dried to give the crude
product which was re-dissolved in water (300 mL) and stirred at the
ambient temperature. The resulting precipitates were collected by
filtration, washed by water, and dried to give Compound 7 as beige
solid (3.098 g, 88.6%).
Step 3) 6-iodo-3-methylimidazo[1,2-a]pyridin-2-amine
[0528] Compound 7 (3.098 g, 8.394 mmol) and lithium hydroxide
monohydrate (1.057 g, 25.181 mmol) in water (15 mL)/ethanol (30 mL)
was mixed at the room temperature and then heated at 140.degree. C.
under the microwaves for 30 min, cooled down to the room
temperature, and concentrated under the reduced pressure. The
residue was diluted with aqueous saturated ammonium chloride
solution (20 mL) and stirred at the ambient temperature. The
resulting precipitates were collected by filtration, washed by
water, and dried to give Compound 8 as light yellow solid (1.400 g,
61.1%).
Step 4) (1 S,2
S)-2-fluoro-N-(6-iodo-3-methylimidazo[1,2-a]pyridin-2-yl)cyclopropane-1-c-
arboxamide
[0529] A mixture of Compound 8 (1.400 g, 5.127 mmol), (1 S,2
S)-2-fluorocyclopropane-1-carboxylic acid (0.640 g, 6.152 mmol) and
1-[bis (dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium
3-oxide hexafluorophosphate (HATU, 2.924 g, 7.690 mmol) in
N,N-dimethylformamide (20 mL) was treated at the room temperature
with N,N-diisopropylethylamine (2.679 mL, 15.380 mmol), stirred at
60.degree. C. for 48 hr, cooled down to the room temperature, and
concentrated under the reduced pressure. The residue was diluted
with water (100 mL) and stirred at the ambient temperature. The
resulting precipitates were collected by filtration, washed by
water, and dried to give the crude product which was re-dissolved
in ethyl acetate (50 mL) and stirred at the ambient temperature.
The resulting precipitates were collected by filtration, washed by
ethyl acetate, and dried to give Compound 9 as white solid (1.070
g, 58.1%).
[0530] 1H NMR (400 MHz, DMSO-d6) .delta.10.24 (s, 1H), 8.51 (s,
1H), 7.36 (dd, J=9.2, 1.6 Hz, 1H), 7.27 (d, J=9.2 Hz, 1H),
4.97.about.4.80 (m, 1H), 2.25 (s, 3H), 2.03 (m, 1H),
1.60.about.1.53 (m, 1H), 1.11.about.1.06 (m, 1H).
Step 5) (1 S,2
S)-2-fluoro-N-(3-methyl-6-(4-methylpyridin-3-yl)imidazo[1,
2-a]pyrid in-2-yl)cyclopropane-1-carboxamide
[0531] Compound 9 (0.200 g, 0.557 mmol),
(4-methylpyridin-3-yl)boronic acid (0.099 g, 0.724 mmol),
[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II)
(Pd(dppf)Cl.sub.2, 0.041 g, 0.056 mmol) and potassium carbonate
(0.231 g, 1.671 mmol) in water (3 mL)/tetrahydrofuran (12 mL) was
mixed at the room temperature and then heated at 120.degree. C.
under the microwaves for 1 hr, cooled down to the room temperature,
and partitioned between ethyl acetate and water. The organic layer
was washed with aqueous saturated sodium chloride solution,
separated, dried (anhydrous MgSO.sub.4), filtered, and concentrated
in vacuo. The residue was chromatographed (SiO.sub.2, 10 g
cartridge; tetrahydrofuran/ethyl acetate =0% to 10%) to give the
crude product which was dissolved in diethylether (5 mL) and hexane
(20 mL) and stirred at the ambient temperature. The resulting
precipitates were collected by filtration, washed by hexane, and
dried to give Example 5 as beige solid (0.100 g, 55.4%).
[0532] 1H NMR (400 MHz, DMSO-d6) .delta.10.25 (s, 1H), 8.47 (s,
1H), 8.44 (d, J=5.2 Hz, 1H), 8.26 (s, 1H), 7.51 (d, J=9.2 Hz, 1H),
7.34 (d, J=5.2 Hz, 1H), 7.24 (d, J=9.2 Hz, 1H), 4.99.about.4.81 (m,
1H), 2.29 (s, 6H), 2.07.about.2.03 (m, 1H), 1.63.about.1.56 (m,
1H), 1.15 1.05 (m, 1H).
[0533] Synthetic Method D
Example 29
(1 S,2
S)-2-fluoro-N-(6-(2-methyl-5-(1H-pyrazol-3-yl)phenyl)imidazol[1,2-a-
]pyridin-2-yl)cyclopropane-1-carboxamide
##STR00017##
[0534] Step 1) (1 S,2 S)-2-fluoro-N-(6-(2-methyl-5-(1
H-pyrazol-3-yl)phenyl)imidazo[1,2-a]pyridin-2-yl)cyclopropane-1-carboxami-
de
[0535] Example 26 (0.100 g, 0.291 mmol), (1H-pyrazol-3-yl)boronic
acid (0.042 g, 0.378 mmol),
[1,1'-bis(di-tert-butylphosphino)ferrocene]palladium(II) dichloride
(Pd(dtbpf)Cl.sub.2, 0.019 g, 0.029 mmol) and cesium carbonate
(0.284 g, 0.873 mmol) in 1,4-dioxane (12 mL) /water (3 mL) was
mixed at the room temperature and then heated at 140.degree. C.
under the microwaves for 1 hr, cooled down to the room temperature,
and partitioned between ethyl acetate and water. The organic layer
was washed with aqueous saturated sodium chloride solution,
separated, dried (anhydrous MgSO.sub.4), filtered, and concentrated
in vacuo. The residue was chromatographed (SiO2, 10 g cartridge;
tetrahydrofuran/ethyl acetate =0% to 20%) to give the crude product
which was dissolved in dichloromethane (3 mL) and hexane (20 mL)
and stirred at the ambient temperature. The resulting precipitates
were collected by filtration, washed by diethylether, and dried to
give Example 29 as beige solid (0.005 g, 4.6%).
[0536] 1H NMR (400 MHz, DMSO-d6) .delta.12.82 (s, 1H), 10.99 (s,
1H), 8.58 (s, 1H), 8.08 (s, 1H), 7.73.about.7.69 (m, 2H),
7.46.about.7.23 (m, 4H), 6.70 (s, 1H), 4.97.about.4.80 (m, 1H),
2.25 (s, 3H), 2.14.about.2.09 (m, 1H), 1.66.about.1.59 (m, 1H),
1.13.about.1.08 (m, 1H).
[0537] Synthetic Method E
Example 34. (1 S,2
S)-2-fluoro-N-(3-fluoro-6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin--
2-yl)cyclopropanecarboxamide
##STR00018##
[0538] Step 1) (1 S,2
S)-2-fluoro-N-(3-fluoro-6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin--
2-yl)cyclopropanecarboxamide
[0539] A solution of Example 1 (0.1 g, 0.3055 mmol) in
tetrahydrofuran (4 mL) was mixed at 0.degree. C. with
1-(chloromethyl)-4-fluoro-1,4-diazoniabicyclo[2.2.2]octane
ditetrafluoroborate (Selectfluor.RTM., 0.162 g, 0.4582 mmol),
stirred at the room temperature for 3 hr, and partitioned between
dichloromethane and saturated aqueous sodium bicarbonate solution.
The organic layer was washed with aqueous saturated sodium chloride
solution, separated, dried (anhydrous Na.sub.2SO.sub.4), filtered,
and concentrated in vacuo. The residue was chromatographed
(SiO.sub.2, 12 g cartridge; ethyl acetate/hexane =0% to 30%) to
give Example 34 as yellow solid (0.021 g, 15%).
[0540] 1H NMR (400 MHz, DMSO-d6) .delta.10.56 (s, 1H), 8.23 (s,
1H), 7.49 (d, J=9.6 Hz, 1H), 7.33.about.7.27 (m, 1H),
7.24.about.7.16 (m, 3H), 5.01.about.4.81 (m, 1H), 2.15 (s, 3H),
2.05.about.2.05 (m, 1H), 1.63.about.1.56 (m, 1H), 1.17.about.1.09
(m, 1H).
[0541] Synthetic Method F
Example 41
(1 S,2
S)-2-fluoro-N-(6-(2-methyl-5-(1H-pyrrol-3-yl)phenyl)imidazol[1,2-a]-
pyridin-2-yl)cyclopropane-1-carboxamide
##STR00019##
[0543] Step 1) 3-(2-((1 S,2
S)-2-fluorocyclopropane-1-carboxamido)imidazo[1,
2-a]pyridin-6-yl)-4-methylphenyl trifluoromethanesulfonate
[0544] A mixture of Example 12 (0.842 g, 2.588 mmol) and pyridine
(0.313 mL, 3.882 mmol) in dichloromethane (100 mL) was treated at
0.degree. C. with Trifluoromethanesulfonic anhydride (0.479 mL,
2.847 mmol), stirred at the same temperature for 1 hr, and
partitioned between dichloromethane and saturated aqueous sodium
bicarbonate solution. The organic layer was washed with aqueous
saturated sodium chloride solution, separated, dried (anhydrous
MgSO.sub.4), filtered, and concentrated in vacuo. The residue was
chromatographed (SiO.sub.2, 10 g cartridge; ethyl
acetate/hexane=80% to 100%) to give Compound 10 as purple solid
(0.056 g, 4.7%).
Step 2) (1 S,2
S)-2-fluoro-N-(6-(2-methyl-5-(1H-pyrrol-3-yl)phenyl)imidazo[1,2-a]pyridin-
-2-yl)cyclopropane-1-carboxamide
[0545] Compound 10 (0.056 g, 0.122 mmol),
3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-1H-pyrrole (0.031
g, 0.159 mmol), [1,1'-bis(diphenylphosphino)
ferrocene]dichloropalladium(11) (Pd(dppf)Cl.sub.2, 0.009 g, 0.012
mmol) and potassium carbonate (0.051 g, 0.367 mmol) in water (3
mL)/tetrahydrofuran (12 mL) was mixed at the room temperature and
then heated at 120.degree. C. under the microwaves for 30 min,
cooled down to the room temperature, and partitioned between ethyl
acetate and water. The organic layer was washed with aqueous
saturated sodium chloride solution, separated, dried (anhydrous
MgSO.sub.4), filtered, and concentrated in vacuo. The residue was
chromatographed (SiO.sub.2, 10 g cartridge; tetrahydrofuran/ethyl
acetate =0% to 10%) to give the crude product which was dissolved
in diethylether (5 mL) and hexane (5 mL) and stirred at the ambient
temperature. The resulting precipitates were collected by
filtration, washed by diethylether, and dried to give Example 41 as
white solid (0.005 g, 10.9%).
[0546] 1H NMR (400 MHz, DMSO-d6) .delta.10.97 (s, 1H), 10.86 (bs,
1H), 8.54 (s, 1H), 8.07 (s, 1H), 7.44.about.7.40 (m, 3H),
7.23.about.7.19 (m, 3H), 6.74 (dd, J=4.4, 2.8 Hz, 1H), 6.41 (dd,
J=4.4, 2.8 Hz, 1H), 4.97 4.79 (m, 1H), 2.20 (s, 3H), 2.11 (m, 1H),
1.66.about.1.59 (m, 1H), 1.15.about.1.10 (m, 1H).
[0547] Synthetic Method G
Example 44
(15
,25)-2-fluoro-N-(6-(4-fluoro-5-hydroxy-2-methylphenyl)imidazo[1,2-a]py-
ridin-2-yl)cyclopropanecarboxamide
##STR00020##
[0549] Step 1) (15,25)-2-fluoro-N-(6-(4,4, 5, 5-tetramethyl-1,
3,2-d
ioxaborolan-2-yl)imidazo[1,2-a]pyridin-2-yl)cyclopropane-1-carboxamide
[0550] Compound 3 (0.800 g, 2.318 mmol),
4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane, 1.177
g, 4.636 mmol),
[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II)
(Pd(dppf)Cl2, 0.169 g, 0.231 mmol) and potassium acetate (0.796 g,
8.113 mmol) were mixed at the room temperature in DMSO (20 mL) and
then stirred at 90.degree. C. for 24 hr, cooled down to the room
temperature, filtered through a celite pad to remove solids, and
partitioned between ethyl acetate and water. The organic layer was
washed with aqueous saturated sodium chloride solution, separated,
dried with anhydrous MgSO.sub.4, filtered, and concentrated in
vacuo. The residue was chromatographed (SiO2, 12 g cartridge; ethyl
acetate/hexane =0% to 100%) to give Compound 11 as brown solid
(0.560 g, 69.9%).
Step 2) (15 , 25)-2-fluoro-N-(6-(4-fluoro-5-hydroxy-2-methylphenyl)
imidazo[1,2-a]pyridin-2-yl)cyclopropanecarboxamide
[0551] Compound 11 (0.080 g, 0.231 mmol),
5-bromo-2-fluoro-4-methylphenol (0.056 g, 0.277 mmol),
[1,1'-bis(diphenylphosphino)ferrocene]dichloropalladium(II)
(Pd(dppf)Cl.sub.2, 0.017 g, 0.023 mmol) and Na.sub.2CO.sub.3 (0.049
g, 0.462 mmol) in dioxane (2 mL)/water (0.5 mL) was mixed at the
room temperature and then the mixture was degassed and purged with
N.sub.2 for 1 minutes, after then the mixture was stirred at
80.degree. C. for 12 hours under N.sub.2 atmosphere. The reaction
mixture was concentrated to give a residue. The residue was
purified. The residue was chromatographed (SiO.sub.2, 12 g
cartridge; ethyl acetate/hexane =80% to 100%) to give Example 44 as
white solid (0.031 g, 39.8%).
[0552] 1H NMR (400 MHz, DMSO-d6) .delta.10.98 (s, 1H), 9.75 (bs,
1H), 8.47 (s, 1H), 8.05 (s, 1H), 7.40 (d, J=9.2 Hz, 1H), 7.13 (dd,
J=9.2, 2.0 Hz, 1H), 7.06 (d, J=12.4 Hz, 1H), 6.81 (d, J=9.2 Hz,
1H), 4.98.about.4.78 (m, 1H), 2.14.about.2.07 (m, 4H),
1.65.about.1.58 (m, 1H), 1.16.about.1.07 (m, 1H).
[0553] Synthetic Method H
Example 66
(1 S,2 S)-2-fluoro-N-(6-(3-fluoro-2-(methoxymethyl)phenyl)
imidazo[1,2-a]pyridin-2-yl)cyclopropanecarboxamide
##STR00021##
[0554] Step 1) 1-bromo-3-fluoro-2-(methoxymethyl)benzene
[0555] To a solution of Compound 12 (500 mg, 2.44 mmol, 1 eq) in
THF (10 mL) was added NaH (146.31 mg, 3.66 mmol, 60% purity, 1.5
eq) in portions at 0.degree. C. under N.sub.2, and reaction mixture
was stirred at 0.degree. C. for 0.5 hour under N2, after then Mel
(692.30 mg, 4.88 mmol, 303.64 .mu.L, 2 eq) was added dropwise, then
the mixture was stirred at 20.degree. C. for another 1 hour under
N.sub.2. Saturated aqueous solution of NH.sub.4Cl (30 mL) was added
into the reaction mixture, then the mixture was extracted with
ethyl acetate (20 mL*2), the combined organic layers were dried
over Na.sub.2SO.sub.4, filtered and concentrated under reduced
pressure to give a residue. Compound 13 (510 mg, crude) was
obtained as a yellow oil.
[0556] 1H NMR (400MHz, CDCl.sub.3) .delta.7.41 (d, J=8.1 Hz, 1H),
7.18 (dt, J=5.9, 8.2 Hz, 1H), 7.10.about.7.00 (m, 1H), 4.64 (d,
J=2.3 Hz, 2H), 3.42 (s, 3H).
Step 2) (1 S,2 S)-2-fluoro-N-(6-(3-fluoro-2-(methoxymethyl)phenyl)
imidazo[1,2-a]pyridin-2-yl)cyclopropanecarboxamide
[0557] To a solution of Compound 13 (80 mg, 365.21 .mu.mol, 1 eq)
and Compound 11 (151.27 mg, 438.25 .mu.mol, 1.2 eq) in dioxane (2
mL) and H.sub.2O (0.4 mL) were added Pd(dppf)Cl.sub.2 (26.72 mg,
36.52 .mu.mol, 0.1 eq) and Na.sub.2CO.sub.3 (77.42 mg, 730.42
.mu.mol, 2 eq), then the mixture was stirred at 90.degree. C. for
12 hours under N.sub.2. The reaction mixture was diluted with ethyl
acetate (300 mL), then the mixture was filtered with silica gel,
and the filtrate was concentrated to give a residue. The residue
was purified by prep-HPLC (column: Phenomenex luna C18 150*40mm*
15um; mobile phase: [water(0.1%TFA)-ACN];B%: 17%-47%,10min).
Example 66 (91.3 mg, 193.69 .mu.mol, 53.03% yield, 100% purity,
TFA) was obtained as a white solid.
[0558] 1H NMR (400MHz, DMSO-d6) .delta.11.25 (s, 1H), 8.68 (s, 1H),
8.14 (s, 1H), 7.60 (d, J=9.2 Hz, 1H), 7.52 (dt, J=6.0, 7.9 Hz, 1H),
7.44 (dd, J=1.6, 9.2 Hz, 1H), 7.33 (d, J=8.7 Hz, 1H),
7.30.about.7.25 (m, 1H), 5.11.about.4.76 (m, 1H), 4.30 (br d, J=1.3
Hz, 2H), 3.25 (s, 3H), 2.23.about.2.08 (m, 1H), 1.76.about.1.59 (m,
1H), 1.20 (tdd, J=6.3, 9.1, 12.4 Hz, 1H).
[0559] Synthetic Method I
Example 67
(1 S,2 S)-2-fluoro-N-(6-(3-fluoro-2-(furan-2-yl)phenyl)imidazo
[1,2-a]pyridin-2-yl)cyclopropanecarboxamide
##STR00022##
[0560] Step 1) 2-(2-bromo-6-fluorophenyl)furan
[0561] To a solution of Compound 14 (511.74 mg, 1.70 mmol, 1.1 eq)
and 2-(furan-2-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane (300 mg,
1.55 mmol, 1 eq) in dioxane (3 mL) and H.sub.2O (0.6 mL) were added
Pd(dppf)Cl.sub.2 (113.13 mg, 154.61 .mu.mol, 0.1 eq) and
Na.sub.2CO.sub.3 (491.61 mg, 4.64 mmol, 3 eq), then the reaction
mixture was stirred at 80.degree. C. for 3 hr under N.sub.2. The
reaction mixture was poured into water (50 mL), then the mixture
was extracted with ethyl acetate (50 mL*2), the combined organic
layers were dried over Na.sub.2SO.sub.4, filtered and concentrated
under reduced pressure to give a residue. The residue was purified
by prep-TLC (SiO.sub.2, Petroleum ether: Ethyl acetate=3:1). The
residue was purified by prep-TLC (SiO.sub.2, Petroleum ether: Ethyl
acetate=1:0). Compound 15 (70 mg, 290.39 .mu.mol, 18.78% yield) was
obtained as a yellow oil.
[0562] 1H NMR (400 MHz, CDCl.sub.3) .delta.7.61 (dd, J=0.8, 1.8 Hz,
1H), 7.48 (td, J=1.1, 8.0 Hz, 1H), 7.21 (dt, J=5.8, 8.1 Hz, 1H),
7.15.about.7.08 (m, 1H), 6.70 (td, J=0.9, 3.3 Hz, 1H), 6.56 (dd,
J=1.8, 3.3 Hz, 1H).
Step 2) (1 S,2
S)-2-fluoro-N-(6-(3-fluoro-2-(furan-2-yl)phenyl)imidazo[1,
2-a]pyridin-2-yl)cyclopropanecarboxamide
[0563] To a solution of Compound 15 (70 mg, 290.39 .mu.mol, 1 eq)
and Compound 11 (110.26 mg, 319.43 .mu.mol, 1.1 eq) in dioxane (1
mL) and H.sub.2O (0.2 mL) were added Pd(dppf)Cl.sub.2 (21.25 mg,
29.04 .mu.mol, 0.1 eq) and Na.sub.2CO.sub.3 (92.33 mg, 871.17 pmol,
3 eq), then the reaction mixture was stirred at 80.degree. C. for
12 hr under N.sub.2. The reaction mixture was poured into brine (10
mL), then the mixture was extracted with ethyl acetate (10 mL*2),
the combined organic layers were dried over Na.sub.2SO.sub.4,
filtered and concentrated under reduced pressure to give a residue.
The residue was dissolved with methanol: dichloromethane (1:10, 100
mL), then the mixture was filtered with silica gel, and the
filtrate was concentrated to give a residue. The residue was
purified by prep-HPLC (column: Phenomenex Synergi C18 150*2510 um;
mobile phase: [water(0.1%TFA)-ACN];B%: 34%-54%,9min). Example 67
(38.3 mg, 77.63 .mu.mol, 26.73% yield, 100% purity, TFA) was
obtained as a white solid.
[0564] 1H NMR (400 MHz, DMSO-d6) .delta.11.20 (s, 1H), 8.61 (s,
1H), 8.08 (s, 1H), 7.61 (dd, J=0.9, 1.6 Hz, 1H), 7.60.about.7.54
(m, 1H), 7.45.about.7.41 (m, 1H), 7.40.about.7.36 (m, 2H), 6.93
(dd, J=1.3, 9.3 Hz, 1H), 6.56.about.6.48 (m, 2H), 5.05.about.4.83
(m, 1H), 2.19.about.2.09 (m, 1H), 1.75.about.1.59 (m, 1H), 1.19
(tdd, J=6.3, 9.1, 12.4 Hz, 1H).
[0565] Synthetic Method J
Example 72
N-(6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cyclopropanecarbo-
xamide
##STR00023##
[0566] Step 1)
2,2,2-trifluoro-N-(6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)-
acetamide
[0567] To a solution of Compound 1 (1 g, 2.82 mmol, 1 eq) in
dioxane (10 mL) and H.sub.2O (1 mL) was added Compound 2 (520.30
mg, 3.38 mmol, 1.2 eq), Pd(dppf)Cl.sub.2 (206.08 mg, 281.65
.mu.mol, 0.1 eq) and Na.sub.2CO.sub.3 (298.52 mg, 2.82 mmol, 1 eq).
The mixture was stirred at 80.degree. C. for 16 hr under N.sub.2
atmosphere. The reaction mixture diluted with water 30 mL and
extracted with Ethyl acetate (30 mL*2). The combined organic layers
were washed with brine (30 mL*2), dried over Na.sub.2SO.sub.4,
filtered and the filtrate was concentrated under reduced pressure
to give a residue. The residue was purified by column
chromatography (Silica gel, Petroleum ether: Ethyl acetate=20:1 to
5:1). Compound 16 (500 mg, 1.48 mmol, 52.64% yield) was obtained as
a white solid.
Step 2)
6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-amine
[0568] To a solution of Compound 16 (500 mg, 1.48 mmol, 1 eq) in
MeOH (10 mL) and H.sub.2O (10 mL) was added K.sub.2CO.sub.3 (1.02
g, 7.41 mmol, 5 eq). The mixture was stirred at 75.degree. C. for 2
hr. The reaction mixture was added with water 50 m L, and extracted
with Ethyl acetate (50 mL*2). The combined organic layers were
washed with brine (50 mL*2), dried over Na.sub.2SO.sub.4, filtered
and the filtrate was concentrated under reduced pressure to give a
residue. Compound 17 (300 mg, 1.24 mmol, 83.88% yield) was obtained
as a yellow solid
Step 3)
N-(6-(3-fluoro-2-methylphenyl)imidazo[1,2-a]pyridin-2-yl)cycloprop-
anecarboxamide
[0569] To a solution of Compound 17 (100 mg, 414.49 .mu.mol, 1 eq)
in EtOAc (2 mL) was added cyclopropanecarboxylic acid (53.52 mg,
621.73 .mu.mol, 49.10 .mu.L, 1.5 eq) and DCC (85.52 mg, 414.49
.mu.mol, 83.84 .mu.L, 1 eq). The mixture was stirred at 20.degree.
C. for 32 hr. Then DMAP (5.06 mg, 41.45 .mu.mol, 0.1 eq) was added
to the mixture and stirred at 20.degree. C. for 16 hr. The reaction
mixture was diluted with water 20 mL and extracted with Ethyl
acetate (20 mL*2). The combined organic layers were washed with
brine (20 mL*2), dried over Na.sub.2SO.sub.4, filtered and the
filtrate was concentrated under reduced pressure to give a residue.
The residue was purified by prep-HPLC (column: Phenomenex Luna C18
150*25mm*10 um;mobile phase: [water(0.1%TFA)-ACN]; B%:
22%-52%,10min). Example 72 (45.9 mg, 106.25 .mu.mol, 25.63% yield,
98% purity, TFA) was obtained as a pink solid.
[0570] 1H NMR (400MHz, DMSO-d6) .delta.11.22 (br s, 1H), 8.66 (s,
1H), 8.09 (s, 1H), 7.59 (d, J=9.2 Hz, 1H), 7.40 (br d, J=9.3 Hz,
1H), 7.38.about.7.30 (m, 1H), 7.28.about.7.21 (m, 1H), 7.17 (d,
J=7.5 Hz, 1H), 2.18 (d, J=2.3 Hz, 3H), 1.94 (quin, J=6.2 Hz, 1H),
0.85 (d, J=6.1 Hz, 4H).
[0571] Synthetic Method K
Example 77
(1 S,2 S)-N-(6-(2-(acetam
idomethyl)-3-fluorophenyl)imidazo[1,2-a]pyridin-2-yl)-2-fluorocyclopropan-
ecarboxamide
##STR00024##
[0573] Step 1) N-(2-bromo-6-fluorobenzyl)acetamide
[0574] To a solution of Compound 18 (200 mg, 695.94 .mu.mol, 1 eq)
in Py (5 mL) was added Ac.sub.2O (85.26 mg, 835.13 .mu.mol, 78.22
.mu.L, 1.2 eq). The mixture was stirred at 25.degree. C. for 3 hr.
Desired MS was detected by LC-MS. The mixture was concentrated
under reduced pressure to give a residue. The residue was adjusted
to pH=6 with HCI, and extracted with EA (30 mL*3). The organic
phase was concentrated under reduced pressure to give a residue.
Compound 19 (130 mg, 412.07 .mu.mol, 59.21% yield, 78% purity) was
obtained as light yellow solid.
Step 2) (1 S,2 S)-N-(6-(2-(acetam
idomethyl)-3-fluorophenyl)imidazo[1,
2-a]pyridin-2-yl)-2-fluorocyclopropanecarboxamide
[0575] A mixture of Compound 19 (100 mg, 361.68 .mu.mol, 1 eq),
Compound 11 (122.35 mg, 354.44 .mu.mol, 0.98 eq), Pd(dppf)Cl.sub.2
(26.46 mg, 36.17 .mu.mol, 0.1 eq) and Na.sub.2CO.sub.3 (76.67 mg,
723.35 .mu.mol, 2 eq) in Water (1 mL) and dioxane (4 mL) was
degassed and purged with N.sub.2 for 3 times, and then the mixture
was stirred at 80.degree. C. for 16 hr under N.sub.2 atmosphere.
Desired MS was detected by LC-MS. The mixture was filtered, and the
filtrate was concentrated under reduced pressure to give a residue.
The residue was purified by prep-HPLC (column: Phenomenex luna C18
250*50mm*10 um ;mobile phase: [water(0.1%TFA)-ACN]; B')/0:
10%-40%,9m in). Example 77 (15.3 mg, 29.84 .mu.mol, 8.25% yield,
97.2% purity, TFA) was obtained as white solid
[0576] 1H NMR (400 MHz, CD3OD) .delta.8.67 (s, 1H), 7.81.about.7.71
(m, 2H), 7.49-7.47 (m, 1H), 7.31-7.22 (m, 2H), 5.04.about.5.01 (m,
0.5H), 4.87-4.85 (m, 0.5H), 4.38 (s, 2H), 2.16-2.12 (m, 1H),
1.90-1.84 (m, 1H), 1.31-1.28 (m, 1H).
[0577] Synthetic Method L
Example 84
(1 S,2 S)-2-fluoro-N-(6-(3-fluoro-2)-((2-methoxyethoxy)methyl)
phenyl)imidazof1,2-alpyridin-2-yl)cyclopropanecarboxamide. TFA
salt
##STR00025##
[0578] Step 1)
1-bromo-3-fluoro-2-((2-methoxyethoxy)methyl)benzene
[0579] Compound 20 (445.00 mg, 2.17 mmol, 1 eq) was dissolved in
DMF (15 mL), to which NaH (130.22 mg, 3.26 mmol, 60% purity, 1.5
eq) was added at 0.degree. C. in portions. The resulting mixture
was then stirred under N.sub.2 atmosphere for 30 min, before
1-bromo-2-methoxy-ethane (362.01 mg, 2.60 mmol, 244.60 .mu.L, 1.2
eq) was added at 0.degree. C. The mixture was then stirred under
N.sub.2 atmosphere at 15.degree. C. for another 11.5 hr. The
mixture was quenched with EtOH (5 mL), diluted with water (20 mL)
and extracted with EA (20 mL.times.3). The combined organic layers
were concentrated under reduced pressure. The residue was purified
by silica gel chromatography (pure PE to PE/EA=4/1) to afford
Compound 21 (178 mg, 676.54 .mu.mol, 31.17% yield) as a light
yellow oil.
Step 2) (15,25)-2-fluoro-N-(6-(3-fluoro-2-((2-methoxyethoxy)methyl)
phenyl)imidazo[1,2-a]pyridin-2-yl)cyclopropanecarboxamide. TFA
salt
[0580] The mixture of Compound 21 (178 mg, 676.54 .mu.mol, 1 eq)
and Compound 11 (210.17 mg, 608.89 .mu.mol, 0.9 eq) was dissolved
in dioxane (10 mL) and H.sub.2O (2 mL), to which Pd(dppf)Cl.sub.2
(99.01 mg, 135.31 .mu.mol, 0.2 eq) and Na.sub.2CO.sub.3 (215.12 mg,
2.03 mmol, 3 eq) were added in portions. The resulting mixture was
then stirred under N.sub.2 atmosphere at 80.degree. C. for 16 hr.
Desired m/z was detected by LC-MS. The mixture was filtered and the
filtrate was diluted with water (20 mL) and extracted with EA (20
mL.times.3). The combined organic layers were concentrated under
reduced pressure. The residue was purified by silica gel
chromatography (PE/EA=10/1 to 1/1) and then Prep-HPLC (column:
Phenomenex Gemini-NX C18 75*30mm*3um;mobile phase:
[water(0.1%TFA)-ACN]; B%: 18%-48%,7m in) and lyophilized to afford
Example 84 (32.2 mg, 62.10 .mu.mol, 9.18% yield, 99.4% purity, TFA)
as an off-white solid.
[0581] 1H NMR (400 MHz, DMSO) .delta.11.23.about.11.19 (br s, 1H),
8.72 (s, 1H), 8.10 (s, 1H), 7.56-7.50 (m, 3H), 7.32.about.7.28 (m,
2H), 5.04.about.4.84 (m, 1H), 4.35 (s, 2H), 3.47-3.44 (m, 4H), 3.25
(s, 3H), 2.16.about.2.11 (m, 1H), 1.70-1.64 (m, 1H), 1.21-1.16 (m,
1H).
[0582] Synthetic Method M
Example 85
(15,25)-2-fluoro-N-(6-(3-fluoro-24(2-hydroxyethoxy)methyl)
phenyl)imidazof1,2-alpyridin-2-yl)cyclopropanecarboxamide
##STR00026##
[0583] Step 1)
(2-((2-bromo-6-fluorobenzyl)oxy)ethoxy)(tert-butyl)dimethylsilane
[0584] Compound 22 (1 g, 4.88 mmol, 1 eq) was dissolved in DMF (50
mL), NaH (292.65 mg, 7.32 mmol, 60% purity, 1.5 eq) was added at
0.degree. C. in portions. The resulting mixture was then stirred
under N.sub.2 atmosphere for 30 min, before
2-bromoethoxy-tert-butyl-dimethyl-silane (1.40 g, 5.85 mmol, 109.93
.mu.L, 1.2 eq) was added at 0.degree. C. The mixture was then
stirred under N.sub.2 atmosphere at 15.degree. C. for another 11.5
hr. New spots were formed according to the result of TLC (PE/EA
=4/1). The mixture was quenched with EtOH (5 mL), diluted with
water (20 mL) and extracted with EA (20 mL.times.3). The combined
organic layers were concentrated under reduced pressure. The
residue was purified together with the former batch by silica gel
chromatography (pure PE to PE/EA=4/1) to afford Compound 23 (372
mg, 1.02 mmol, 20.99% yield) as a white solid.
[0585] 1H NMR (400 MHz, DMSO-d6) .delta.7.52-7.50 (m, 1H),
7.37-7.36 (m, 1H), 7.34-7.30 (m, 1H), 4.61-4.60 (m, 2H), 3.90-3.80
(m, 2H), 3.58-3.47 (m, 2H), 0.835 (s, 9H), 0.02 (s, 6H).
Step 2) 2-((2-bromo-6-fluorobenzyl)oxy)ethanol
[0586] Compound 23 (352 mg, 968.80 .mu.mol, 1 eq) was dissolved in
DMF (10 mL), CsF (147.16 mg, 968.80 .mu.mol, 35.72 .mu.L, 1 eq) was
added. The resulting mixture was then stirred at 80.degree. C. for
12 hr. The starting material was consumed according to the result
of TLC (PE/EA=4/1). The mixture was filtered and the filtrate was
concentrated under reduced pressure. The residue was purified by
silica gel chromatography (PE to PE/EA=5/1) to afford Compound 24
(120 mg, 481.78 .mu.mol, 49.73% yield) as an off-white solid.
[0587] 1H NMR (400 MHz, DMSO-d6) .delta.7.52-7.50 (m, 1H),
7.36-7.28 (m, 2H), 4.60-4.59 (m, 2H), 3.52-3.47 (m, 4H).
Step 3 (15 ,
25)-2-fluoro-N-(6-(3-fluoro-2-((2-hydroxyethoxy)methyl)phenyl)
imidazo[1,2-a]pyridin-2-yl)cyclopropanecarboxamide
[0588] The mixture of Compound 24 (120 mg, 481.78 .mu.mol, 1 eq)
and Compound 11 (149.67 mg, 433.60 .mu.mol, 0.9 eq) was dissolved
in the mixture of dioxane (10 mL) and H.sub.2O (2 mL),
Pd(dppf)Cl.sub.2 (35.25 mg, 48.18 .mu.mol, 0.1 eq) and
Na.sub.2CO.sub.3 (153.19 mg, 1.45 mmol, 3 eq) were added in
portions. The resulting mixture was then stirred under N.sub.2
atmosphere at 80.degree. C. for 12 hr. Desired m/z was detected by
LC-MS. The mixture was filtered and the filtrate was diluted with
water (20 mL) and extracted with EA (20 mL.times.3). The combined
organic layers were concentrated under reduced pressure. The
residue was purified by silica gel chromatography (PE/EA =2/1 to
EA/MeOH=10/1) and then by Prep-HPLC (column: Phenomenex Gemini-NX
C18 75*30mm*3um;mobile phase: [water(0.1%TFA)-ACN]; B%: 12%-42%,9m
in) and lyophilized to afford Example 85 (74.1 mg, 143.65 .mu.mol,
29.82% yield, 97.2% purity, TFA) as an off-white solid .
[0589] 1H NMR (400 MHz, DMSO-d6) .delta.11.21 (s, 1H), 8.78 (s,
1H), 8.14 (s, 1H), 7.58-7.47 (m, 3H), 7.33-7.29 (m, 2H), 5.05-4.85
(m, 1H), 4.36 (s, 2H), 3.55-3.52 (m, 2H), 3.47-3.45 (m, 2H),
2.16-2.13 (m, 1H), 1.71-1.69 (m, 1H), 1.65-1.64 (m, 1H).
[0590] Synthetic Method N
Example 105
(1 S,2 S)-2-fluoro-N-(6-(2-methyl-5-(1H-pyrazol-1-yl)phenyl)
imidazo[1,2-a]pyridin-2-yl)cyclopropane-1-carboxamide
##STR00027##
[0592] Step 1) 3-bromo-4-methyl-2-nitrophenol
[0593] To a solution of Compound 25 (5 g, 26.73 mmol, 1 eq) in
CHCl.sub.3 (50 mL) was added HNO.sub.3 (2.85 g, 29.41 mmol, 2.04
mL, 1.1 eq) dropwise at -50.degree. C., then the reaction mixture
was stirred at -50.degree. C. for 1 hr. The reaction mixture was
slowly poured into ice water (200 mL), then the mixture was
extracted with dichloromethane (100 mL* 2), the combined organic
layers were dried over Na.sub.2SO.sub.4, filtered and concentrated
under reduced pressure to give a residue. The residue was purified
by column chromatography (SiO.sub.2, Petroleum ether/Ethyl
acetate=1/0 to 100/1). Compound 26 (550 mg, 2.37 mmol, 8.87% yield)
was obtained as a yellow oil.
[0594] 1H NMR (400 MHz, CDCl.sub.3) .delta.8.84-8.20 (m, 1H), 7.31
(d, J=8.7 Hz, 1H), 7.00 (d, J=8.6 Hz, 1H), 2.41 (s, 3H).
Step 2) 2-amino-3-bromo-4-methylphenol
[0595] To a solution of Compound 26 (450 mg, 1.94 mmol, 1 eq) in
EtOH (5 mL) and H.sub.2O (5 mL) were added Fe (649.83 mg, 11.64
mmol, 6 eq) and NH.sub.4Cl (622.44 mg, 11.64 mmol, 6 eq). The
suspension was degassed and purged with N.sub.2 for 3 times. The
reaction mixture was stirred under N.sub.2 at 80.degree. C. for 2
hours. The reaction mixture was filtered, the filter cake was
washed with methanol (50 mL* 3) and the filtrate was concentrated
under reduced pressure to give a residue. The residue was poured
into water (50 mL), then the mixture was extracted with ethyl
acetate (50 mL* 2), the combined organic layers were dried over
Na.sub.2SO.sub.4, filtered and concentrated under reduced pressure
to give a residue. The residue was purified by reverse flase
(MeCN/H.sub.2O, CF.sub.3COOH), then the mixture was concentrated to
remove MeCN, after then the mixture's pH was adjust to pH=7 by
using saturated aqueous solution of sodium bicarbonate, then the
mixture was extracted with ethyl acetate (100 mL*2), the combined
organic layers were dried over saturated sodium sulfate, filtered
and concentrated under reduced pressure to give a residue. Compound
27 (210 mg, 1.02 mmol, 52.52% yield, 98% purity) was obtained as a
yellow solid.
[0596] 1H NMR (400 MHz, CDCl.sub.3) .delta.6.64-6.59 (m, 1H),
6.54-6.50 (m, 1H), 2.30 (s, 3H).
Step 3) 4-bromo-5-methylbenzo[d]oxazole
[0597] To a solution of Compound 27 (210 mg, 1.02 mmol, 1 eq) and
trimethoxymethane (162.14 mg, 1.53 mmol, 167.50 .mu.L, 1.5 eq) in
EtOH (3 mL) was added tris(trifluoromethylsulfonyloxy)ytterbium
(14.19 mg, 22.87 .mu.mol, 2.25e-2 eq), then the reaction mixture
was stirred at 90.degree. C. for 12 hr. LCMS showed 19% of Compound
3 was remained and 81% of desired mass was detected.
trimethoxymethane (108.09 mg, 1.02 mmol, 111.66 .mu.L, 1 eq) was
added to the reaction mixture, then the reaction mixture was
stirred at 90.degree. C. for another 2 hr. The reaction mixture was
concentrated under reduced pressure to remove solvent. Saturated
aqueous solution of NaHCO.sub.3 (50 mL) was added into the residue,
then the mixture was extracted with ethyl acetate (30mL* 3), the
combined organic layers were dried over Na.sub.2SO.sub.4, filtered
and concentrated under reduced pressure to give a residue. Compound
28 (160 mg, crude) was obtained as a brown solid.
[0598] 1H NMR (400 MHz, CDCl.sub.3) .delta.8.12 (s, 1H), 7.43 (d,
J=8.3 Hz, 1H), 7.29 (d, J=8.4 Hz, 1H), 2.54 (s, 3H).
Step 4) (1 S,2
S)-2-fluoro-N-(6-(5-methylbenzo[d]oxazol-4-yl)imidazo[1,
2-a]pyridin-2-yl)cyclopropanecarboxamide
[0599] To a solution of Compound 28 (130 mg, 613.08 .mu.mol, 1 eq)
and Compound 11 (253.95 mg, 735.70 .mu.mol, 1.2 eq) in dioxane (2
mL) and H.sub.2O (0.4 mL) were added Pd(dppf)Cl.sub.2 (44.86 mg,
61.31 .mu.mol, 0.1 eq) and Na.sub.2CO.sub.3 (194.94 mg, 1.84 mmol,
3 eq), then the reaction mixture was stirred at 90.degree. C. for
12 hr under N.sub.2. The reaction mixture was poured into brine (30
mL), then the mixture was extracted with ethyl acetate (30 mL* 2),
the combined organic layers were dried over Na.sub.2SO.sub.4,
filtered and concentrated under reduced pressure to give a residue.
The residue was dissolved with methanol: dichloromethane (1:10, 100
mL), then the mixture was filtered with silica gel, and the
filtrate was concentrated to give a residue. The residue was
purified by prep-HPLC (column: Xtimate C18 150*40mml Oum;mobile
phase: [water (0.05% ammonia hydroxide v/v)-ACN];B%:
25%-55%,10min). Example 105 (118.4 mg, 333.33 pmol, 54.37% yield,
98.633% purity) was obtained as a white solid.
[0600] 1H NMR (400 MHz, DMSO-d6) .delta.11.07 (s, 1H), 8.70 (s,
1H), 8.65 (s, 1H), 8.13 (s, 1H), 7.71 (d, J=8.3 Hz, 1H), 7.53 (d,
J=9.2 Hz, 1H), 7.43 (d, J=8.4 Hz, 1H), 7.29 (dd, J=1.6, 9.2 Hz,
1H), 5.05-4.81 (m, 1H), 2.38 (s, 3H), 2.20-2.10 (m, 1H), 1.73-1.59
(m, 1H), 1.17 (tdd, J=6.2, 9.1, 12.2 Hz, 1H).
[0601] Table 1 below shows the compounds of Examples along with
general synthetic methods used to make the compound and
characterization data.
TABLE-US-00001 TABLE 1 Compounds of Examples Synthetic Ex #
Structure/Name 1H NMR/MS (M + 1) Method 1 ##STR00028## 1H NMR (400
MHz, DMSO-d6) .delta. 11.67 (s, 1H), 8.74 (s, 1H), 8.13 (s, 1H),
7.69 (d, J = 9.2 Hz, 1H), 7.55 (d, J = 9.2 Hz, 1H), 7.35~7.30 (m,
1H), 7.23 (t, J = 9.2 Hz, 1H), 7.15 (d, J = 7.2 Hz, 1H), 5.05~4.85
(m, 1H), 7.21~7.14 (m, 4H), 1.69~1.63 (m, 1H), 1.21~1.18 (m, 1H);
LCMS (electrospray) m/z 327.88 (M + H)+. A 2 ##STR00029## 1H NMR
(400 MHz, DMSO-d6) .delta. 11.00 (s, 1H), 8.53 (s, 1H), 8.06 (s,
1H), 7.46 (d, J = 9.2 Hz, 1H), 7.35~7.29 (m, 1H), 7.17~7.09 (m,
3H), 4.98~4.78 (m, 1H), 2.16~2.09 (m, 4H), 1.66~1.59 (m, 1H),
1.16~1.08 (m, 1H); LCMS (electrospray) m/z 327.96 (M + H)+. A 3
##STR00030## 1H NMR (400 MHz, DMSO-d6); .delta. 10.44 (s, 1H), 8.21
(s, 1H), 7.62 (d, J = 9.6 Hz, 1H), 7.35 (dd, J = 9.2, 1.6 Hz, 1H),
7.30 (d, J = 7.0 Hz, 1H), 7.24~7.19 (m, 2H), 5.01~4.83 (m, 1H),
2.15 (d, J = 2.4 Hz, 3H), 2.06~2.03 (m, 1H), 1.64~1.56 (m, 1H),
1.15~1.08 (m, 1H); LCMS (electrospray) m/z 361.95 (M + H))+. B 4
##STR00031## 1H NMR (400 MHz, DMSO-d6); .delta. 10.46 (s, 1H), 8.27
(s, 1H), 7.64 (d, J = 8.4 Hz, 1H), 7.38~7.33 (m, 1H), 7.27 (d, J =
8.8 Hz, 1H), 7.19~7.12 (m, 2H), 5.01~4.83 (m, 1H), 2.17 (s, 3H),
2.12~2.05 (m, 1H), 1.63~1.56 (m, 1H), 1.20~1.10 (m, 1H); LCMS
(electrospray) m/z 361.95 (M + H)+. B 5 ##STR00032## 1H NMR (400
MHz, DMSO-d6); .delta. 10.25 (s, 1H), 8.47 (s, 1H), 8.44 (d, J =
5.2 Hz, 1H), 8.26 (s, 1H), 7.51 (d, J = 9.2 Hz, 1H), 7.34 (d, J =
5.2 Hz, 1H), 7.24 (d, J = 9.2 Hz, 1H), 4.99~4.81 (m, 1H), 2.29 (s,
6H), 2.07~2.03 (m, 1H), 1.63~1.56 (m, 1H), 1.15~1.05 (m, 1H); LCMS
(electrospray) m/z 324.95 (M + H)+. C 6 ##STR00033## 1H NMR (400
MHz, DMSO-d6); .delta. 11.01 (s, 1H), 8.61 (s, 1H), 8.44~8.42 (m,
2H), 7.47 (d, J = 9.2 Hz, 1H), 7.33 (d, J = 5.2 Hz, 1H), 7.25 (dd,
J = 9.2, 2.0 Hz, 1H), 4.99~4.78 (m, 1H), 2.28 (s, 3H), 2.15~2.08
(m, 1H), 1.66~1.59 (m, 1H), 1.15~1.12 (m, 1H)); LCMS (electrospray)
m/z 311.00 (M + H)+. A 7 ##STR00034## 1H NMR (400 MHz, DMSO-d6);
.delta. 10.46 (s, 1H), 8.47 (s, 1H), 8.30 (s, 1H), 7.63 (d, J = 9.2
Hz, 1H), 7.40 (dd, J = 9.2, 1.6 Hz, 1H), 7.35 (d, J = 4.8 Hz, 1H),
5.01~4.83 (m, 1H), 2.28 (s, 3H), 2.08~2.01 (m, 1H), 1.63~1.56 (m,
1H), 1.20~1.05 (m, 1H); LCMS (electrospray) m/z 344.91 (M + H)+. B
8 ##STR00035## 1H NMR (400 MHz, DMSO-d6); .delta. 10.24 (s, 1H),
8.19 (s, 1H), 7.49 (d, J = 9.2 Hz, 1H), 7.29 (m, 1H), 7.22~7.18 (m,
3H), 4.99~4.81 (m, 1H), 2.29 (s, 3H), 2.15 (s, 3H), 2.07~2.03 (m,
1H), 1.63~1.56 (m, 1H), 1.12~1.05 (m, 1H); LCMS (electrospray) m/z
341.99 (M + H)+. C 9 ##STR00036## 1H NMR (400 MHz, DMSO); .delta.
10.25 (s, 1H), 8.22 (s, 1H), 7.51 (d, J = 8.0 Hz, 1H), 7.33 (dd, J
= 14.2, 7.8 Hz, 1H), 7.18~7.08 (m, 3H), 4.99~4.81 (m, 1H), 2.27 (s,
3H), 2.17 (s, 3H), 2.06 (m, 1H), 1.64~1.56 (m, 1H), 1.12~1.05 (m,
1H); LCMS (electrospray) m/z 341.99 (M + H)+. C 10 ##STR00037## 1H
NMR (400 MHz, DMSO-d.sub.6) .delta. 10.27 (s, 1H), 8.52 (s, 1H),
8.41 (s, 1H), 8.32 (s, 1H), 7.53 (d, J = 9.2 Hz, 1H), 7.26 (dd, J =
9.4, 1.4 Hz, 1H), 4.99~4.81 (m, 1H), 2.30 (s, 3H), 2.23 (s, 3H),
2.07~2.04 (m, 1H), 1.63~1.56 (m, 1H), 1.10~1.09 (m, 1H); LCMS
(electrospray) m/z 342.96 (M + H)+. C 11 ##STR00038## .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 11.00 (s, 1H), 8.56 (s, 1H), 8.06
(s, 1H), 7.44 (d, J = 9.2 Hz, 1H), 7.32 (t, J = 7.2 Hz, 1H), 7.22
(dd, J = 9.2, 2.0 Hz, 1H), 7.12~7.09 (m, 2H), 4.99~4.78 (m, 1H),
2.21 (s, 3H), 2.11~2.10 (m, 1H), 1.66~1.59 (m, 1H), 1.17~1.12 (m,
1H); LCMS (electrospray) m/z 327.92 (M + H)+. A 12 ##STR00039##
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 10.97 (s, 1H), 8.48 (s,
1H), 8.06 (s, 1H), 7.41 (d, J = 8.8 Hz, 1H), 7.15 (dd, J = 9.4, 1.4
Hz, 1H), 7.06 (d, J = 8.4 Hz, 1H), 6.69~6.64 (m, 2H), 4.98~4.78 (m,
1H), 2.12~2.07 (m, 4H), 1.66~1.58 (m, 1H), 1.16~1.09 (m, 1H); LCMS
(electrospray) m/z 325.90 (M + H)+. A 13 ##STR00040## .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 11.00 (s, 1H), 8.59 (s, 1H), 7.86
(dd, J = 7.8, 1.8 Hz, 1H), 7.81 (d, J = 1.6 Hz, 1H), 7.48~7.44 (m,
2H), 7.22 (dd, J = 9.2, 1.6 Hz, 1H), 4.99~4.78 (m, 1H), 3.82 (s,
3H), 2.32 (s, 3H), 2.12~2.11 (m, 1H), 1.65~1.59 (m, 1H), 1.15~1.10
(m, 1H); LCMS (electrospray) m/z 367.98 (M + H)+. A 14 ##STR00041##
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.03 (s, 1H), 8.66 (s,
1H), 8.50 (s, 1H), 8.35 (s, 1H), 8.35 (s, 1H), 8.08 (s, 1H), 7.49
(d, J = 9.2 Hz, 1H), 7.27 (dd, J = 9.0, 1.8 Hz, 1H), 4.99~4.79 (m,
1H), 2.23 (s, 3H), 2.12~2.11 (m, 1H), 1.66~1.59 (m, 1H), 1.16~1.10
(m, 1H); LCMS (electrospray) m/z 328.96 (M + H)+. A 15 ##STR00042##
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.68 (bs, 1H), 1.16
(s, 1H), 8.74 (s, 1H), 8.15 (s, 1H), 7.75 (d, J = 9.2 Hz, 1H), 7.59
(d, J = 9.2 Hz, 1H), 7.34 (d, J = 8.4 Hz, 1H), 7.29 (t, J = 2.8 Hz,
1H), 7.04 (d, J = 8.4 Hz, 1H), 6.08 (s, 1H), 5.07~4.87 (m, 1H),
2.24 (s, 3H), 2.17 (m, 1H), 1.71~1.65 (m, 1H), 1.25~1.19 (m, 1H);
LCMS (electrospray) m/z 349.04 (M + H)+. A 16 ##STR00043## .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. 10.48 (s, 1H), 8.53 (s, 1H),
8.40 (s, 1H), 8.37 (s, 1H), 7.66 (d, J = 10.0 Hz, 1H), 7.41 (dd, J
= 9.0, 1.4 Hz, 1H), 5.01~4.83 (m, 1H), 2.22 (d, J = 2.0 Hz, 3H),
2.11~2.03 (m, 1H), 1.63~1.56 (m, 1H), 1.14~1.11 (m, 1H); LCMS
(electrospray) m/z 362.92 (M + H)+. B 17 ##STR00044## .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 8.59 (s, 1H), 8.06 (s, 1H),
7.76~7.74 (m, 2H), 7.52 (d, J = 8.4 Hz, 1H), 7.46 (d, J = 9.2 Hz,
1H), 7.23 (dd, J = 9.2, 1.6 Hz, 1H), 4.99~4.78 (m, 1H), 2.33 (s,
3H), 2.14~2.08 (m, 1H), 1.66~1.59 (m, 1H), 1.17~1.03 (m, 1H); LCMS
(electrospray) m/z 335.01 (M + H)+. A 18 ##STR00045## .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 12.90 (s, 1H), 10.97 (s, 1H), 8.94
(s, 1H), 8.05 (s, 1H), 7.78 (s, 1H), 7.67 (d, J = 9.2 Hz, 1H), 7.41
(d, J = 9.2 Hz, 1H), 6.67 (s, 1H), 4.98~4.78 (m, 1H), 2.11~2.09 (m,
1H), 1.65~1.59 (m, 1H), 1.51~1.09 (m, 1H); LCMS (electrospray) m/z
285.93 (M + H)+. A 19 ##STR00046## .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 12.50 (s, 1H), 10.67 (s, 1H), 8.65 (s, 1H),
8.09 (s, 1H), 7.53~7.39 (m, 3H), 4.93~4.76 (m, 1H), 2.19~2.11 (m,
4H), 1.69~1.62 (m, 1H), 1.15~1.07 (m, 1H); LCMS (electrospray) m/z
299.96 (M + H)+ A 20 ##STR00047## .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 10.69 (s, 1H), 9.44 (s, 1H), 8.45 (s, 1H),
8.05 (s, 1H), 7.40 (d, J = 9.2 Hz, 1H), 7.13 (dd, J = 9.2, 2.0 Hz,
1H), 7.08~7.01 (m, 1H), 6.81 (d, J = 7.6 Hz, 1H), 6.89 (d, J = 6.8
Hz, 1H), 4.98~4.79 (m, 1H), 2.13~2.09 (m, 1H), 2.02 (s, 3H),
1.65~1.58 (m, 1H), 1.14~1.09 (m, 1H); LCMS (electrospray) m/z
326.00 (M + H)+ A 21 ##STR00048## .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 11.04 (s, 1H), 8.73 (s, 1H), 8.65 (s, 1H),
8.55 (d, J = 5.2 Hz, 1H), 8.09 (s, 1H), 7.68 (d, J = 5.6 Hz, 1H),
7.50 (d, J = 9.2 Hz, 1H), 7.32 (dd, J = 9.2, 2.0 Hz, 1H), 4.99~4.79
(m, 1H), 2.11~2.10 (m, 1H), 1.65~1.59 (m, 1H), 1.17~1.10 (m, 1H);
LCMS (electrospray) m/z 330.88 (M + H)+ A 22 ##STR00049## .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. 10.97 (s, 1H), 8.45 (s, 1H),
8.06 (s, 1H), 7.42 (d, J = 9.2 Hz, 1H), 7.19~7.06 (m, 4H),
4.98~4.78 (m, 1H), 2.27 (s, 3H), 2.21~2.11 (m, 4H), 1.66~1.58 (m,
1H), 1.16~1.11 (m, 1H); LCMS (electrospray) m/z 323.83 (M + H)+. A
23 ##STR00050## .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 10.96
(s, 1H), 8.44 (s, 1H), 8.06 (s, 1H), 7.39 (d, J = 8.0 Hz, 1H), 7.12
(dd, J = 9.2, 1.6 Hz, 1H), 6.91 (d, J = 8.4 Hz, 1H), 6.50~6.46 (m,
2H), 4.98~4.78 (m, 3H), 2.12~2.09 (m, 1H), 2.05 (s, 3H), 1.66~1.58
(m, 1H), 1.14~1.11 (m, 1H); LCMS (electrospray) m/z 324.95 (M +
H)+. A 24 ##STR00051## .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
10.97 (s, 1H), 8.46 (s, 1H), 8.06 (s, 1H), 7.39 (d, J = 9.2 Hz,
1H), 7.14 (d, J = 9.2 Hz, 1H), 6.98 (d, J = 8.0 Hz, 1H), 6.46 (d, J
= 7.6 Hz, 1H), 6.41 (s, 1H), 5.49 (d, J = 5.2 Hz, 1H), 4.96-~4.80
(m, 1H), 2.63 (d, J = 4.4 Hz, 3H), 2.10~2.07 (m, 4H), 1.64~1.59 (m,
1H), 1.12 (m, 1H); LCMS (electrospray) m/z 338.99 (M + H)+. A 25
##STR00052## .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 10.99 (s,
1H), 9.90 (s, 1H), 8.50 (s, 1H), 8.07 (s, 1H), 7.49~7.42 (m, 3H),
7.19 (d, J = 8.4 Hz, 1H), 7.16 (dd, J = 9.2, 1.6 Hz, 1H), 4.99~4.78
(m, 1H), 2.17 (s, 3H), 2.13~2.11 (m, 1H), 1.99 (s, 3H), 1.66~1.58
(m, 1H), 1.15~1.10 (m, 1H); LCMS (electrospray) m/z 366.98 (M +
H)+. A 26 ##STR00053## .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
11.00 (s, 1H), 8.56 (s, 1H), 8.05 (s, 1H), 7.43 (d, J = 9.2 Hz,
1H), 7.36~7.31 (m, 3H), 7.20 (dd, J = 9.2, 1.6 Hz, 1H), 4.99~4.78
(m, 1H), 2.22 (s, 3H), 2.12~2.10 (m, 1H), 1.66~1.59 (m, 1H),
1.13~1.07 (m, 1H); LCMS (electrospray) m/z 343.94 (M + H)+. A 27
##STR00054## .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.71 (s,
1 H), 10.99 (s, 1 H), 8.89 (s, 1 H), 8.50 (d, J = 1.6 Hz, 1 H),
8.20 (d, J = 1.6 Hz, 1 H), 8.07 (s, 1 H), 7.59 (d, J = 1.6 Hz, 1
H), 7.50~7.47 (m, 2 H), 4.99~4.79 (m, 1 H), 2.12~2.11 (m, 1 H),
1.67~1.59 (m, 1 H), 1.17~1.09 (m, 1 H); LCMS (electrospray) m/z
335.91 (M + H)+. A 28 ##STR00055## .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 12.82 (s, 1H), 10.99 (s, 1H), 8.58 (s, 1H),
8.08 (s, 1H), 7.73~7.69 (m, 2H), 7.46~7.23 (m, 4H), 6.70 (s, 1H),
4.97~4.80 (m, 1H), 2.25 (s, 3H), 2.14~2.09 (m, 1H), 1.66~1.59 (m,
1H), 1.13~1.08 (m, 1H); LCMS (electrospray) m/z 376.00 (M + H)+. D
29 ##STR00056## .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 10.99
(s, 1H), 8.52 (dd, J = 1.8, 1.0 Hz, 1H), 8.06 (s, 1H), 7.44~7.40
(m, 2H), 7.33~7.26 (m, 2H), 7.18 (dd, J = 9.2, 2.0 Hz, 1H),
4.98~4.78 (m, 1H), 2.24 (s, 3H), 2.11 (m, 1H), 1.66~1.58 (m, 1H),
1.13~1.09 (m, 1H); LCMS (electrospray) m/z 343.94 (M + H)+. A 30
##STR00057## .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.00 (s,
1H), 8.53 (s, 1H), 8.06 (s, 1H), 7.48~7.43 (m, 2H), 7.30~7.24 (m,
2H), 7.18 (dd, J = 9.2, 1.2 Hz, 1H), 4.98~4.79 (m, 1H), 2.25 (s,
3H), 2.11 (m, 1H), 1.65~1.58 (m, 1H), 1.15~1.10 (m, 1H); LCMS
(electrospray) m/z 343.94 (M + H)+. A 31 ##STR00058## .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 11.05 (s, 1H), 8.89 (d, J = 5.6 Hz,
1H), 8.65 (s, 1H), 8.10 (s, 1H), 7.86 (d, J = 5.6 Hz, 1H), 7.49 (d,
J = 9.2 Hz, 1H), 7.19 (d, J = 10.0 Hz, 1H), 4.99~4.79 (m, 1H),
2.13~2.10 (m, 1H), 1.66~1.59 (m, 1H), 1.16~1.11 (m, 1H); LCMS
(electrospray) m/z 364.86 (M + H)+. A 32 ##STR00059## .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 10.97 (s, 1H), 8.47 (s, 1H), 8.05
(s, 1H), 7.41 (d, J = 9.2 Hz, 1H), 7.16~7.04 (m, 4H), 4.97~4.79 (m,
1H), 2.28 (s, 3H), 2.20 (s, 3H), 2.14~2.10 (m, 1H), 1.65~1.58 (m,
1H), 1.16~1.05 (m, 1H); LCMS (electrospray) m/z 323.75 (M + H)+. A
33 ##STR00060## .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 10.56
(s, 1H), 8.23 (s, 1H), 7.49 (d, J = 9.6 Hz, 1H), 7.33~7.27 (m, 1H),
7.24~7.16 (m, 3H), 5.01~4.81 (m, 1H), 2.15 (s, 3H), 2.05~2.05 (m,
1H), 1.63~1.56 (m, 1H), 1.17~1.09 (m, 1H); LCMS (electrospray) m/z
345.96 (M + H)+. E 34 ##STR00061## .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 10.97 (s, 1H), 8.49 (s, 1H), 8.05 (s, 1H),
7.41 (d, J = 8.8 Hz, 1H), 7.17 (dd, J = 9.2, 1.6 Hz, 2H), 7.08 (d,
J = 7.6 Hz, 2H), 4.98~4.78 (m, 1H), 2.27 (s, 3H), 2.19 (s, 3H),
2.11~2.11 (m, 1H), 1.65~1.58 (m, 1H), 1.15~1.09 (m, 1H); LCMS
(electrospray) m/z 323.68 (M + H)+. A 35 ##STR00062## .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 10.98 (s, 1H), 10.50 (s, 1H), 8.83
(t, J = 1.2 Hz, 1H), 8.08 (s, 1H), 7.45 (d, J = 1.2 Hz, 2H), 7.27
(d, J = 7.2 Hz, 1H), 7.20 (dd, J = 7.6, 1.6 Hz, 1H), 7.02 (d, J =
1.2 Hz, 1H), 4.99~4.78 (m, 1H), 3.49 (s, 2H), 2.12~2.09 (m, 1H),
1.66~1.59 (m, 1H), 1.15~1.10 (m, 1H); LCMS (electrospray) m/z
350.99 (M + H)+. A 36 ##STR00063## .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 11.09 (s, 1H), 8.95 (s, 1H), 8.91 (s, 1H),
8.82 (d, J = 4.8 Hz, 1H), 8.13 (s, 1H), 7.99 (dd, J = 4.8, 0.8 Hz,
1H), 7.58 (d, J = 9.2 Hz, 1H), 7.49 (dd, J = 9.2, 2.0 Hz, 1H),
5.00~4.79 (m, 1H), 2.14~2.10 (m, 1H), 1.67~1.60 (m, 1H), 1.18~1.10
(m, 1H); LCMS (electrospray) m/z 321.95 (M + H)+. A 37 ##STR00064##
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 10.98 (s, 1H), 8.44
(dd, J = 1.8, 1.0 Hz, 1H), 8.05 (s, 1H), 7.42 (d, J = 9.2 Hz, 1H),
7.14~7.09 (m, 2H), 7.04 (m, 1H), 4.98~4.78 (m, 1H), 2.18 (d, J =
2.0 Hz, 3H), 2.14~2.08 (m, 4H), 1.65~1.58 (m, 1H), 1.15~1.09 (m,
1H); LCMS (electrospray) m/z 341.99 (M + H)+. A 38 ##STR00065##
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 10.99 (s, 1H), 8.35 (s,
1H), 8.03 (s, 1H), 7.45 (d, J = 9.2 Hz, 1H), 6.99~6.94 (m, 3H),
4.97~4.79 (m, 1H), 2.11 (m, 1H), 2.03 (s, 3H), 2.02 (s, 3H),
1.66~1.58 (m, 1H), 1.13~1.11 (m, 1H); LCMS (electrospray) m/z
341.84 (M + H)+. A 39 ##STR00066## .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 10.98 (s, 1H), 8.50 (s, 1H), 8.05 (s, 1H),
7.42 (d, J = 9.2 Hz, 1H), 7.31~7.27 (m, 1H), 7.17 (dd, J = 9.2, 1.6
Hz, 2H), 7.08 (dt, J = 14.4, 4.2 Hz, 1H), 4.98~4.78 (m, 1H), 2.24
(s, 3H), 2.11~2.09 (m, 1H), 1.66~1.58 (m, 1H), 1.16~1.08 (m, 1H);
LCMS (electrospray) m/z 328.10 (M + H)+. A 40 ##STR00067## .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. 10.97 (s, 1H), 10.86 (bs, 1H),
8.54 (s, 1H), 8.07 (s, 1H), 7.44~7.40 (m, 3H), 7.23~7.19 (m, 3H),
6.74 (dd, J = 4.4, 2.8 Hz, 1H), 6.41 (dd, J = 4.4, 2.8 Hz, 1H),
4.97~4.79 (m, 1H), 2.20 (s, 3H), 2.11 (m, 1H), 1.66~1.59 (m, 1H),
1.15~1.10 (m, 1H); LCMS (electrospray) m/z 375.10 (M + H)+. F 41
##STR00068## .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.00 (s,
1H), 8.66 (t, J = 0.8 Hz, 1H), 8.11 (s, 1H), 7.47~7.44 (m, 2H),
7.26 (dd, J = 9.2, 2.0 Hz, 1H), 6.99 (d, J = 4.8 Hz, 1H), 4.99~4.78
(m, 1H), 2.26 (s, 3H), 2.11 (m, 1H), 1.66~1.59 (m, 1H), 1.15~1.10
(m, 1H); LCMS
(electrospray) m/z 316.10 (M + H)+. A 42 ##STR00069## .sup.1H NMR
(400 MHz, DMSO-d6) .delta. 10.98 (s, 1H), 8.35 (s, 1H), 8.03 (s,
1H), 7.45 (d, J = 9.2 Hz, 1H), 7.19~7.10 (m, 3H), 6.97 (dd, J =
9.0, 1.8 Hz, 1H), 4.98~4.78 (m, 1H), 2.11~2.10 (m, 1H), 2.02 (s,
3H), 2.01 (s, 3H), 1.64~1.58 (m, 1H), 1.44~1.10 (m, 1H); LCMS
(electrospray) m/z 325.00 (M + H)+. A 43 ##STR00070## .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 10.98 (s, 1H), 9.75 (bs, 1H), 8.47
(s, 1H), 8.05 (s, 1H), 7.40 (d, J = 9.2 Hz, 1H), 7.13 (dd, J = 9.2,
2.0 Hz, 1H), 7.06 (d, J = 12.4 Hz, 1H), 6.81 (d, J = 9.2 Hz, 1H),
4.98~4.78 (m, 1H), 2.14~2.07 (m, 4H), 1.65~1.58 (m, 1H), 1.16~1.07
(m, 1H); LCMS (electrospray) m/z 343.90 (M + H)+. G 44 ##STR00071##
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.00 (s, 1H), 8.54 (s,
1H), 8.07 (s, 1H), 7.45 (d, J = 9.2 Hz, 1H), 7.36 (m, 1H),
7.19~7.13 (m, 2H), 4.99~4.78 (m, 1H), 2.19 (d, J = 2.8 Hz, 3H),
2.11 (m, 1H), 1.66~1.58 (m, 1H), 1.15~1.10 (m, 1H); LCMS
(electrospray) m/z 346.00 (M + H)+. G 45 ##STR00072## .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 11.02 (s, 1H), 8.57 (s, 1H), 8.07
(s, 1H), 7.49 (d, J = 9.2 Hz, 1H), 7.26 (m, 1H), 7.19 (m, 1H), 7.12
(dd, J = 9.0, 1.0 Hz, 1H), 4.99~4.78 (m, 1H), 2.10 (m, 1H), 2.06
(d, J = 2.4 Hz, 3H), 1.66~1.59 (m, 1H), 1.15~1.10 (m, 1H); LCMS
(electrospray) m/z 345.96 (M + H)+. G 46 ##STR00073## 1H NMR (400
MHz, DMSO-d6) .delta. 11.01 (s, 1H), 8.56 (s, 1H), 8.07 (s, 1H),
7.49~7.44 (m, 2H), 7.20~7.15 (m, 2H), 4.98~4.79 (m, 1H), 2.19 (d, J
= 2.8 Hz, 3H), 2.11 (m, 1H), 1.65~1.59 (m, 1H), 1.15~1.10 (m, 1H);
LCMS (electrospray) m/z 362.00 (M + H)+. G 47 ##STR00074## .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. 11.03 (s, 1H), 8.61 (s, 1H),
8.11 (d, J = 5.2 Hz, 1H), 8.06 (s, 1H), 7.49 (d, J = 9.2 Hz, 1H),
7.34 (d, J = 5.2 Hz, 1H), 7.16 (d, J = 9.2 Hz, 1H), 4.99~4.78 (m,
1H), 2.24 (s, 3H), 2.17~2.09 (m, 1H), 1.66~1.59 (m, 1H), 1.17~1.11
(m, 1H); LCMS (electrospray) m/z 329.01 (M + H)+. A 48 ##STR00075##
.sup.1H NMR (400 MHz, DMSO-d.sub.6) 11.00 (s, 1H), 8.46 (s, 1H),
8.06 (s, 1H), 7.47 (d, J = 9.2 Hz, 1H), 7.40~7.38 (m, 1H),
7.31~7.30 (m, 2H), 7.02 (dd, J = 9.2, 1.6 Hz, 1H), 4.99~4.78 (m,
1H), 2.13~2.09 (m, 4H), 1.71~1.58 (m, 1H), 1.15~1.10 (m, 1H); LCMS
(electrospray) m/z 343.94 (M + H)+. A 49 ##STR00076## .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 11.03 (s, 1H), 8.55 (s, 1H), 7.88
(s, 1H), 7.80 (bs, 2H), 7.47 (d, J = 9.2 Hz, 1H), 7.21 (dd, J =
9.2, 2.0 Hz, 1H), 6.84 (s, 1H), 4.99~4.79 (m, 1H), 2.25 (s, 3H),
2.14~2.07 (m, 1H), 1.65~1.58 (m, 1H), 1.16~1.05 (m, 1H); LCMS
(electrospray) m/z 325.70 (M + H)+. A 50 ##STR00077## .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 10.98 (s, 1H), 8.48 (dd, J = 1.6,
0.8 Hz, 1H), 8.07 (s, 1H), 7.41 (d, J = 9.2 Hz, 1H), 7.12 (dd, J =
9.2, 2.0 Hz, 1H), 6.35~6.31 (m, 2H), 5.26 (bs, 2H), 4.97~4.78 (m,
1H), 2.10 (m, 1H), 1.93 (d, J = 2.0 Hz, 3H), 1.65~1.58 (m, 1H),
1.15~1.09 (m, 1H); LCMS (electrospray) m/z 343.10 (M + H)+. G 51
##STR00078## .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 10.97 (s,
1H), 10.32 (s, 1H), 8.50 (s, 1H), 8.03 (s, 1H), 7.43 (d, J = 9.2
Hz, 1H), 7.14~7.10 (m, 2H), 6.73 (d, J = 8.0 Hz, 1H), 4.98~4.78 (m,
1H), 3.30 (s, 2H), 2.11~2.09 (m, 4H), 1.66~1.59 (m, 1H), 1.16~1.11
(m, 1H); LCMS (electrospray) m/z 365.02 (M + H)+. G 52 ##STR00079##
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.00 (s, 1H), 8.46 (s,
1H), 8.06 (s, 1H), 7.47 (d, J = 9.2 Hz, 1H), 7.40~7.38 (m, 1H),
7.31~7.30 (m, 2H), 7.02 (dd, J = 9.2, 1.6 Hz, 1H), 4.99~4.78 (m,
1H), 2.13~2.09 (m, 4H), 1.71~1.58 (m, 1H), 1.15~1.10 (m, 1H); LCMS
(electrospray) m/z 343.94 (M + H)+. A 53 ##STR00080## .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 11.35 (s, 1H), 10.99 (s, 1H), 8.91
(d, J = 0.8 Hz, 1H), 8.48 (d, J = 2.0 Hz, 1H), 8.16 (d, J = 2.4 Hz,
1H), 8.07 (s, 1H), 7.61 (dd, J = 9.2, 1.6 Hz, 1H), 7.48 (d, J = 9.2
Hz, 1H), 7.25 (s, 1H), 4.99~4.49 (m, 1H), 2.28 (s, 3H), 2.11 (m,
1H), 1.66~1.60 (m, 1H), 1.16~1.10 (m, 1H); LCMS (electrospray) m/z
350.17 (M + H)+. G 54 ##STR00081## .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 11.00 (s, 1H), 8.86 (s, 1H), 7.64 (d, J = 8.4
Hz, 1H), 7.47 (s, 2H), 7.39 (dd, J = 8.4, 1.2 Hz, 1H), 7.30 (s,
1H), 4.99~4.78 (m, 1H), 2.14~2.07 (m, 1H), 1.67~1.59 (m, 1H),
1.17~1.08 (m, 1H); LCMS (electrospray) m/z 369.00 (M + H)+. G 55
##STR00082## .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 10.96 (s,
1H), 8.73 (s, 1H), 8.21 (d, J = 2.4 Hz, 1H), 8.01 (s, 1H), 7.66
(dd, J = 8.8, 2.8 Hz, 1H), 7.42 (s, 2H), 6.51 (s, 1H), 6.06 (s,
2H), 4.98~4.78 (m, 1H), 2.12~2.04 (m, 1H), 1.66~1.58 (m, 1H),
1.16~1.58 (m, 1H); LCMS (electrospray) m/z 311.67 (M + H)+. G 56
##STR00083## .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.00 (s,
1H), 8.62 (t, J = 0.8 Hz, 1H), 8.50 (d, J = 2.4 Hz, 1H), 8.08 (s,
1H), 7.77~7.74 (m, 2H), 7.69 (d, J = 2.0 Hz, 1H), 7.47~7.40 (m,
2H), 7.27 (dd, J = 9.2, 2.0 Hz, 1H), 6.50 (t, J = 2.0 Hz, 1H),
4.99-4.78 (m, 1H), 2.27 (s, 3H), 2.13-2.09 (m, 4H), 1.66-1.58 (m,
1H), 1.15-1.09 (m, 1H); LCMS (electrospray) m/z 376.13 (M + H)+. D
57 ##STR00084## .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.34
(br s, 1H), 8.74 (s, 1H), 8.14 (s, 1H), 7.66- 7.55 (m, 2H), 7.46
(dt, J = 5.9, 8.0 Hz, 1H), 7.30 (d, J = 8.6 Hz, 1H), 7.28-7.22 (m,
1H), 5.09-4.84 (m, 1H), 4.41 (d, J = 1.4 Hz, 2H), 2.20-2.11 (m,
1H), 1.76-1.61 (m, 1H), 1.29-1.13 (m, 1H); LCMS (electrospray) m/z
344.40 (M + H)+. G 58 ##STR00085## 1H NMR (400 MHz, DMSO-d6);
.delta. 10.42 (s, 1H), 8.20 (s, 1H), 7.65 (d, J = 9.6 Hz, 1H), 7.40
(dd, J = 9.2, 1.6 Hz, 1H), 7.39~7.35 (m, 1H), 7.25~7.22 (m, 1H),
5.03~4.86 (m, 1H), 2.17 (d, J = 2.4 Hz, 3H), 2.10~2.05 (m, 1H),
1.66~1.58 (m, 1H), 1.15~1.08 (m, 1H); LCMS (electrospray) m/z
408.00 (M + H)+. B (NBS reagent) 59 ##STR00086## .sup.1H NMR (400
MHz, DMSO-d.sub.6) .delta. 11.31 (s, 1H), 8.81 (s, 1H), 8.17 (s,
1H), 7.62- 7.57 (m, 2H), 7.35-7.22 (m, 3H), 5.11- 4.82 (m, 1H),
3.75 (s, 3H), 2.19-2.09 (m, 1H), 1.72-1.65 (m, 1H), 1.23-1.13 (m,
1H); LCMS (electrospray) m/z 344.1 (M + H)+. G 60 ##STR00087##
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.14 (s, 1H), 8.92 (s,
1H), 8.17 (s, 1H), 7.90- 7.88 (m, 1H), 7.65-7.54 (m, 3H), 7.46 (s,
1H), 5.12-4.79 (m, 1H), 2.23-2.12 (m, 1H), 1.76-1.56 (m, 1H),
1.32-1.08 (m, 1H); LCMS (electrospray) m/z 339.1 (M + H)+. G 61
##STR00088## .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.14 (s,
1H), 8.74 (s, 1H), 8.14 (s, 1H), 7.58- 7.49 (m, 3H), 7.40-7.39 (m,
2H), 5.11-4.78 (m, 1H), 2.17-2.12 (m, 1H), 1.70- 1.63 (m, 1H),
1.21-1.15 (m, 1H); LCMS (electrospray) m/z 348.0 (M + H)+. G 62
##STR00089## .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.16 (s,
1H), 8.89 (s, 1H), 8.16 (s, 1H), 7.60- 7.57 (m, 1H), 7.52-7.44 (m,
3H), 7.42- 7.36 (m, 1H), 5.09-4.85 (m, 1H), 2.17- 2.13 (m, 1H),
1.78-1.63 (m, 1H), 1.21- 1.16 (m, 1H); LCMS (electrospray) m/z
332.1 (M + H)+. G 63 ##STR00090## .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 11.20 (s, 1H), 10.75 (s, 1H), 8.45 (s, 1H),
8.11 (s, 1H), 7.55 (d, J = 8.8 Hz, 1H), 7.32- 7.24 (m, 2H),
7.05-6.99 (m, 2H), 5.05- 4.85 (m, 1H), 2.19-2.16 (m, 1H), 2.14 (d,
J = 2.9 Hz, 3H), 1.73-1.66 (m, 1H), 1.63 (dd, J = 0.7, 4.4 Hz, 3H),
1.25-1.12 (m, 1H); LCMS (electrospray) m/z 363.2 (M + H)+. G 64
##STR00091## .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.25 (s,
1H), 8.68 (s, 1H), 8.14 (s, 1H), 7.60 (d, J = 9.2 Hz, 1H), 7.52
(dt, J = 6.0, 7.9 Hz, 1H), 7.44 (dd, J = 1.6, 9.2 Hz, 1H), 7.33 (d,
J = 8.7 Hz, 1H), 7.30-7.25 (m, 1H), 5.11- 4.76 (m, 1H), 4.30 (br d,
J = 1.3 Hz, 2H), 3.25 (s, 3H), 2.23-2.08 (m, 1H), 1.76- 1.59 (m,
1H), 1.20 (tdd, J = 6.3, 9.1, 12.4 Hz, 1H); LCMS (electrospray) m/z
358.5 (M + H)+. H 65 ##STR00092## .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 11.20 (s, 1H), 8.61 (s, 1H), 8.08 (s, 1H),
7.61 (dd, J = 0.9, 1.6 Hz, 1H), 7.60-7.54 (m, 1H), 7.45-7.41 (m,
1H), 7.40-7.36 (m, 2H), 6.93 (dd, J = 1.3, 9.3 Hz, 1H), 6.56-6.48
(m, 2H), 5.05-4.83 (m, 1H), 2.19-2.09 (m, 1H), 1.75-1.59 (m, 1H),
1.19 (tdd, J = 6.3, 9.1, 12.4 Hz, 1H); LCMS (electrospray) m/z
380.5 (M + H)+. I 66 ##STR00093## .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 11.16 (s, 1H), 8.65 (s, 1H), 8.13 (s, 1H),
7.56- 7.50 (m, 1H), 7.50-7.45 (m, 1H), 7.41- 7.33 (m, 2H), 7.29
(dd, J = 1.0, 7.6 Hz, 1H), 5.05-4.82 (m, 1H), 2.28 (s, 3H),
2.21-2.09 (m, 1H), 1.77-1.59 (m, 1H), 1.26-1.11 (m, 1H); LCMS
(electrospray) m/z 360.1 (M + H)+. G 67 ##STR00094## .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 11.21 (s, 1H), 8.69 (s, 1H), 8.13
(m, 1H), 8.12 (s, 1H), 7.62-7.55 (m, 1H), 7.43-7.35 (m, 1H),
7.25-7.20 (m, 1H), 5.06-5.03 (m, 1H), 4.89-4.86 (m, 1H), 2.38 (s,
3H), 2.22-2.11 (m, 1H), 1.76-1.59 (m, 1H), 1.26-1.13 (m, 1H); LCMS
(electrospray) m/z 329.1 (M + H)+. G 68 ##STR00095## .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 11.81 (s, 1H), 8.66 (br s, 1H),
8.15 (s, 1H), 7.67- 7.58 (m, 1H), 7.53 (d, J = 9.2 Hz, 1H), 7.41
(t, J = 9.2 Hz, 1H), 7.36 (dd, J = 0.7, 7.7 Hz, 1H), 7.25-7.18 (m,
1H), 5.03 (td, J = 3.1, 6.2 Hz, 1H), 4.88-4.85 (m, 1H), 2.40 (s,
3H), 2.20-2.09 (m, 1H), 1.74- 1.60 (m, 1H), 1.25-1.12 (m, 1H); LCMS
(electrospray) m/z 356.1 (M + H)+. G 69 ##STR00096## .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 11.00 (s, 1H), 8.55 (s, 1H), 8.08
(s, 1H), 7.96 (s, 1H), 7.44 (d, J = 9.2 Hz, 1H), 7.20 (dd, J = 9.2,
1.6 Hz, 1H), 6.60 (s, 1H), 5.01- 4.82 (m, 1H), 3.05 (s, 6H), 2.23
(s, 3H), 2.18-2.09 (m, 1H), 1.73-1.58 (m, 1H), 1.22-1.08 (m, 1H);
LCMS (electrospray) m/z 354.2 (M + H)+. G 70 ##STR00097## .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. 11.22 (br s, 1H), 8.66 (s, 1H),
8.09 (s, 1H), 7.59 (d, J = 9.2 Hz, 1H), 7.40 (br d, J = 9.3 Hz,
1H), 7.38-7.30 (m, 1H), 7.28-7.21 (m, 1H), 7.17 (d, J = 7.5 Hz,
1H), 2.18 (d, J = 2.3 Hz, 3H), 1.94 (quin, J = 6.2 Hz, 1H), 0.85
(d, J = 6.1 Hz, 4H); LCMS (electrospray) m/z 310.1 (M + H)+. J 71
##STR00098## .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.34 (s,
1H), 8.65 (s, 1H), 8.09 (s, 1H), 7.58 (d, J = 9.2 Hz, 1H),
7.40-7.35 (m, 1H), 7.35- 7.30 (m, 1H), 7.28-7.20 (m, 1H), 7.17 (d,
J = 7.5 Hz, 1H), 5.03-4.80 (m, 1H), 2.53- 2.42 (m, 1H), 2.18 (d, J
= 2.2 Hz, 3H), 1.62- 1.49 (m, 1H), 1.27 (qd, J = 6.5, 13.1 Hz, 1H);
LCMS (electrospray) m/z 328.1 (M + H)+. J 72 ##STR00099## .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. 11.31 (s, 1H), 8.64 (d, J = 0.6
Hz, 1H), 8.08 (s, 1H), 7.56 (d, J = 9.1 Hz, 1H), 7.38-7.30 (m, 2H),
7.27-7.21 (m, 1H), 7.17 (d, J = 7.5 Hz, 1H), 5.03-4.81 (m, 1H),
2.54- 2.42 (m, 1H, 2.18 (d, J = 2.3 Hz, 3H), 1.62- 1.49 (m, 1H),
1.26 (qd, J = 6.5, 13.1 Hz, 1H); LCMS (electrospray) m/z 328.5 (M +
H)+. J 73 ##STR00100## .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
11.27 (s, 1H), 8.67 (s, 1H), 8.13 (s, 1H), 7.59 (d, J = 9.2 Hz,
1H), 7.40 (dd, J = 1.6, 9.2 Hz, 1H), 7.38-7.31 (m, 1H), 7.28-7.21
(m, 1H), 7.18 (d, J = 7.5 Hz, 1H), 5.07-4.85 (m, 1H), 2.18 (d, J =
2.2 Hz, 3H), 2.16- 2.12 (m, 1H), 1.74-1.61 (m, 1H), 1.20 (tdd, J =
6.2, 9.1, 12.5 Hz, 1H); LCMS (electrospray) m/z 328.1 (M + H)+. J
74 ##STR00101## .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.15
(s, 1H), 8.61 (s, 1H), 8.14 (s, 1H), 8.13- 8.10 (m, 2H), 7.62-7.56
(m, 2H), 7.46- 7.43 (m, 1H), 7.31-7.29 (m, 2H), 5.05- 5.01 (m,
0.5H), 4.88-4.86 (m, 0.5H), 4.06-4.04 (m, 2H), 2.18-2.14 (m, 1H),
1.69-1.63 (m, 1H), 1.21-1.16 (m, 1H); LCMS (electrospray) m/z 343.2
(M + H)+. G 75 ##STR00102## .sup.1H NMR (400 MHz, CD3OD) .delta. =
8.67 (s, 1H), 7.81-7.71 (m, 2H), 7.49-7.47 (m, 1H), 7.31-7.22 (m,
2H), 5.04-5.01 (m, 0.5H), 4.87-4.85 (m, 0.5H), 4.38 (s, 2H),
2.16-2.12 (m, 1H), 1.90-1.84 (m, 1H), 1.31-1.28 (m, 1H); LCMS
(electrospray) m/z 385.1 (M + H)+. K 76 ##STR00103## .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 10.80 (s, 1H), 8.69 (s, 1H), 8.15
(s, 1H), 7.59 (d, J = 9.1 Hz, 1H), 7.41 (dd, J = 1.5, 9.3 Hz, 1H),
7.38-7.31 (m, 1H), 7.29-7.21 (m, 1H), 7.18 (d, J = 7.5 Hz, 1H),
3.35 (quin, J = 8.3 Hz, 1H), 2.30-2.20 (m, 2H), 2.18 (d, J = 2.3
Hz, 3H), 2.17-2.07 (m, 2H), 2.02-1.90 (m, 1H), 1.88-1.77 (m, 1H);
LCMS (electrospray) m/z 324.5 (M + H)+. J 77 ##STR00104## .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. 11.35 (s, 1H), 8.64 (s, 1H),
8.14 (s, 1H), 7.56 (d, J = 9.1 Hz, 1H), 7.38-7.29 (m, 2H), 7.28-
7.21 (m, 1H), 7.18 (d, J = 7.5 Hz, 1H), 2.93 (ddd, J = 8.3, 10.7,
13.5 Hz, 1H), 2.18 (d, J = 2.3 Hz, 3H), 2.11-1.96 (m, 2H); LCMS
(electrospray) m/z 364.4 (M + H)+. J 78 ##STR00105## .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 11.01 (s, 2H), 8.68 (d, J = 0.9 Hz,
2H), 8.17 (d, J = 4.1 Hz, 2H), 7.58 (dd, J = 2.0, 9.1 Hz, 2H),
7.42-7.37 (m, 2H), 7.36-7.31 (m, 2H), 7.28-7.21 (m, 2H), 7.18 (d, J
= 7.5 Hz, 2H), 5.37-5.15 (m, 1H), 5.14-4.92 (m, 1H), 3.41-3.29 (m,
1H), 2.88-2.76 (m, 1H), 2.61-2.52 (m, 4H), 2.49-2.26 (m, 4H), 2.18
(d, J = 2.1 Hz, 6H); LCMS (electrospray) m/z 342.5 (M + H)+. J 79
##STR00106## .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.10 (s,
1H), 8.67 (s, 1H), 8.18 (s, 1H), 7.56 (d, J = 9.3 Hz, 1H),
7.39-7.30 (m, 2H), 7.27- 7.21 (m, 1H), 7.18 (d, J = 7.5 Hz, 1H),
3.23 (dquin, J = 3.3, 8.4 Hz, 1H), 2.88-2.75 (m, 4H), 2.18 (d, J =
2.3 Hz, 3H); LCMS (electrospray) m/z 360.5 (M + H)+. J 80
##STR00107## .sup.1H NMR (400 MHz, DMOS-d.sub.6) .delta. 11.22 (s,
1H), 8.75 (br s, 2H), 8.64 (s, 1H), 8.14 (s, 1H), 7.63-7.60 (m,
2H), 7.50-7.40 (m, 1H), 7.34-7.30 (m, 1H), 5.05-5.03 (m, 0.5H),
4.88-4.84 (m, 0.5H), 4.19 (s, 2H), 2.47 (s, 3H), 2.18-2.14 (m, 1H),
1.70-1.63 (m, 1H), 1.22-1.16 (m, 1H); LCMS (electrospray) m/z 357.2
(M + H)+. G 81 ##STR00108## .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 11.15 (s, 1H), 8.64 (s, 1H), 8.60 (br s, 2H), 8.15 (s, 1H),
7.62-7.59 (m, 2H), 7.50-7.40 (m, 2H), 7.33-7.30 (m, 2H), 5.05-5.03
(m, 0.5H), 4.87-4.86 (m, 0.5H), 4.18 (m, 2H), 3.31-3.25 (m, 1H),
2.18-2.15 (m, 1H), 1.71-1.60 (m, 1H), 1.21-1.16 (m, 1H), 1.12 (d, J
= 6.8 Hz, 6 H); LCMS (electrospray) m/z 385.2 (M + H)+. G 82
##STR00109## .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.23-
11.19 (br s, 1H), 8.72 (s, 1H), 8.10 (s, 1H), 7.56-7.50 (m, 3H),
7.32-7.28 (m, 2H), 5.04-4.84 (m, 1H), 4.35 (s, 2H), 3.47-3.44 (m,
4H), 3.25 (s, 3H), 2.16- 2.11 (m, 1H), 1.70-1.64 (m, 1H), 1.21-
1.16 (m, 1H); LCMS
(electrospray) m/z 402.0 (M + H)+. L 83 ##STR00110## .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 11.21 (s, 1H), 8.78 (s, 1H), 8.14
(s, 1H), 7.58- 7.47 (m, 3H), 7.33-7.29 (m, 2H), 5.05- 4.85 (m, 1H),
4.36 (s, 2H), 3.55-3.52 (m, 2H), 3.47-3.45 (m, 2H), 2.16-2.13 (m,
1H), 1.71-1.69 (m, 1H), 1.65-1.64 (m, 1H); LCMS (electrospray) m/z
387.9 (M + H)+. M 84 ##STR00111## .sup.1H NMR (400 MHz, CD3OD)
.delta. 8.65 (s, 1H), 7.74-7.70 (m, 2H), 7.60-7.55 (m, 1H),
7.48-7.38 (m, 2H), 5.05-5.00 (m, 0.5H), 4.86-4.84 (m, 0.5H), 4.53
(s, 2H), 2.74 (s, 6H), 2.16 (br s, 1H), 1.87-1.81 (m, 1H),
1.31-1.25 (m, 1H); LCMS (electrospray) m/z 371.2 (M + H)+. G 85
##STR00112## .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. = 11.86
(s, 1H), 11.40 (s, 1H), 9.07 (s, 1H), 8.58 (d, J = 2.1 Hz, 1H),
8.30 (d, J = 1.9 Hz, 1H), 8.14 (s, 1H), 7.91-7.83 (m, 1H),
7.75-7.65 (m, 1H), 7.60-7.55 (m, 1H), 6.60-6.53 (m, 1H), 5.10-4.87
(m, 1H), 2.23-2.12 (m, 1H), 1.78-1.63 (m, 1H), 1.30-1.16 (m, 1H);
LCMS (electrospray) m/z 336.1 (M + H)+. G 86 ##STR00113## .sup.1H
NMR (400 MHz, DMSO-d.sub.6) .delta. 11.94 (s, 1H), 11.48 (s, 1H),
8.76 (s, 1H), 8.20 (s, 1H), 8.18-8.14 (m, 1H), 7.77-7.65 (m, 1H),
7.60 (dd, J = 1.6, 9.2 Hz, 1H), 7.58-7.54 (m, 1H), 6.72-6.59 (m,
1H), 5.11-4.80 (m, 1H), 2.52 (s, 3H), 2.25- 2.08 (m, 1H), 1.80-1.58
(m, 1H), 1.34- 1.11 (m, 1H); LCMS (electrospray) m/z 350.1 (M +
H)+. G 87 ##STR00114## .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
12.18 (s, 1H), 11.24 (s, 1H), 8.78 (s, 1H), 8.29 (s, 1H), 8.15 (s,
1H), 7.72-7.66 (m, 1H), 7.64-7.59 (m, 1H), 7.54-7.49 (m, 1H), 6.59
(dd, J = 1.9, 3.4 Hz, 1H), 5.10-4.84 (m, 1H), 2.21-2.13 (m, 1H),
1.78-1.59 (m, 1H), 1.31-1.09 (m, 1H); LCMS (electrospray) m/z 370.1
(M + H)+. G 88 ##STR00115## .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 11.26 (s, 1H), 8.64 (s, 1H), 8.12 (s, 1H), 7.58 (d, J = 9.2
Hz, 1H), 7.41 (br d, J = 9.0 Hz, 1H), 7.36-7.27 (m, 4H), 5.08-4.84
(m, 1H), 2.28 (s, 3H), 2.19-2.10 (m, 1H), 1.74-1.62 (m, 1H),
1.25-1.16 (m, 1H); LCMS (electrospray) m/z 310.1 (M + H)+. G 89
##STR00116## .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. = 11.22
(s, 1H), 9.94-9.83 (m, 1H), 8.79 (s, 1H), 8.13 (s, 1H), 7.57 (s,
2H), 7.24 (br d, J = 8.9 Hz, 1H), 7.19 (br d, J = 7.9 Hz, 1H), 6.93
(dt, J = 5.3, 7.9 Hz, 1H), 5.08-4.83 (m, 1H), 2.21-2.09 (m, 1H),
1.76-1.60 (m, 1H), 1.27-1.12 (m, 1H); LCMS (electrospray) m/z 329.8
(M + H)+. G 90 ##STR00117## .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 11.31 (s, 1H), 8.69 (s, 1H), 8.12 (s, 1H), 7.62 (d, J = 9.0
Hz, 1H), 7.45 (br d, J = 9.2 Hz, 1H), 7.09 (ddd, J = 1.4, 8.1, 11.4
Hz, 1H), 6.93 (d, J = 7.5 Hz, 1H), 6.66 (dt, J = 5.3, 7.9 Hz, 1H),
5.11-4.81 (m, 1H), 2.23- 2.05 (m, 1H), 1.79-1.59 (m, 1H), 1.34-
1.11 (m, 1H); LCMS (electrospray) m/z 328.8 (M + H)+. G 91
##STR00118## .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 1.27 (br
s, 1H), 11.08 (br s, 1H), 8.64 (s, 1H), 8.13 (s, 1H), 7.58 (d, J =
9.1 Hz, 1H), 7.45 (br s, 2H), 7.36 (t, J = 2.7 Hz, 1H), 7.29 (s,
1H), 6.39 (t, J = 2.0 Hz, 1H), 5.19-4.74 (m, 1H), 5.35-4.58 (m,
1H), 2.30 (s, 3H), 2.20-2.12 (m, 1H), 1.75-1.63 (m, 1H), 1.26-1.15
(m, 1H); LCMS (electrospray) m/z 348.9 (M + H)+. G 92 ##STR00119##
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.28- 11.20 (m, 1H),
11.05 (br s, 1H), 8.60 (s, 1H), 8.11 (s, 1H), 7.55 (br d, J = 9.4
Hz, 1H), 7.44 (s, 2H), 7.35-7.30 (m, 2H), 6.44-6.39 (m, 1H),
5.09-4.79 (m, 1H), 2.32 (s, 3H), 2.19-2.10 (m, 1H), 1.77- 1.56 (m,
1H), 1.29-1.07 (m, 1H); LCMS (electrospray) m/z 348.8 (M + H)+. G
93 ##STR00120## .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.30
(br s, 1H), 8.70 (s, 1H), 8.13 (s, 1H), 7.62- 7.49 (m, 2H),
7.27-7.16 (m, 3H), 5.07- 4.86 (m, 2H), 2.63 (d, J = 2.0 Hz, 6H),
2.20-2.11 (m, 1H), 1.75-1.62 (m, 1H), 1.26-1.14 (m, 1H); LCMS
(electrospray) m/z 357.5 (M + H)+. G 94 ##STR00121## .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 11.14 (s, 1H), 9.45 (s, 1H), 8.64
(s, 1H), 8.14 (s, 1H), 7.80 (s, 1H), 7.74 (s, 1H), 7.55 (d, J = 9.3
Hz, 1H), 7.33 (dd, J = 1.6, 9.3 Hz, 1H), 5.14-4.79 (m, 1H), 2.41
(s, 3H), 2.16 (td, J = 7.1, 14.0 Hz, 1H), 1.74-1.60 (m, 1H),
1.27-1.08 (m, 1H); LCMS (electrospray) m/z 349.9 (M + H)+. G 95
##STR00122## .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.13 (br
s, 1H), 8.60 (s, 1H), 8.13 (s, 1H), 7.54 (d, J = 9.0 Hz, 1H),
7.39-7.28 (m, 1H), 7.28-7.20 (m, 2H), 7.15-7.11 (m, 1H), 5.08-4.79
(m, 1H), 2.61-2.53 (m, 2H), 2.23-2.09 (m, 1H), 1.75-1.57 (m, 1H),
1.25-1.12 (m, 1H), 1.05 (t, J = 7.6 Hz, 3H); LCMS (electrospray)
m/z 342.1 (M + H)+. G 96 ##STR00123## .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 11.20 (s, 1H), 8.62 (s, 1H), 8.12 (s, 1H),
7.89 (d, J = 7.8 Hz, 1H), 7.81-7.74 (m, 1H), 7.72- 7.65 (m, 1H),
7.58-7.50 (m, 2H), 7.25 (d, J = 9.2 Hz, 1H), 5.06-4.83 (m, 1H),
2.20-2.10 (m, 1H), 1.75-1.60 (m, 1H), 1.28-1.10 (m, 1H); LCMS
(electrospray) m/z 364.0 (M + H)+. G 97 ##STR00124## .sup.1H NMR
(400 MHz, DMSO-d.sub.6) .delta. 11.16 (br s, 1H), 8.69 (s, 1H),
8.11 (s, 1H), 7.57- 7.42 (m, 2H), 7.39-7.32 (m, 1H), 7.24- 7.16 (m,
2H), 5.11-4.76 (m, 1H), 2.23- 2.07 (m, 1H), 1.99-1.85 (m, 1H),
1.77- 1.56 (m, 1H), 1.31-1.05 (m, 1H), 0.80- 0.69 (m, 2H),
0.44-0.30 (m, 2H); LCMS (electrospray) m/z 353.9 (M + H)+. G 98
##STR00125## .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.25 (br
s, 1H), 8.63 (s, 1H), 8.11 (s, 1H), 7.57 (br d, J = 9.0 Hz, 1H),
7.36 (br d, J = 9.0 Hz, 1H), 7.12 (ddd, J = 1.3, 8.1, 13.0 Hz, 1H),
6.95 (d, J = 7.7 Hz, 1H), 6.77 (dt, J = 5.0 7.8 Hz, 1H), 5.06-4.85
(m, 1H), 2.66 (d, J = 3.6 Hz, 3H), 2.19-2.09 (m, 1H), 1.74- 1.60
(m, 1H), 1.20 (ddd, J = 2.8, 6.2, 12.2 Hz, 1H); LCMS (electrospray)
m/z 343.3.00 (M + H)+. G 99 ##STR00126## .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 11.05 (s, 1H), 8.76 (s, 1H), 8.60 (dd, J =
0.9, 1.6 Hz, 1H), 8.11 (s, 1H), 7.77 (s, 1H), 7.73 (s, 1H), 7.49
(d, J = 9.2 Hz, 1H), 7.27 (dd, J = 1.8, 9.2 Hz, 1H), 5.04-4.82 (m,
1H), 2.36 (s, 3H), 2.19-2.10 (m, 1H), 1.71- 1.59 (m, 1H), 1.16
(tdd, J = 6.2, 9.1, 12.3 Hz, 1H); LCMS (electrospray) m/z 351.5 (M
+ H)+. G 100 ##STR00127## .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 11.13 (s, 1H), 9.42 (s, 1H), 8.68 (s, 1H), 8.13 (s, 1H),
7.79 (d, J = 8.4 Hz, 1H), 7.68-7.51 (m, 2H), 7.27 (dd, J = 1.6, 9.0
Hz, 1H), 5.11-4.80 (m, 1H), 2.39-2.37 (s, 3H), 2.19-2.14 (m, 1H),
1.74-1.60 (m, 1H), 1.23-1.12 (m, 1H); LCMS (electrospray) m/z 350.2
(M + H)+. G 101 ##STR00128## .sup.1H NMR (400 MHz, DMSO-d.sub.6)
.delta. 11.27 (s, 1H), 9.30 (s, 1H), 8.70 (s, 1H), 8.08- 8.05 (m,
2H), 7.67-7.61 (m, 1H), 7.48- 7.44 (m, 1H), 7.43-7.39 (m, 1H),
5.06- 4.86 (m, 1H), 2.37 (s, 3H), 2.18-2.15 (m, 1H), 1.75-1.60 (m,
1H), 1.23-1.17 (m, 1H); LCMS (electrospray) m/z 367.2 (M + H)+. G
102 ##STR00129## .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.07
(s, 1H), 8.70 (s, 1H), 8.65 (s, 1H), 8.13 (s, 1H), 7.71 (d, J = 8.3
Hz, 1H), 7.53 (d, J = 9.2 Hz, 1H), 7.43 (d, J = 8.4 Hz, 1H), 7.29
(dd, J = 1.6, 9.2 Hz, 1H), 5.05-4.81 (m, 1H), 2.38 (s, 3H),
2.20-2.10 (m, 1H), 1.73-1.59 (m, 1H), 1.17 (tdd, J = 6.2, 9.1, 12.2
Hz, 1H); LCMS (electrospray) m/z 351.2 (M + H)+. N 103 ##STR00130##
.sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 11.07 (s, 1H), 9.40 (s,
1H), 8.64 (dd, J = 0.9, 1.6 Hz, 1H), 8.12 (s, 1H), 8.11 (s, 1H),
8.07 (s, 1H), 7.51 (d, J = 9.2 Hz, 1H), 7.30 (dd, J = 1.8, 9.2 Hz,
1H), 5.05-4.82 (m, 1H), 2.42 (s, 3H), 2.21-2.10 (m, 1H), 1.74- 1.59
(m, 1H), 1.24-1.12 (m, 1H); LCMS (electrospray) m/z 367.5 (M + H)+
G 104 ##STR00131## .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta.
11.07 (s, 1H), 9.45 (s, 1H), 8.67-8.61 (m, 1H), 8.13 (s, 1H), 8.03
(d, J = 8.3 Hz, 1H), 7.52 (dd, J = 7.2, 8.7 Hz, 2H), 7.30 (dd, J =
1.8, 9.2 Hz, 1H), 5.05-4.80 (m, 1H), 2.54 (s, 3H), 2.20-2.10 (m,
1H), 1.74-1.59 (m, 1H), 1.24-1.11 (m, 1H); LCMS (electrospray) m/z
367.5 (M + H)+. G 105 ##STR00132## .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 11.12 (br s, 1H), 8.55 (s, 1H), 8.12 (s, 1H),
7.51 (br d, J = 8.9 Hz, 1H), 7.35-7.27 (m, 1H), 7.26-7.20 (m, 1H),
7.20-7.16 (m, 1H), 7.10 (d, J = 7.3 Hz, 1H), 5.12-4.78 (m, 1H),
3.07-2.82 (m, 1H), 2.22-2.09 (m, 1H), 1.74-1.58 (m, 1H), 1.25 (br
d, J = 6.8 Hz, 6H), 1.20-1.13 (m, 1H); LCMS (electrospray) m/z
355.9 (M + H)+. G
[0602] Evaluation of Compounds
[0603] c-abl Kinase Assay
[0604] ADP-Glo assay kit was purchased from Promega. Magnesium
chloride (MgCl.sub.2), bovine serum albumin (BSA), ethylene
glycol-bis(p-aminoethyl ether)-N,N,N'-tetraacetic acid (EGTA),
triton X-100, 1,4-dithiothreitol (DTT) and dimethyl sulfoxide
(DMSO) were purchased from Sigma-Aldrich. HEPES buffer was
purchased from Gibco. ABL1 kinase and Abltide were purchased from
Signalchem.
[0605] c-Abl kinase activity was measured by Promega's ADP-Glo.TM.
Assay. In this assay, His-tagged recombinant human ABL1 (0.25
ng/.mu.l) is incubated with 5 .mu.L of compounds (0.5% DMSO), 5
.mu.L of Abltide (0.01 .mu.g/.mu.l) and 5 .mu.L of ATP (25 pM) in
buffer (50 mM HEPES,7.5; 10 mM MgCl2; 1 mM EGTA; 0.05% BSA; 0.01%
Triton X-100; 2 mM DTT.). The assay was started by incubating the
reaction mixture in a 96-well plate at 30.degree. C. for 30-min.
After the incubation, 25 .mu.L ADP-Glo reagent was added and the
reaction was incubated at room temperature for 40-min to stop the
reaction and degrade residual ATP. The ADP product was then
converted to ATP by adding 50 .mu.L per well of detection reagent.
Luminescence was detected after 30-min room temperature incubation
with the Molecular device I3X plate reader. The IC50 values were
calculated from a series of percent inhibition values determined at
a range of inhibitor concentration using software routines as
implemented in the GraphPad Prism 7 software and Sigma Plot
13.0.
[0606] c-Kit Kinase Assay
[0607] ADP-Glo assay kit was purchased from Promega. Magnesium
chloride (MgCl.sub.2), ethylene glycol-bis(8-aminoethyl
ether)-N,N,N',N'-tetraacetic acid (EGTA), manganese (II) chloride
(MnCl.sub.2), bovine serum albumin (BSA), 1,4-dithiothreitol (DTT)
and dimethyl sulfoxide (DMSO) were purchased from Sigma-Aldrich.
HEPES buffer was purchased from Gibco. c-Kit kinase and poly (4:1
Glu, Tyr) peptide were purchased from Signalchem.
[0608] c-Kit kinase activity was measured by Promega's ADP-Glo.TM.
Assay. In this assay, 100ng of recombinant human c-Kit is incubated
with 5 .mu.L of compounds (0.5% DMSO), 5 .mu.L of Poly (4:1 Glu,
Tyr) peptide (50 ng/.mu.l) and 5 .mu.L of ATP (50 .mu.M) in buffer
(50 mM HEPES, pH7.5; 10 mM MgCl.sub.2; 1 mM EGTA; 0.05% BSA;
50.mu.M DTT; 2mM MnCl.sub.2). The assay was started by incubating
the reaction mixture in a 96-well plate at 30.degree. C. for
120-min. After the incubation, 25 .mu.L ADP-Glo reagent was added
and the reaction was incubated at room temperature for 40-min to
stop the reaction and degrade residual ATP. The ADP product was
then converted to ATP by adding 50 .mu.L per well of detection
reagent. Luminescence was detected after 30-min room temperature
incubation with the Molecular device I3X plate reader. The IC50
values were calculated from a series of percent inhibition values
determined at a range of inhibitor concentration using software
routines as implemented in the GraphPad Prism 8 software and Sigma
Plot 13.0.
[0609] c-Kit (D816V) Kinase Assay
[0610] ADP-Glo assay kit was purchased from Promega. Magnesium
chloride (MgCl.sub.2), ethylene glycol-bis(.beta.-aminoethyl
ether)-N,N,N',N'-tetraacetic acid (EGTA), bovine serum albumin
(BSA), 1,4-dithiothreitol (DTT) and dimethyl sulfoxide (DMSO) were
purchased from Sigma-Aldrich. HEPES buffer was purchased from
Gibco. c-Kit (D816V) kinase and poly (4:1 Glu, Tyr) peptide were
purchased from Signalchem.
[0611] c-Kit (D816V) kinase activity was measured by Promega's
ADP-GIoTM Assay. In this assay, 2.5ng of recombinant human c-Kit
(D816V) is incubated with 5 .mu.L of compounds (0.5% DMSO), 5 .mu.L
of Poly (4:1 Glu, Tyr) peptide (50 ng/.mu.l) and 5 .mu.L of ATP (15
.mu.M) in buffer (50 mM HEPES, pH7.5; 10 mM MgCl.sub.2; 1 mM EGTA;
0.05% BSA; 50 .mu.M DTT). The assay was started by incubating the
reaction mixture in a 96-well plate at 30.degree. C. for 120-min.
After the incubation, 25 .mu.L ADP-Glo reagent was added and the
reaction was incubated at room temperature for 40-min to stop the
reaction and degrade residual ATP. The ADP product was then
converted to ATP by adding 50 .mu.L per well of detection reagent.
Luminescence was detected after 30-min room temperature incubation
with the Molecular device I3X plate reader. The IC50 values were
calculated from a series of percent inhibition values determined at
a range of inhibitor concentration using software routines as
implemented in the GraphPad Prism 8 software and Sigma Plot
13.0.
[0612] PDGFR.alpha. Kinase Assay
[0613] ADP-Glo assay kit was purchased from Promega. Magnesium
chloride (MgCl.sub.2), ethylene glycol-bis(p-aminoethyl
ether)-N,N,N',N'-tetraacetic acid (EGTA), bovine serum albumin
(BSA), 1,4-dithiothreitol (DTT) and dimethyl sulfoxide (DMSO) were
purchased from Sigma-Aldrich. HEPES buffer was purchased from
Gibco. PDGFR.alpha. Kinase and poly (4:1 Glu, Tyr) peptide were
purchased from Signalchem.
[0614] PDGFR.alpha. kinase activity was measured by Promega's
ADP-Glo.TM. Assay. In this assay, 40ng of recombinant human
PDGFR.alpha. is incubated with 5 .mu.L of compounds (0.5% DMSO), 5
.mu.L of Poly (4:1 Glu, Tyr) peptide (100 ng/.mu.l) and 5 .mu.L of
ATP (25 pM) in buffer (50 mM HEPES, pH7.5; 10 mM MgCl.sub.2; 1 mM
EGTA; 0.05% BSA; 50 .mu.M DTT). The assay was started by incubating
the reaction mixture in a 96-well plate at 30.degree. C. for
60-min. After the incubation, 25 .mu.L ADP-Glo reagent was added
and the reaction was incubated at room temperature for 40-min to
stop the reaction and degrade residual ATP. The ADP product was
then converted to ATP by adding 50 .mu.L per well of detection
reagent. Luminescence was detected after 30-min room temperature
incubation with the Molecular device I3X plate reader. The
IC.sub.50 values were calculated from a series of percent
inhibition values determined at a range of inhibitor concentration
using software routines as implemented in the GraphPad Prism 8
software and Sigma Plot 13.0.
[0615] PDGFR.alpha. (D842V) Kinase Assay
[0616] ADP-Glo assay kit was purchased from Promega. Magnesium
chloride (MgCl.sub.2), ethylene glycol-bis(p-aminoethyl ether)-N,
N, N', N'-tetraacetic acid (EGTA), bovine serum albumin (BSA),
1,4-dithiothreitol (DTT) and dimethyl sulfoxide (DMSO) were
purchased from Sigma-Aldrich. HEPES buffer was purchased from
Gibco. PDGFR.alpha. (D842V) Kinase and poly (4:1 Glu, Tyr) peptide
were purchased from Signalchem.
[0617] PDGFR.alpha. (D842V) kinase activity was measured by
Promega's ADP-Glo.TM. Assay. In this assay, 10 ng of recombinant
human PDGFR.alpha. (D842V) is incubated with 5 .mu.L of compounds
(0.5% DMSO), 5 .mu.L of Poly (4:1 Glu, Tyr) peptide (100 ng/.mu.l)
and 5 .mu.L of ATP (3 pM) in buffer (50 mM HEPES, pH7.5; 10 mM
MgCl.sub.2; 1 mM EGTA; 0.05% BSA; 50pM DTT). The assay was started
by incubating the reaction mixture in a 96-well plate at 30.degree.
C. for 120-min. After the incubation, 25 .mu.L ADP-Glo reagent was
added and the reaction was incubated at room temperature for 40-min
to stop the reaction and degrade residual ATP. The ADP product was
then converted to ATP by adding 50 .mu.L per well of detection
reagent. Luminescence was detected after 30-min room temperature
incubation with the Molecular device I3X plate reader. The
IC.sub.50 values were calculated from a series of percent
inhibition values determined at a range of inhibitor concentration
using software routines as implemented in the GraphPad Prism 8
software and Sigma Plot 13.0.
[0618] Table 2 shows IC.sub.50 values of the invented compounds
which represent +for >1000 nM, ++for 101-1000 nM, +++for 10-100
nM, ++++for <10 nM.
TABLE-US-00002 TABLE 2 In vitro kinase activity c-KIT PDGFR.alpha.
c-Abl c-KIT D816V PDGFRa D842V IC.sub.50 IC.sub.50 IC.sub.50
IC.sub.50 IC.sub.50 Example (nM) (nM) (nM) (nM) (nM) 1 ++++ Not
tested Not tested Not tested Not tested 57 ++++ + ++ ++ +++ 64 ++++
+ + + ++ 65 +++ + + + + 68 +++ + + + + 74 + + + + + 75 ++ + + + +
80 + + + + + 81 + + + + + 82 +++ + + ++ ++ 83 ++ + + ++ ++ 84 + + +
Not tested Not tested
[0619] K562 Cell Proliferation Assay
[0620] K562 human leukemia cell line purchased from Korean cell
line bank (KCLB) and were cultured in Roswell Park Memorial
Institute (RPMI) 1640 Medium supplemented with 10% fetal bovine
serum (FBS) and 1% penicillin-streptomycin in a humidified
incubator in an atmosphere of 5% CO.sub.2 at 37.degree. C. Cells
were seeded in 96-well plates at a density of 2.times.103
cells/well in 100 p1 media. Compounds were diluted as two times
concentration in 100 .mu.l of media and added to each well.
Compounds were 5-fold serially diluted for 6 points and treated
from 5 .mu.M to 1.6 nM in K562 cells. After 48 hr incubation,
Compound treated cells were analyzed for anti-proliferation assay.
Cell viability was investigated using the Cell Titer 96 Aqueous One
Solution Reagent. Briefly, 200 .mu.l of media were supplemented
with 40 .mu.l of MTS solution, incubated for 4hr, and then the
absorbance was recorded at 490 nm with a 96-well plate reader. G150
values were calculated from a series of percent of cell viability
at a range of compound concentration. GraphPad Prism 8 software or
SigmaPlot 13.0 was used to generate G150 values.
[0621] Table 3 shows 1050 values of the invented compounds which
represent +for >1000 nM, ++for 101-1000 nM, +++for 10-100 nM,
++++for <10 nM.
TABLE-US-00003 TABLE 3 K562 cell activity K562 IC.sub.50 Example
(nM) 1 ++ 11 ++ 12 +++ 15 +++ 24 +++ 40 +++ 57 ++ 70 ++ 77 ++ 85 ++
92 +++ 94 ++ 103 +++
* * * * *